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ABSTRACT
The chemistry and structure of Poly (glycerol adipate) facilitate its substitution
with various pendant functional groups leading to modifications of the
physicochemical properties of the polymer. Modified backbones then can be
selected based upon the properties of the compound to be incorporated. Thus,
this could be explored as a drug delivery system without many of the limitations
of commercially available polymers. The aim of this study was investigate
whether various polymers and drugs interact in a specific manner and whether
the nature of these interactions influence the physicochemical characteristics of
the particles and their drug loading and release profile.
By investigating drugs belonging to various classes and with different properties
it has been possible to correlate properties associated with drugs and pendant
functional groups of the polymer which are ultimately responsible for the drug
loading and release characteristics. For some drug polymer formulations, good
loading and controlled release rates have been achieved. Compared to various
conventional polymer systems reported for nanoparticle formulations, poly
(glycerol adipate) polymers have also demonstrated the ability to control rate of
release of highly water soluble drugs, even from the most hydrophilic polymer
backbone in its unsubstituted form.
From the various drug loading and release profiles it has been demonstrated that,
unlike reported literature, particle size is not the primary factor influencing drug
release over the relatively small range of particle sizes seen in this study. Neither
is the water solubility of either the drug or the polymer alone responsible for the
rapid and uncontrolled release profile from nanoparticles.
ABSTRACT
XIV
Thus, Drug polymer interactions are more likely to influence drug loading and
release and unlike common reports in the literature, hydrophilicity, molecular
weight or concentration of polymer / drug are less likely to affect these
parameters in isolation.
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CHAPTER 1. INTRODUCTION
1.1. A Brief Overview of Nanoparticle Delivery Systems
Biodegradable polymers have been studied extensively over the past few decades
to fabricate various novel drug delivery systems such as nanoparticles,
microparticles, microspheres, liposomes etc. Considerable research is being
directed towards developing biodegradable polymeric nanoparticles for drug
delivery and tissue engineering, in view of their applications in providing
controlled release of drugs, effectiveness in stabilising labile drug molecules
such as proteins, peptides, or DNA from degradation and site specific drug
targeting.
The late 1960’s and early 1970’s saw the advent of polymer nanoparticles based
on acrylamide micelle polymerisation [1]. Since then, along with different
polymerisation methods, use of preformed polymers have also been developed
and studied [1-3]. The majority of studies on nanoparticles reported to date have
dealt with NPs of poly (D,L lactide), poly (lactic acid) PLA, poly (D,L
glycolide) [PLG], poly (lactide-co-glycolide) [PLGA] and poly- cyanoacrylate
[PCA] [3].
1.2. Review of Nanoparticle Delivery Systems
Nanoparticles are solid, colloidal particles consisting of macromolecular
substances that vary in size from 10 nm to 1000 nm [1]. The drug of interest is
dissolved, entrapped, adsorbed, attached or encapsulated into the nanoparticle
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matrix. Depending on the method of preparation, nanoparticles, nanospheres or
nanocapsules can be obtained with different properties and release characteristics
for the encapsulated therapeutic agent [2-4]. Nanocapsules are vesicular systems
in which the drug is confined to a cavity surrounded by a polymer membrane,
whereas nanospheres are matrix systems in which the drug is physically and
uniformly dispersed (See Fig. 1.1)
Fig. 1.1. Schematics of exemplary types of drug nanoparticles. A. Matrix type
nanosphere, drug molecules are evenly dispersed in the polymer matrix. B. Core
shell nanocapsule, drug molecule is presented in a core covered with a polymer
shell. C. Matrix type nanosphere where drug crystals are embedded in a polymer
matrix [5]
1.2.1. Applications and advantages as drug carrier vehicle
Polymeric nanoparticles made from natural and synthetic polymers have received
the majority of attention due to higher stability and the opportunity for further
surface nanoengineering [6, 7]. They can be tailor-made to achieve both
controlled drug release and disease specific localization by tuning the polymer
characteristics and surface chemistry [8-11]. It has been established that
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nanocarriers can become concentrated preferentially in the tumour mass,
inflammatory sites, and at infectious sites by virtue of the enhanced permeability
and retention (EPR) effect of the vasculature. Once accumulated at the target
site, hydrophobic biodegradable polymeric nanoparticles can act as a local drug
depot depending upon the make-up of the carrier, thus providing a source for a
continuous supply of encapsulated therapeutic compound at the disease site, such
as, a solid tumour. These systems in general can be used to provide targeted
(cellular/tissue) delivery of drugs, to improve oral bioavailability, to sustain
drug/gene effect in the target tissue, to solubilize drugs for intravascular delivery,
and to improve the stability of therapeutic agents against enzymatic degradation
(nucleases and proteases), especially of protein, peptide, and nucleic acids drugs
[12]. Thus, the advantages of using nanoparticles for drug delivery result from
two main basic properties viz. small size and use of biodegradable materials.
Nanoparticles, because of their small size, can extravasate through the sites of
inflammation and cancer cells or penetrate into smaller capillaries, cross the
fenestration present in the epithelial lining (e.g., liver), and are generally taken
up efficiently by the cells which allow efficient drug accumulation at the target
sites [8, 9, 13]. Many studies have demonstrated that nanoparticles of sub-micron
size have a number of advantages over microparticles as a drug delivery system
[14]. Nanoparticles have a further advantage over larger microparticles as they
are better suited for intravenous (i.v.) delivery. The smallest capillaries in the
body are 5–6 ȝm in diameter. The size of particles being distributed into the
bloodstream must be significantly smaller than 5 ȝm, without forming aggregates
to ensure that the particles do not form an embolism. In some cell lines, only
submicron nanoparticles can be taken up but not large size microparticles.
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Generally nanoparticles have relatively higher intracellular uptake compared to
microparticles and are available to a much wider range of biological targets due
to their small size and relative mobility. Desai et al. found that 100 nm
nanoparticles had a 2.5 fold greater uptake than 1 µm microparticles, and 6 fold
greater uptake than 10 µm microparticles in a Caco-2 cell line [13]. In a similar
study, the nanoparticles penetrated throughout the submucosal layers in a rat in
situ intestinal loop model, while microparticles were predominantly localized in
the epithelial lining [15]. Secondly, the use of biodegradable materials for
nanoparticle preparation allows sustained drug release within the target site over
a period of days or even weeks. Biodegradable nanoparticles formulated from
poly DL-lactide co-glycolide (PLGA) and polylactide (PLA) have been developed
for intracellular sustained drug delivery, especially for drugs with an intracellular
target [9, 16, 17]. Rapid escape of PCL nanoparticles from the endo-lysosomal
compartment to the cytoplasmic compartment has been demonstrated [16, 18].
Thus, nanoparticles could be an effective drug delivery mechanism for drugs
whose targets are cytoplasmic. Greater and sustained antiproliferative activity
was observed in vascular smooth muscle cells which were treated with
dexamethasone-loaded nanoparticles compared to that seen with drug in solution
[19]. Nanoparticles were effective in sustaining intracellular dexamethasone
levels, thus allowing a more efficient interaction with the glucocorticoid
receptors which are cytoplasmic.
1.2.2. Targeted drug delivery
The development of nanoparticulate delivery systems for targeted drug delivery
has been reviewed recently by Moghimi et al. [10]. Targeted delivery can be
achieved by either active or passive targeting. Active targeting of a therapeutic
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agent is achieved by conjugating the therapeutic agent or the carrier system to a
tissue or cell-specific ligand [20]. Passive targeting is achieved by incorporating
the therapeutic agent into a macromolecule or nanoparticle that passively reaches
the target organ. Drugs encapsulated in nanoparticles or drugs coupled to
macromolecules such as high molecular weight polymers passively target the
tumour tissue through the enhanced permeation and retention (EPR) effect. The
alternative approach involves the infusion of a nanoparticle suspension to the
accessible target organ or tissue using infusion catheters. Localized delivery of
nanoparticles in restenosis may be a useful strategy as it may provide a sustained
drug effect in the target artery [21, 22].
Solid Lipid Nanoparticles and liposomes are also useful for the delivery of
pharmaceutical agents after binding to target cellular epitopes by a mechanism
called ‘contact facilitated drug delivery’. Binding and close apposition to the
targeted cell membrane permits enhanced lipid–lipid exchange with the lipid
monolayer of the nanoparticle, which accelerates convective flux of lipophilic
drugs (e.g. paclitaxel) dissolved in the outer lipid membrane of the nanoparticles
into the targeted cells [23]. Such nanosystems can serve as drug depots
exhibiting prolonged release kinetics and long persistence at the site.
Another characteristic function of nanoparticles is their ability to deliver drugs
across several biological barriers to the target site [24, 25]. The brain delivery of
a wide variety of drugs, such as antineoplastics and anti-HIV drugs is markedly
hindered because they have great difficulty in crossing the Blood–Brain Barrier
(BBB) .The application of nanoparticles to brain delivery is a promising way of
overcoming this barrier. It has been reported that nanoparticles can cross the
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Table 1.1 Summary of applications of various colloidal carriers as targeted drug delivery system [118].
Nanoparticle Size
(nm)
Carried therapeutic
agent
Examples of potential targeted therapeutic application Advantage
Polymeric
biodegradable
nanoparticles
10-
1,000
Plasmid DNA, proteins, peptides,
low molecular weight compounds
Brain tumor therapy [Olivier et al., [1999]]; Kreuter et al., [2003]], bone healing
[Labhasetwar et al., [1999]], vaccine adjuvant [Raghuvanshi et al., [2001]],
coating gut suture [Cohen et al., [2000]], restenosis [Guzman et al., [1996];
Panyam et al., [2002], inflamed colonic mucosa [Lamprecht et al., [2001]],
diabetes therapy [Al Khouri et al., [1986]]; Watnasirichailkul et al., [2000]]
Sustain localized drug
therapeutic agent for
weeks
Silica
nanoparticles
<100
Proteins, DNA, anticancer
therapeutic agents, high molecular
weight compounds
Photodynamic therapy [Roy et al., [2003b]], liver therapy [Roy et al., [2003a];
Dey, [2005]], diabetes therapy [Cherian et al., [2000]]
Can be easily prepared,
water-soluble, and stable
in biological
environment
Metallic
nanoparticles
<50
Anticancer therapeutic agents,
proteins, DNA
Cancer therapy [Wang et al., [2004]; Priyabrata et al., [2005]]
Extremely small size
with vast surface area to
carry large dose
Polymeric
micelles
<100
DNA, anticancer therapeutic
agents, proteins
Solid tumors therapy [Yokoyama et al., [1990]; Kataoka et al., [2001]; Rapoport
et al., [2003]], antifungal treatment [Yu et al., [1998]]
Have hydrophobic core,
and so they are suitable
carriers for water-
insoluble drug
Liposomes
50-
100
Proteins, DNA, anticancer
therapeutic agents
Tumors therapy [Goren et al., [1996]; Versluis et al., [1998]; Lasic et al.,
[1999]], HIV therapy [Slepushkin et al., [1996]], vaccine delivery [Rao and
Alving, [2000]]
Effective in reducing
system toxicity and can
stay longer in targeted
tissue
Dendrimers <10
DNA, anticancer therapeutic
agents, antibacterial therapeutic
agents, antiviral therapeutic
agents, high molecular weight
compounds
Tumors therapy [Kobayashi et al., [2001]; Quintana et al., [2002]; Latallo et al.,
[2005]], bacterial infection treatment [Chen and Cooper, [2002]; Boas and
Heegaard, [2004]], HIV therapy [Witvrouw et al., [2000]; Rojo and Delgado,
[2004]]
Can be modified to carry
hydrophobic or
hydrophilic drug
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blood-brain barrier following the opening of tight junctions by hyperosmotic
mannitol, which may provide sustained delivery of therapeutic agents for
difficult-to-treat diseases like brain tumours [26]. Tween 80 coated nanoparticles
have also been shown to cross the blood-brain barrier [27]. A range of different
types of nanoparticles and their applications are outlined in Table 1.1.
1.2.3. Polymers used in nanoparticle formulations
Common classes of polymers used to encapsulate drugs in colloidal systems
include polyamides, poly(amino acids), polyesters, polyorthoesters and
polyanhydrides [14, 28].
1.2.3.1. Polyesters
Recently, biodegradable polyesters such as poly (lactic acid), poly (glycolic acid)
and the copolymers of lactic and glycolic acid, i.e., poly (lactide-co-glycolide).
(PLGA) have been used extensively for biomedical applications. Being
biodegradable they have the advantage of not requiring surgery for removal after
they have served their purposes. They protect the entrapped drug against
degradation and control its site specific delivery. They are synthesised through
ring opening polymerisation of cyclic lactones. These copolymers (with varying
lactide: glycolide ratios) are amorphous and easily dissolve in organic solvents
such as dichloromethane and ethyl acetate. The degradation rate in water is a
function of the molecular weight and the lactide:glycolide ratio [29]. Higher
glycolide content and lower molecular weight increase the degradation rate. As
they are all strongly hydrophobic they are more efficient for encapsulation of
hydrophobic drugs than hydrophilic drugs. A burst release is another
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characteristic observed with nanoparticles made from PLGA. The drug release
from PLGA microparticles often has a tri-phasic pattern in vitro [30] as well as
in vivo. A fast initial release phase (burst) followed by a second slow release
phase lasting days or weeks and a third rapid release phase is seen in particular
with peptide and protein drugs. The burst release is undesirable in most of the
sustained-drug delivery applications, since the dosage of the potent drug
encapsulated is required to be released over a long period of time. Even a small
percentage of the drug immediately released would increase its local
concentration to an extent near or above that at which the drug becomes toxic in
vivo. The defence mechanism of the body would respond to this increased
toxicity level by forming additional layers of tissues on the polymer surface,
thereby disrupting the entire release profile and mechanism. Any drug released
during the burst stage may be metabolized and excreted without being effectively
utilized as it may not reach its target tissue [31]. Except for vaccines, a tri-phasic
drug release is generally not desirable for most drug therapies. Insufficient drug
may be delivered to maintain the desired pharmacological effect in the slow
release phase and toxicity problems may occur during the rapid initial and third
release phases because of too high drug levels.
The fast initial release (burst) is commonly attributed to drug localised on the
surface of particles [32, 33] or to easily accessible drug, for example, in the case
of highly porous microparticles [34]. Thereafter, a diffusion-controlled slower
release phase follows. Finally, when the molecular weight of PLGA approaches a
certain lower threshold, the weight of the microparticles decreases rapidly and an
erosion-controlled rapid release phase occurs [35]. Recently, the formation of a
nonporous film around the microparticles after incubation in the release medium
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has been reported [34]. The decreased surface porosity of the microparticles led
to reduced drug permeability and resulted in the slow release phase without burst
release.
1.2.3.2. Poly (Ethylene glycol) based Block Co Polymers
The nature of the surface of the nanoparticles largely influences their
biodistribution following in vivo adminstration. Hydrophobic nanoparticles are
rapidly cleared from the systemic circulation by the MPS, ending in the liver or
in the spleen. The hydrophobic nature of most biodegradable particles could limit
the applicability of these carriers in many drug delivery applications. In order to
overcome concerns of clearance by the MPS, surface modification techniques
have been utilised. These modification techniques ultimately produce a particle
that is not recognized by the MPS by rendering the surface of the particle
hydrophilic.
Several types of surface modified nanoparticles have been described in recent
literature. The most common moiety used for surface modification is poly
(ethylene glycol) (PEG). PEG is a hydrophilic, non-ionic polymer that has been
shown to exhibit excellent biocompatibility. PEG molecules can be added to the
particles via covalent bonding or by surface adsorption. The presence of a PEG-
brush on the surface of nanoparticles besides increasing residence time in the
systemic circulation can also reduce protein and enzyme adsorption on the
surface and thus can retard particle degradation. The degree of protein adsorption
can be minimized by altering the density and molecular weight of PEG on the
surface [36]. The stability of PLA particles has been shown to increase in
simulated gastric fluid (SGF) with the addition of PEG on the particle surface.
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After 4 hours in Simulated Gastric Fluid, 9% of the PLA nanoparticles converted
to lactate versus 3% conversion for PEG-PLA particles [37]. PEG is also
believed to facilitate transport through the Payer’s patches of the Gut-associated
lymphoreticular tissue [38]. Usually PEG block co polymers show quite different
properties compared to the constituent polymers lactic acid and glycolic acid.
PLGA – PEG block co polymers are hence used as biomaterials with their own
unique properties and classified as triblock, star block, branched or graft block co
polymers as illustrated in Fig. 1.2 [27, 39-41].
Fig. 1.2. Schematic representation of (a) diblock, (b) and (c )triblock,
(d)multiblock, (e) multiblock branched or comb, (f) star shaped. (Adapted from
[42] )
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PLGA degradation shows autocatalysis wherein bulk degradation occurs with a
decrease in pH resulting from the release of lactic acid and glycolic acid
monomers. The resulting carboxyl groups, oligomeric PLGA etc can increase
degradation of the PLGA formulation. Block co polymers with PEG have also
gained attention as an alternative for overcoming these side effects. Another
main drawback of these polymers is their non specific interaction with cells and
plasma proteins, leading to accumulation in non target cells causing limitations
in practical drug formulations. Hence, surface modified nanoparticles have been
developed to control their interactions. PEG coated (sterically stabilised)
nanoparticles can avoid sequestration by the Mononucleur Phagocyte system
(MPS) and hence show increased circulation time in the body. However, these
coated nanoparticles lack functional groups for ligand coupling. Some successful
attempts have been reported for PEG systems where a terminal functional group
has been added to PEG [43]. Polysaccharide coatings have also been studied
since they are alternative hydrophilic molecules. Some polysaccharides facilitate
mucoadhesion or function as recognition factors allowing recognition. For
example PEG Dextran [30] or Dextran PLA [44].
Biodegradable and biocompatible polymers such as poly (lactide) (PLA) [45],
poly (İ-caprolactone) (PCL) [46], poly (ȕ-benzyl L-aspartate) (PLBA) [47], and
SRO\ȖEHQ]\O/JOXWDPDWH3/%*>@KDYHEHHQFRPPRQO\XVHGIRUWKHFRUH
material of micelles while PEO and PEG are used as hydrophilic blocks. Studies
on polymeric micelles comprised of PEO as hydrophilic block and PCL, PLA,
PLBA, PLBG as hydrophobic block have been carried out by many groups.
Amphiphilic block copolymers have the ability to produce nanoparticles by self
assembling in an aqueous environment [49-51]. The hydrophobic blocks of the
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copolymer form the core of the micelle, while the hydrophilic blocks form the
corona or outer shell. The solubility of the hydrophobic drug in the aqueous
media is greatly increased by the use of micelles. Thus, incorporating a drug in
the micelle is an effective method of preparing an efficient drug delivery system.
1.2.3.3. Polycaprolactones (PCL)
Poly(İ-caprolactone) (PCL) obtained by ring opening polymerisation of İ-
caprolactone was first reported by Pitt et al. [52] for the controlled release of
steroids and narcotic antagonists as well as to deliver opthalmic agents. PCL,
aliphatic polyester has been intensively investigated as a biomedical material. It
demonstrates a low melting point (57°C) and a low glass-transition temperature
(í62°C). Under physiological conditions, PCL can be degraded by micro-
organisms as well as by hydrolysis [3]. Under certain circumstances, it is
possible to enzymatically degrade crosslinked PCL (termed enzymatic surface
erosion). Low molecular-weight fragments of PCL are also reportedly absorbed
by macrophages intracellularly [18]. The rate of biodegradation for PCL is
slower than other biodegradable materials thus making it suitable for design of
long term implantable systems. For example, Capronor, a US FDA approved
contraceptive device. Another interesting property of PCL is its propensity to
form compatible blends with a wide variety of polymers.
Molpeceres et al. studied cyclosporine encapsulation within Polycaprolactone
nanoparticles and reported 95% encapsulation efficiency within the particles.
They also showed that this formulation offered a good alternative to existing
cyclosporine formulations as far as drug monitoring is concerned [53].
Lemarchand et al have reported synthesis of amphiphilic copolymer based on
Dextran grafted with PCL chains which significantly reduced protein absorption
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[54]. Recently, Merle and coworkers reported encapsulation of vancomycin in
biodegradable PCL microparticles for bone implantation [55].
1.2.3.4. Poly (alkylcyanoacrylates)
Poly (alkylcyanoacrylate)s have been used as tissue adhesives in surgery since
these are well tolerated in vivo [56, 57]. Unlike PLA and PGA, here only the side
chains are biodegradable and not the backbone. Their delayed degradation
characteristics thus do not generate an acidic environment during drug release.
This has prompted intense research for their use in many nanoparticle
formulations. Couvreur [56] reported the production of NPs by mechanically
polymerizing the dispersed methyl or ethyl cyanoacrylate in aqueous acidic
medium without irradiation or an initiator in the presence of polysorbate-20 as a
surfactant. Layre et al. studied busulfan entrapment by nanoprecipitation into
five different types of poly (alkyl cyanoacrylate) polymers. The polymers leading
to the highest busulfan loading efficiencies were poly(isobutyl cyanoacrylate)
(PIBCA) and poly (ethyl cyanoacrylate) nanoparticles displaying busulfan
loading ratios equal to 5.9% (w/w) together with nanoparticle yields of 71%
(w/w). The in vitro release studies under sink conditions, in water, or in rat
plasma showed a fast release in the first 10 min followed by a slower one over 6
h [58]. Vauthier et al demonstrated the potential of poly (alkylcyanoacrylate)
(PACA) NPs to overcome multidrug resistance problems at cellular level and in
relation to drug biodistribution [7]. Resistant cells treated with doxorubicin-
loaded poly (alkyl cyanoacrylate) nanoparticles showed a much higher sensitivity
to the drug, relative to the free drug when compared with NPs using other
biodegradable polymers [59]. The mechanism proposed to explain the ability of
doxorubicin-loaded PACA nanoparticles to overcome the resistance to
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doxorubicin in resistant cancer cells was based on the adhesion of the
nanoparticles to the cell surface, followed by the simultaneous release of the drug
and nanoparticle degradation product (poly cyanoacrylic acid) that combine as an
ion-pair able to cross the cell membrane without being recognized by the P-
glycoprotein [60]. To date, only the poly (alkyl cyanoacrylate) nanoparticles
have been identified as to be fulfilling these requirements to overcome the
resistance caused by the P- glycoprotein complex. Lipid nanocapsules prepared
using poly (alkyl cyanoacrylates) were between 25 to 100 nm in size and showed
fast initial release of 60 to 75% in the first 48 hours. However the major
limitations associated with use of this polymer are the particle size, high cell
uptake and toxicity [57]
1.2.3.5. Poly (ortho-esters) (POE)
Poly (orthoesters) is another important group of hydrophobic polymer with drug
delivery applications and are synthesised by the addition of polyols to diketene
acetals. POEs possess acid sensitive orthoester linkages that undergo rapid
hydrolysis at physiological pH and an even faster rate in an acidic pH. Therefore,
incorporation of a small amount of acidic excipients may help to control the
hydrolysis rate. On the other hand, incorporation of basic excipients stabilises the
bulk of the matrix but facilitates erosion at the surface. Wan et al have studied
poly (phosphoester) ionomers as tissue engineering scaffolds [61]. The polymers
conjugated with N- hydroxysuccimide were hydrolyzed in a biphasic mode, with
a fast initial phase occurring in the first few hours, followed by a slower phase in
the next few days. These ionomers represent a novel class of biomaterials with
readily controllable physical and chemical attributes for tissue engineering.
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1.2.3.6. Polyanhydrides (PA)
Polyanhydrides are hydrophobic and contain water sensitive linkages that may
undergo hydrolytic bond cleavage to generate water-soluble degradation
products. Surface erosion takes place due to water sensitive linkages. The
majority of Polyanhydrides studied are based on sebacic acid (SA), p-
(carboxyphenoxy) propane (CPP) and p-(carboxyphenoxy) hexane (CPH) [62].
The Sebacic acid component of biodegradable PAs is utilised as a surface
eroding drug delivery device. A wide variety of drug and proteins have been
incorporated into PAs and their modified forms e.g. poly (anhydride-esters), poly
(anhydride-imides) etc. and their potential release characteristics have been
evaluated [63].
1.2.3.7. Polyamides
Polyamides form another important class of polymers particularly as drug
delivery matrices. Polyamides with a structural resemblance to polypeptides are
used as matrices for the transport of drugs.
Examples include different types of poly (amino acids) [64, 65] such as poly (L-
glutamic acid), poly (aspartic acid) are derived from the corresponding natural
amino acids. Nakanishi and co-workers have developed a polymeric micelle
carrier system consisting of PEG-conjugated doxorubicin: poly (aspartic acid) for
the transport of doxorubicin. This carrier system has a highly hydrophobic inner
core, and therefore, it can also entrap a useful amount of doxorubicin in addition
to the conjugated doxorubicin. It circulated in the blood for a long-time and
evaded RES uptake due to the hydrophilic polyethylene glycol outer layer. It was
effectively accumulated in the tumour tissue by the EPR effect. The entrapped
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Doxorubicin was released from the inner core by diffusion and expressed
stronger activity than free Doxorubicin against all the tumour lines tested [66].
Li and co-workers have synthesised a novel biodegradable poly (ester amide)
derived from 3-morpholine and İ-caprolactone. Increase in morpholine content
enhanced water absorption of the polymers In vitro degradation data and release
profiles of 5-fluorouracil showed that both the degradation rate and drug release
rate increased with an enhanced morpholine content in the polymers [67].
1.2.4. Approaches towards functionalization of polyesters
Extensive studies are been directed towards functionalising polyesters in order to
enhance the range of drugs / molecules that can be incorporated to a significant
extent within the polymeric particles and also to provide a controlled release
profile. Copolymerization of monomers and blending of polyesters have also
been investigated to control physicochemical properties and biodegradation rate.
Most polyesters do not have functional groups that could enhance their potential
applications. Such applications are greatly broadened when functional pendant
groups are incorporated into the polymer backbone. Introduction of functional
groups that can be easily substituted or conjugated with the compound of interest
is a challenge. A number of synthetic approaches have been used to introduce
functional groups, and following are some examples of reported conjugations.
Feijen investigated synthesis of poly (ester amide) with pendant carboxyl or
amine groups polymerised with (D,L) Lactic acid or caprolactone [68]. Barerra et
al synthesised poly (lactic acid-co-lysine) with pendant amino groups. However,
only 2 mol% lysine units were incorporated into the polymer backbone and it
failed to produce a polymer that could be introduced as a successful delivery
system [16]. Zhao et al have reported synthesis of a series of multiblock co
CHAPTER 1 Introduction
17
polymers PLGA-(L- Asp-alt-diol) x – PLGA with different contents of
functional pendant amino groups. Its fabrication into drug encapsulated delivery
system however has not yet been reported [69].
Synthetic pathways to introduce functional groups into degradable polyesters
may follow two general strategies. One is pre-functionalization, in which
functional monomers are prepared prior to polymerization. The other is post-
functionalization, where functional groups are introduced after polymerization.
Thus, a general synthetic
route would involve (1) preparation of protected functional monomers, (2)
polymerization of the monomers, and (3) deprotection
Yao et al. prepared poly [(L-lactic acid)-co-(citric acid)] by direct
polycondensation of L-lactic acid and citric acid to introduce both carboxyl and
hydroxyl groups [70].
Some authors recently demonstrated direct coupling of unprotected functional
groups to the polymer backbone under mild reaction conditions. For example, the
selective coupling between ketone-bearing aliphatic polyesters and aminooxy-
terminated functional groups [71].
Most of the polyesters developed had low molecular weight, which could be
attributed to the poor reactivity of the functional monomers during
polymerization or degradation of the backbone during deprotection of functional
groups [71]. The synthesis of most functional polyesters requires a complex
multistep synthesis of protected functional monomers before polymerization.
Molecular weights of the resulting polymers are usually not high enough for use,
likely because bulky protecting groups decrease monomer reactivity.
Copolymerization of functional monomers with the parent or other monomers
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has thus been studied. However, due to the large differences in monomer
reactivity, incorporation of functional monomers into the polymer chain has not
been easy to control, and the polymers obtained generally have low molecular
weight, large polydispersity, and poor physical properties. Furthermore, the
protecting groups must be subsequently removed prior to further chemical
manipulation, which often causes degradation of the polymer backbone.
Lipases have been used for preparation of polyesters by polycondensation
reactions, with the advantage that the enzyme catalyzed reaction proceeds
without the need for protection of the pendant functional groups.
This background formed the rationale for the synthesis of a novel polyester poly
(glycerol adipate) with the aim of achieving better drug incorporation and
controlled release of a wide range of drugs. Kallinteri et al reported the synthesis
of Poly Glycerol adipate using divinyl adipate and glycerol based on the method
by Kline, The specificity of lipase to acylate only the primary hydroxyl groups
was exploited thus leading to synthesis of polyesters with free secondary
hydroxyl groups that were available for further substitution and modifications.
The polymer yield and configuration was controlled [72]. Jerome et al.
developed İ-CL derivatives via a Baeyer–Villiger oxidation of cyclohexanedione
derivatives, Ȗ-ethylene ketal and triethylsilyloxy-İ-CLs [73]. Deacetalization of
Ȗ-ethylene ketal followed by reduction of the resulting ketone produced a
hydroxyl group. Incorporated triethylsilyloxy groups when hydrolysed further
resulted in hydroxyl group formation. Gimenez and others reported carboxyl-
bearing PCL by extracting Į-hydrogen with lithium N, N-diisopropylamide
followed by the addition of carbon dioxide [74]. A 4-hydroxy-L-proline, was
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also employed as a monomer unit having a pendant amine, and polymerized by
polycondensation after protection of the amine group [75].
Ketal-İ-CL synthesised by Jerome and coworkers seems to be very promising,
due to its comparable ring opening reactivity to İ-CL and ability to produce high-
molecular-weight polyesters. Its potential to produce a successful drug delivery
system is currently under investigation.
Taniguchi et al. employed ketone-bearing PCL as the functionalized backbone to
which PEO side chains were conjugated. They found that PCL- PEO
copolymers with PEO contents above 30 wt% completely inhibit cell adhesion,
and become water
soluble when the PEO content was over 50 wt%. In addition, free hydroxyl end
groups of the PEO side chains allow further chemical manipulations. As an
example, the cell-signalling peptide RGD was conjugated to PEO side chains,
and the resulting RGD-bearing copolymer showed NR6 WT fibroblast adhesion
through receptor-ligand recognition. Use of free hydroxyl groups for drug
conjugation has not yet been investigated [76].
1.2.5. Recent advances in PLGA chemistry for colloidal drug delivery
Jiang et al synthesised a new class of polyanhydrides of alternate poly (ester-
anhydrides) containing a para-hydroxy benzoic acid moiety. This has the
potential to be used as a polymeric prodrug for malaria and hepatitis B. Little
work has been reported on modifying the hydrophobic segments of
homopolymers like PLA or PCL [77]. Haixiong et al developed amphiphilic
block copolymers with PEG as middle block and PCl/PLA copolymers as other
blocks. They studied the effect of changes in caprolactone / lactic acid ratio in
the hydrophobic blocks on size, encapsulation efficiency and release of
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nimodipine. The PCL block favours chain flexibility and lowered bulk modulus
while the PLA block increases the rate of biodegradation thus resulting in
particles with good permeability and favourable biodegradability [12] .
The self assembling characteristics of elastin like proteinaceous polymers was
explored by Vanrell et al. in their study with poly (L-valine-L-proline-L-alanine-
L-valine-L-glycine) (VPAVG), forming stable microparticles that could be used
as vehicles for controlled release formulations. Mucoadhesive polymers have
been studied for targeting to the mucus covering the intestinal epithelium [6].
Prego et al encapsulated calcitonin within chitosan nanocapsules [78].
Amphiphilic diblock co polymer micelles are reported to be effective for
hydrophobic drugs, either by covalent coupling to the block co polymer or by
physical incorporation within the hydrophobic cores [79]. Polymer drug
conjugation is gathering attention to improve physicochemical and
biopharmaceutical properties of drugs like Paclitaxel (PTx), Adriamycin etc.
Poly (aspartic acid)-PEG evaluated as a carrier showed high drug loading and
long circulation time for adriamycin [80, 81]. Methoxy (PEG) PLA, PLGA or
PCL copolymers, poly glutamate, albumin etc have been conjugated with PTx as
carriers [82-84]. Major limitations however are obtaining drug derivatives and
functional polymers with suitable chemical functional groups, physicochemical,
biopharmaceutical properties and the multistep reactions necessary to obtain
conjugates [84].
Novel biodegradable polyesters, consisting of short poly (lactone) chains grafted
onto poly (vinyl alcohol) (PVA) or charge-modified sulfobutyl-PVA
biodegradable. (SB-PVA) were prepared by bulk melt polymerization of lactide
and glycolide in the presence of core polyols. The modified backbones were
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obtained by reacting the activated PVA with the sulfobutyl groups. These
polymers undergo spontaneous self-assembly to produce NPs, which form stable
complexes with a number of proteins such as human serum albumin and
cytocrome C. [85].
1.2.6. Methods of preparation
1.2.6.1. Emulsification Solvent Evaporation
The most common method used for the preparation of solid, polymeric
nanoparticles is the emulsification–solvent evaporation technique. The
preparation of particles by the classical method follows the general protocol of
dissolving the polymer in a water immiscible, volatile organic solvent which is
then emulsified with an aqueous phase to stabilise the system. The organic
solvent is then evaporated inducing the formation of polymer particles from the
organic phase droplets. The solvent evaporation method was described by Niwa
et al and has since been widely used to prepare particles from a range of
polymeric materials, particularly PLA and PLGA [86]. This technique has been
successful for encapsulating hydrophobic drugs. However, results for
incorporation of hydrophilic bioactive agents have been poor. A modification of
this procedure has led to the protocol favoured for encapsulating hydrophilic
compounds and proteins viz., the double or multiple emulsion technique. First, a
hydrophilic drug and a stabilizer are dissolved in water. The primary emulsion is
prepared by dispersing the aqueous phase into an organic solvent containing a
dissolved polymer. This is then reemulsified in an outer aqueous phase also
containing stabilizer [6, 45, 87-89]. From here, the procedure for obtaining the
nanoparticles is similar to the single emulsion technique for solvent removal. The
main problem with trying to encapsulate a hydrophilic molecule like a protein or
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peptide-drug is the rapid diffusion of the molecule into the outer aqueous phase
during the emulsification.
Several parameters can influence the properties of the particles produced, these
parameters include:
- nature of polymer
- polymer molecular weight
- nature of organic phase
- polymer concentration in the organic phase
- volume ratio of organic: aqueous phase
- nature of surfactant
- surfactant concentration and molecular weight
- stirring speed.
The main drawback of this method, besides the problem of preparing particles
which are sub 200 nm in diameter is the need for the removal of excipients post
production. Any residual organic solvents will have toxicological implications.
In addition the excess surfactant used is difficult to remove. Another limitation is
that surfactant must be present for preparation of nanoparticles in order to
stabilize the system. Particles therefore cannot be produced naked and then post
adsorbed with a surfactant. polyvinyl alcohol (PVA) is most frequently used as a
stabilizing emulsifier to fabricate nanoparticles. However, PVA has some
problems in that it remains at the surface of the nanoparticles and is difficult to
remove subsequently. It is known that PVA existing on the surface of
nanoparticles changes biodegradability, biodistribution, particle cellular uptake,
and drug-release behaviour [90].
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1.2.6.2. Interfacial Polymer Deposition (IPD) Method
The IDP method was first described by Fessi et al [91]. The technique involves
addition of polymer, dissolved in a water miscible solvent (usually acetone) into
an aqueous non solvent under stirring. The non-solvent is usually an aqueous
surfactant or drug solution without surfactant. The rapid diffusion of solvent into
the aqueous phase causes a decrease in the interfacial tension between the two
phases which, together with the increased interfacial surface area created by the
turbulence, results in the formation of small droplets of organic solvent without
the need for high shear mechanical stirring. The solvent then diffuses further into
the aqueous phase and water concurrently diffuses into the solvent droplets,
resulting in the formation of polymer particles from the droplets. Particles are
stabilised by a layer of polymer deposited at the interface. Thus, polymer
properties may alter the physicochemical properties at the interface as explained
in the Marangoni effect [92].
Decreased miscibility of organic solvents with water is associated with an
increase in their resultant interfacial tension and thus increases the size of the
particles. The higher the viscosity of the organic phase, the greater the surface
tension and hence the size of the particles. An increase in molecular weight of
polymers is associated with a decrease in the number of end carboxyl groups and
hence lowers the zeta potential of the resulting particles. Additives present in the
formulation may also significantly affect this surface charge. Carla et al studied
PLA nanocapsules in the presence and absence of lecithin. PLA with high
molecular weight (109 and 251 kDa) yielded poorly stable nanocapsules larger in
size and susceptible to aggregation. In the presence of lecithin, polymer charges
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were masked and zeta potential was determined by amount of lecithin present on
the outer surface either mixed with or surrounding the polymer film [93].
The presence of surfactant in the system acts as a stabilizer to prevent
coalescence of the droplets. However Fessi et al reported that particles could be
prepared using his method, in presence of water alone as the aqueous phase.
Paclitaxel and mPEG-PLGA nanoparticles prepared without surfactant exhibited
a smaller size and higher encapsulation efficiency. Surfactants like PVA were
important to form nanoparticles in a technique like emulsification as here they
prevent coalescence of newly formed droplets. However, Pluronic F-68 like
surfactants may be added to improve steric stability of particles produced by the
IPD method but are not primarily responsible for formation of particles [94].
A distinct advantage of the IPD method is that there are no residual solvents left
in the system, which is important from a toxicological point of view. Another
advantage, from the viewpoint of using particles as a drug carrier, is that the
particles produced are in the nanometer size range. Fessi et al prepared particles
below 200 nm, and PLGA particles have been prepared which are sub 100 nm. In
addition, the samples exhibit low polydispersity and the preparation of particles
in the absence of surfactant allows the effect of post adsorption of surfactants. In
particular, the in vivo behaviour of the coated and uncoated particles can be
compared in order to determine the role of coating surfactant in preventing
particle recognition by the Mononuclear Phagocytic System (MPS).
1.2.6.3. Spray Drying
In the classical spray drying technique the polymer and drug are dissolved in an
organic solvent and sprayed through a fine nozzle. Solid, spherical particles form
on the immediate evaporation of the solvent. High temperatures are generally
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employed in this process, which can create problems, particularly in the
encapsulation of peptides, and proteins that are easily denatured. Spray drying
produces particles that are in the micrometer size range and hence will not be
considered further here.
1.2.6.4. Salting Out
Bindschaedler and co workers patented this technique in 1988 [95]. The
technique involves the preparation of particles by an emulsification technique but
avoids the use of chlorinated solvents. In brief, a saturated salt solution
containing a stabilizing agent such as PVA is added under stirring to an acetone
solution of the polymer. An o/w emulsion forms as the salt prevents the water
and acetone mixing. Sufficient water is then added to allow the acetone to diffuse
into the external aqueous phase and induce particle formation. Allemann et al
used this technique to prepare Savoxepine nanoparticles. From the perspective of
drug encapsulation, this method is most appropriate for water insoluble
compounds, although the loading of water-soluble compounds can be improved
by techniques such as altering the pH of the aqueous phase [96]. Salts permeate
biological systems and are crucial for life. However, salts also affect the stability
of proteins. It has been reported since many years that neutral salts perturb
various protein structures in ways that go well beyond simple, nonspecific charge
effects [97].
1.2.6.5. Supercritical fluid expansion method
Recently the field of supercritical fluids has been investigated as an approach to
the preparation of sub micron sized particles [94].
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The rapid expansion of supercritical solutions consists in saturating a
supercritical fluid with the substrate(s), then depressurizing this solution through
a heated nozzle into a low pressure chamber in order to cause an extremely rapid
nucleation of the substrate(s) in form of very small particles or fibres, or films
when the jet is directed against a surface that are collected from the gaseous
stream. The major merits of these processes include: production of organic-
solvent free particles, mild operating temperatures for processing biological
materials, and easier micro-encapsulation of drugs for controlled release of the
therapeutic agents [98]. Unfortunately, none of these techniques can produce
small protein particles in the sub-micron range less than 300 nm having a very
narrow size distribution. Fine particles of model compounds cholesterol acetate
(CA), griseofulvin (GF), and megestrol acetate (MA) were produced by
extraction of the internal phase of oil-in-water emulsions using supercritical
carbon dioxide [99].
1.2.6.6. Complex Coacervation
Complex coacervation is a phase separation process that spontaneously occurs
when two oppositely charged polyelectrolytes are mixed in an aqueous solution.
Compared to other methods, this process can be performed entirely in an aqueous
solution and at low temperature and thus has a better chance to preserve activity
of the encapsulated substances. The colloidal particles produced are in the
nanometer or micrometer scale depending on the substrates or the processing
parameters used for example; pH, ionic strength and polyelectrolyte
concentrations [100-102]. The major drawback of this technique is that complex
coacervates have low drug loading efficiency and poor stability. Therefore,
crosslinking of the complex by chemical reagents such as toxic glutaraldehyde is
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necessary. Jiang B et al have reported a modified method called ‘co-
precipitation’ where they chose positively charged and water-soluble Dextran as
a coating layer [103]. The process included precipitation of negatively charged
Ibuprofen in a supersaturated solution and deposition of Dextran onto the
precipitated Ibuprofen particles through electrostatic interaction.
1.2.7. Drug Release Mechanisms
Nanoparticles exhibit their special drug delivery effects in most cases by direct
interaction with their environment, i.e., their biological environment. Drug
release may occur by-
x Desorption of surface bound drug
x Diffusion through the nanoparticle matrix
In the case of Nanocapsules, diffusion through the polymer wall
x Nanoparticle matrix erosion
x A combined erosion diffusion process.
Biodegradable materials are intended to degrade within the body after the release
of the active agent has been completed. This eliminates the need for removal of
the material after drug release.
Extensive research has been dedicated towards the hydrolytic degradation
characteristics of PLA homo- and copolymers in recent years [104]. Internal
autocatalysis is a characteristic phenomenon which results in a concentration
difference in carboxyl end groups between the surface and the centre. PLA
samples that were thicker degraded more rapidly inside than at the surface [105].
The enzymatic degradation of PLA has also been extensively investigated during
the past two decades, and among numerous selected enzymes, proteinase K,
pronase, and bromelain have an acceleration effect on the degradation of PLA
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[106]. Further studies have reported that proteinase K degraded l-lactyl units
preferentially while d-lactyl ones are biostable [104].
Surface biodegradable polymers include polycarbonates, polyanhydrides, and
polyorthoesters. Their matrices were highly hydrophobic, and unstable chemical
bonds exist in the polymer main chains [107]. Degradation studies on pure
polymer implants have shown that solid-state morphology and the polymer
composition (homo- or co-polymers of lactic or glycolic acid), tacticity (D - or L
isomers, racemic mixtures of D, L) can influence polymer degradation [105].
Polymer properties such as molecular weight, crystallinity and glass transition
temperature also control the degradation rate of the polymers. Studies have
shown that the choice of dissolution conditions under which the degradation
process is studied can also influence the degradation process [108].
Most biodegradable polyesters are designed to degrade as a result of hydrolysis
of the polymer chains into biologically acceptable, and progressively smaller,
compounds. For example, polylactides, polyglycolides, and their copolymers
eventually break down to lactic acid and glycolic acid, enters the Kreb's cycle,
and is further broken down into carbon dioxide and water and excreted through
normal processes. Kenley et al extensively studied quantitative correlations
between PLGA physical / chemical properties and degradation rates. For PLGA
50:50 they concluded that polymer erosion proceeds via internal, not surface
hydrolysis. Dissolution, polymer erosion and molecular weight degradation at
37°C, pH 4.5, to 7.4 in vitro accurately model the processes in vivo, and PLGA
degradation adheres to pseudo-first-order kinetics governed by the rate of
macromolecular ester bond cleavage. Also, PLGA erosion initially does not
parallel macromolecular bond heterolysis. Therefore directly relating polymer
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erosion to parameters (e.g. 1actide: glycolide ratio) that control the bond
cleavage kinetics is potentially misleading [109]. Secondly, the (presumably
acidic) microenvironment interior to hydrolyzing PLGAs could potentially
accelerate the degradation of drugs or other materials dispersed throughout the
PLGA matrix material.
Polyamides: Although polyamides contain the same amide linkage that is found
in polypeptides, their rate of biodegradation is much lower than the
polyaminoacids. It is so slow that often they are reported to be nondegradable.
The higher crystallinity of polyamides due to strong interchain interactions (as
compared with the more flexible polyesters with analogous structures), is
responsible for lower rates of biodegradation. Copolymers with both amide and
ester groups are generally found to be readily degraded [110]. The rate of
degradation increases with increasing ester content.
Polyurethanes: Polyurethanes can be considered to have the structural
characteristics of both polyesters and polyamides. Although polyureas might be
viewed as poly (diamides), their susceptibility to biodegradation can be expected
to be similar to that of polyesters and polyamides, with differences in rates. In
general the biodegradability of polyurethanes was shown to be dependent on
whether the prepolymer is a polyester or a polyether [111]. The polyether-based
polyurethanes are resistant to biodegradation whereas the polyester
polyurethanes are readily attacked. It has been observed that the degradation rate
increases with increasing polyester segment length. It has also observed that
polyurethanes derived from aliphatic diisocyanates are degraded faster than those
derived from aromatic diisocyanates [112].
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Aliphatic polyanhydrides degrade within a few days while aromatic
polyanhydrides can degrade slowly over a period of several years. An increase in
the aliphatic chain length between the acid groups not only increases their
molecular weight but also notably improves their hydrolytic stability [113].
Poly (alkyl acrylates) and polycyanoacrylates generally resist biodegradation.
However, they are often referred to as ‘biodegradable’ referring to the loss of the
alkyl chain. Poly (methyl-2-cyanoacrylate) is the most degradable among the
alkyl esters; degradability decreases as alkyl size increases [114].
Thus, depending upon the polymer chemistry, degradation may take place
through bulk hydrolysis, in which the polymer degrades in a fairly uniform
manner throughout the matrix (see Fig. 1.3 a) or in case of polyanhydrides and
polyorthoesters, through surface degradation, in which rate of release is
proportional to surface area of the particles (see Fig. 1.3 b).
Fig. 1.3. Drug delivery from (a) bulk-eroding and (b) surface-eroding
biodegradable systems.
The type of polymer and design of the system (composition and geometry)
controls different physicochemical processes involved in the rate of drug release.
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Thus, the erosion of the polymer may play an important role. In surface eroding
systems, polymer degradation is much faster than the water imbibition into the
polymer bulk. Thus, degradation occurs predominantly within the outermost
polymer layers. Consequently, erosion affects only the surface and not the inner
parts of the system (heterogeneous process). In contrast, bulk eroding polymers
degrade more slowly and the imbibition of water into the system is much faster
than the degradation of the polymer. Hence, these polymers are rapidly wetted
and polymer chain cleavage occurs throughout the system. Consequently, erosion
is not restricted to the polymer surface only (homogeneous process). As a basic
rule, polymers containing very reactive functional groups tend to degrade fast
and tend to be surface eroding, whereas polymers with less reactive functional
groups tend to be bulk eroding. PLGA-based microparticles can generally be
regarded as bulk eroding dosage forms [115].
The release mechanism, the diffusion coefficient, and the biodegradation rate are
the main factors governing the drug release rate. The release rate of drugs is also
strongly influenced by the biological environment. This environmental influence
is far more important in larger dosage forms; nanoparticles may be coated by
plasma proteins, which can establish a significant additional diffusion barrier and
lead to a retardation of release [116]. Nanoparticles also interact with biological
or artificial membranes, in this case leading to an enhanced delivery of drugs
through these membranes in comparison to a simple solution. As a consequence
it has been frequently observed that in vitro drug release may have very little in
common with the delivery and release situation in vivo. Nevertheless, for
characterization purposes and for quality control reasons, the determination of
the in vitro release of drug from nanoparticles is important.
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The characterization of the in vitro drug release from a colloidal carrier is
technically difficult to achieve. This can be attributed to the inability of effective
and rapid separation of the particles from the dissolved or released drug in the
surrounding solution owing to the small size of the particles [109].
1.2.7.1. Methods of determination of drug release
The following methods for the determination of the in vitro release have been
used:
1. Side by side diffusion cells with artificial or biological membranes
2. Dialysis bag diffusion technique
3. Reverse dialysis sac technique
4. Ultracentrifugation
5. Ultra filtration (Centrifugal) technique
The dialysis technique is a very popular method to study the release of drugs
from colloidal suspensions. The limits of this technique have been discussed by
Washington [117], who reported that the colloidal dispersions were not diluted
inside the bag. The release rate of the drug and its appearance in the dissolution
medium is governed by the partition coefficient of the drug between the
polymeric phase and the aqueous environment in the dialysis bag and by the
diffusion of the drug across the membrane as well. This technique thus allows
the comparison of different formulations.
1.2.7.2. Factors affecting Drug Release
x Water permeability and solubility (hydrophilicity/hydrophobicity)
x Chemical composition
x Mechanism of hydrolysis (non catalytic,autocatalytic,enzymatic)
x Additives (acidic,basic,monomers,solvents,drugs)
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x Morphology (crystalline, amorphous)
x Device dimensions (size, shape, surface to volume ratio)
x Porosity
x Glass transition temperature (glassy, rubbery)
x Molecular weight and molecular weight distribution
x Physio-chemical factors (ion exchange, ionic strength, pH)
x Sterilization
x Site of implantation
Table 1.2. Factors affecting hydrolytic degradation behaviour of polyesters
[118].
Besides polymer erosion, a number of interrelated factors govern rate of release
from particles (Table 1.2). Mainly the physicochemical properties associated
with particles such as size, shape, porosity, morphology etc. These, in turn are
influenced by a variety of factors, for example; method of preparation,
formulation parameters to name a few.
1.2.7.2.1. Particle size
As reported by Washington [117], for particles only a few hundred nanometres in
diameter the release can be very rapid with a very high rate of release due to the
large surface area of the particles. Larger particles have a smaller initial burst and
longer sustained release than smaller particles [119]. Increased size and zeta
potential of particles may enhance uptake of particles by the Reticulo -
Endothelial System (RES) while decrease in size and increase zeta potential may
lead to increased stability of the particles. Size also affects fate of the particles
after administration. Smaller particles accumulate in tumour sites due to
facilitated extravasation and greater endocytosis also occurs. Size less than 200
nm greatly reduces filtering and uptake by the spleen. In their study with
chitosan nanocapsules encapsulating calcitonin (CT) Prego et al found that size
of the capsules depends upon chain length of chitosan, it decreased with increase
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in molecular weight of chitosan. They found similar zeta potential values
irrespective of chitosan molecular weight, but an increase in the initial amount of
oil phase decreased the surface charge. Oligomers showed no release for 6 hours
while 20% calcitonin was released rapidly with the medium molecular weight
chitosan. Lack of fast release from oligomers may again be due to reduced
amount of chitosan on the coating and less interference with calcitonin binding
[78].
1.2.7.2.2. Nature of drug/ additives
Besides particle size, many other parameters have been shown to affect the drug
release profiles. The nature of the drug or other additives is obviously very
influential and log P, pKa and molecular weight are some of the important
parameters. Additives through their acidic or basic nature as well as loading level
in the case of therapeutic agents may markedly affect the degradation rate of
microspheres. Maulding et al have reported on the acceleration of microsphere
degradation rates by incorporation of a tertiary amino compound, thioridazine.
They suggested that the nucleophilic nitrogen of the thioridazine base
participated in the degradation of ester bonds as little effect was seen when the
amino group of thioridazine was protonated and the salt (pamoate) was
incorporated in the microspheres [120].
Basic compounds can catalyze ester linkage scission and thus accelerate polymer
degradation. On the other hand, appropriate amounts of basic compounds can
neutralize carboxyl end groups and thus decrease the rate of degradation. In a
study by Li on degradation of PLA in the presence of caffeine it was found that
in the early stages basic catalysis occurs by caffeine as only a few carboxyl
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groups were present and the molecular weight of the matrix was high. As
degradation proceeded, new carboxyl end groups were formed, caffeine was
provided with more chances for interaction with carboxyl end groups and thus
neutralization of the newly formed carboxyl groups became the main factor
responsible for decreasing the rate of degradation [121]. This potential effect by
the acidic / basic nature of the therapeutic agent incorporated in the microspheres
must be considered in the design of the delivery system.
The degree of drug loading is often correlated with the release profile, especially
since the drug may be crystallized in the carrier matrix at high loadings. For
example, PLA nanoparticles containing 16.7% savoxepine released 90% of their
drug load in 24 h as opposed to particles containing 7.1% savoxepine which
released their content over 3 weeks [122].
Some studies have investigated inclusion of various additives that enhanced drug
incorporation and eventually controlled drug release. Encapsulation efficiency of
propafenone HCl in PEG-g-PLA polymer prepared without triethyleneamine
(TEA) was 10%. It increased to 43% with the use of TEA probably due to the
scavenging action of TEA on Propafenone HCl. This set free the pure
hydrophobic base and enhanced its interaction with the hydrophobic PLA core of
the polymer [123]. Okada et al have also shown that increased interactions
between carboxyl groups of PLA and amino groups of basic drugs like
leuprorelin acetate enhances their encapsulation efficiency and reduces rate of
release [124]. The rate of release is also influenced by the method of drug
loading. Fresta et al reported 60 to 70% initial burst for particles incorporating
drug by adsorption. Thus, a method of incorporating drug into the matrix
provides more sustained release profile [125].
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For chemically conjugated drug, release occurred over a period of 25 days
compared to unconjugated drug where all drug release takes place within 5 days
[126]. Also, release of conjugated drug will be influenced by the chemistry of
attachment to the polymer.
1.2.7.2.3. Polymer properties and drug loading
The parameters of the polymer can be selected to influence the release profile.
With PLGA for example, the molecular weight, crystallinity and lactide:
glycolide ratio can be chosen to alter drug release. Duan et al synthesised
monomethoxypolyethylene glycol-PLGA monomethoxypolyethylene glycol
(mPEG-PLGA-mPEG) nanoparticles using mitoxantrone as a model drug [127].
PLGA co polymers with varying molar ratios of lactic acid to glycolic acid and
different molecular weights and contents of mPEGs were synthesised and
evaluated. They found that the amount of mitoxantrone released increased as
mPEG contents increased and the molar ratio of lactic acid decreased. Increase in
drug loading led to a slower release rate than from lower drug loading. Increased
drug loading was observed with increased lactate ratio. Thus, increased lactic
acid led to an increase in hydrohobicity that enhanced drug loading and
decreased rate of drug release. Also, lower the molecular weight of the polymer
faster is the degradation and drug release rate. Higher molecular weight polymers
have a lower number of carboxyl groups and hence decreased solubility. Higher
water solubility of the polymer contributes to lower surface tension and
decreased size which may be responsible for an increase in the rate of release
[128]. To minimise this effect in the pre nanoparticle formation stage several
researchers have explored the possibility of modifying the backbone in order to
decrease burst effect. Hata et al patented a sustained release preparation wherein
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they substituted a 2(N- benzylcarbonyl) - aminoethanol group to the terminal
carboxyl end of PLGA and reported improved rate of incorporation of a
bioactive substance containing acidic groups. They also observed that this
modification suppresses drug leakage early after administration, and exhibits
constantly suppressed release for an extended period of time [129]. Oh et al
conjugated the hydrophobic fluorenylmethoxycarbonyl (FMoc) protected amino
acid tryptophan (Boc-try) to the hydroxyl end of PLGA. They hypothesised that
when conjugated PLGA chains are randomly hydrolysed water soluble fractions
are leeched out and drug bound to terminal ends of cleaved PLGA will be
released concomitantly. Further in vitro and in vivo studies are reported to be in
progress [130].
After water imbibition into PLGA-based microparticles, drug dissolution and the
cleavage of the hydrolytically unstable ester bonds occurs. Simultaneously, the
drug diffuses out of the device due to concentration gradients. Drug diffusion can
occur: (i) predominantly through the polymer matrix; (ii) predominantly through
water-filled pores; or (iii) through both, the macromolecular network and water-
filled cavities in parallel and/or in sequence [131]. Several researchers have tried
to explore the mechanisms of burst and prevent it by several methods such as
surface coating of the polymer [19, 132, 133], changing the surfactant [130],
changing the molecular weight of the polymer [88] etc.
1.2.7.2.4. Porosity
Altering the porosity of the particles also affects the drug diffusion and polymer
degradation rate. Lemaire suggested that if a drug molecule is present within a
network of micropores it will have to diffuse towards the closest pore to be
released outside. Movement of the drug within the porous media is highly
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restricted due to limited space available and is influenced by diffusivity of drug,
porosity and tortuosity of matrix [134]. Rapid release of savoxepine and estradiol
from P(DL)LA nanoparticles prepared using the salting out method and release of
dexamethasone from PEO-P(DL)LA nanoparticles have been explained by
presence of pores in the particles [135-137]. The presence of pores and a high
water uptake of PEO-PLGA nanoparticles led to high permeability of drug in the
polymer matrix. The release was rapid and was complete within 5 hours for the
untreated nanoparticles [136].
1.2.7.2.5. Method of preparation
The method of preparation also plays an important role in drug release. NP
preparation by o/w emulsion is a complex process in which organic solvent
generates pores in the structure on evaporation which may then lead to a change
in the microstructure of NPs and affect their release kinetics. In addition, the
products generated by polymer degradation can significantly alter the
microenvironment conditions, e.g., the H
+
concentration within the system.
Lactic and glycolic acid resulting from the degradation of PLGA polymers can
lead to significantly decreased pH values in the core matrix [137]. As the
degradation of PLGA is catalyzed by protons, this decrease in pH can lead to
autocatalytic effects and thus, to accelerated polymer degradation [138].
Furthermore, degradation products of polymer can crystallise within the core
leading to modified porosities which can enhance their diffusion [139].
Depending on their solubility and the respective microenvironmental conditions,
these degradation products subsequently dissolve more or less rapidly and
diffuse out of the device. At a critical time-point, the polymeric structure of the
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system becomes unstable and leads to the breakdown of the macromolecular
network.
The nature of organic solvent used is also influential in rate of release. For
example, solubility of dichloromethane (DCM) in water is low. After formation
of a primary emulsion DCM gradually diffuses out of the nascent particles,
dissolves in the water and disperses. Slow evaporation leads to good spherical
particles with a porous microstructure. Acetone, due to its high miscibility
dissolves faster in the aqueous phase and hence irregular shaped particles are
formed. When used in combination to form the organic phase, dispersion of the
water soluble solvent would result in a decreased surface tension and size [140].
Increase in water insoluble solvent would lead to further size reduction without
pores. This would also lead to an increased drug loading and decreased rate of
release. Finally, it should be highlighted that the nature of release medium is
extremely important. As yet, there is no defined in vitro dissolution test for
colloidal particles intended for potential administration and as a result, many
types of release medium have been used.
1.2.7.2.6. Physical state of drug and polymer
Physical state of the drug inside the nanoparticles plays a key role in the drug
diffusion from nanoparticles. An amorphous form of the drug may lead to an
increase in the rate of dissolution of the drug. Amorphous materials do not have
any long range order such as crystal lattice as crystalline materials do. They have
a higher internal energy, a larger free volume, and greater molecular mobility in
comparison to the crystalline state. These properties are responsible for greater
solubility and hence fast release. Small drug molecules can also easily crystallise
and consequently both crystalline and amorphous state are possible.
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The physical state of polymer is also instrumental in influencing drug release
rate. Amorphous or crystalline drug may be present in either amorphous or
crystalline polymer. The DSC technique can provide qualitative and quantitative
information about the physicochemical status of the drug in the particles, which
may be involved in either an endothermic or exothermic process [141]. The
related thermal transitions include melting, recrystallization, decomposition, out-
gassing, or a change in heat capacity. DSC is useful to monitor different samples
of the same material to assess their similarities or differences or the effects of
additives on the thermal properties of a material. Using DSC analysis of drug,
polymer materials and the resulting nanoparticles, the nature of the drug inside
the polymer matrix can be assessed, which may be present in a solid solution,
metastable molecular dispersion or in a crystalline form and may display relevant
properties during in vitro release. There is no detectable melting endotherm if the
drug is present in a molecular dispersion or a solid solution state in the polymeric
microspheres loaded with sufficient drug. When the glass transition temperature
(Tg) of polymer is higher than ambient temperature, the polymer is in a glassy
state and the material is brittle and hard. Below the Tg polymer is in a rubbery
state and hence promotes mobility and release of drugs. Drugs or additives if
well dissolved in the particles may act as a plasticizer and reduce the Tg of
nanoparticles. On the other hand, a crystalline form may act as reinforcing filler
and cause an increase in Tg. [142, 143].
1.2.8. Drug Loading
A successful NP system may be one which has a high loading capacity to reduce
the quantity of the carrier required for administration. Drug loading into NPs is
achieved by two methods: one, by incorporating the drug at the time of NP
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production or secondly, by adsorbing the drug after the formation of NPs by
incubating them in the drug solution. A larger amount of drug can be entrapped
by the incorporation method than by adsorption. Couvreur et al reported the
adsorption of two antineoplastic drugs viz, dactinomycin and methotrexate onto
(poly methylcyanoacrylate) and poly (ethylcyanoacrylate) nanoparticles [112].
The capacity of adsorption is thus related to the hydrophobicity of the polymer
and the specific area of the NPs. In the case of entrapment methods, an increase
in concentration of the monomer increases the loading efficiency of drug, but a
reverse trend is observed with an increase in the initial drug concentration in
solution [144].
In addition to adsorption and incorporation, an alternative method of drug
loading was proposed by Yoo and co workers [126]. In this method, the drug was
chemically conjugated to the NPs. The conjugated doxorubicin–PLGA and
doxorubicin-loaded PLGA NPs were prepared by the spontaneous emulsion–
solvent diffusion method. An encapsulation efficiency of 96.6% and drug
loading of 3.5% of doxorubicin–PLGA conjugate were achieved. For the
unconjugated doxorubicin, these values were 6.7% and 0.3% (w/w) respectively.
In a study of encapsulation of calcitonin within Chitosan oligomer,
encapsulation efficiency within the nanocapsules was higher (60%) than when
prepared using medium molecular weight chitosan polymer (44%). This was
attributed to a lower amount of chitosan oligomers forming a coat on the
preformed nanoemulsion compared to medium MW chitosan, thus competition
to associate with the nanoemulsion surface was less and more peptide got
incorporated [78]. Watanabe et al studied the entrapment of various charged and
uncharged molecules within chitosan nanospheres. Chitosan is polycationic in
CHAPTER 1 Introduction
42
nature. Texas red, DNA (negatively charged), Ovalbumin (amphoteric), Trypsin
(positively charged) were successfully incorporated within the nanospheres.
However, there was no entrapment of FITC-dextran (non ionic) [128]. Thus,
electrostatic interaction plays a pivotal role for use of this polymer as a carrier
system and hydrophobic interaction only rarely contributes to entrapment into
these nanoparticles. They also found that the encapsulation efficiency influenced
the size and zeta potential to a small extent as the negatively charged compounds
were incorporated to a greater extent and formed particles slightly larger in size.
Zeta potential varied depending on the charge of the incorporated compound.
1.2.8.1. Factors affecting encapsulation efficiency
The extent of drug entrapment in the polymeric core by physical means is
dependent on several factors, including the molecular volume of the solubilizate,
its interfacial tension against water, length of the core and shell-forming blocks
in the copolymer, and solubilizate concentration [145]. The partition coefficient
of the hydrophobic molecule between the micellar core and surrounding aqueous
medium describes the extent of drug entrapment in polymeric micelles. The
greatest degree of solubilization occurs when high compatibility exists between
the micellar core and the solubilizate, assessed by the Flory–Huggins interaction
SDUDPHWHU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In the case of PLGA / PLA nanoparticles with a suitable size for intravenous
administration, major obstacles to clinical use include the complicated process of
preparation and the low encapsulation efficiency of bioactive molecules. The
efficiency of encapsulating bioactive molecules into PLGA / PLA microparticles
/ nanoparticles largely depends on the physical properties of the molecules.
Chemical modifications of bioactive molecules such as esterification increase
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their encapsulation efficiency, but may decrease their bioactivity. Drug-loading
of ketoprofen-containing biodegradable and biocompatible poly (DL-lactic-co-
glycolic acid) (PLGA) microspheres, prepared by the solvent evaporation
method, were investigated by Gabor et al [146]. For both drug-free and drug-
loaded microspheres; smaller microspheres with a narrower size distribution
were obtained when the stirring rate or the volume of the organic phase was
increased. Incorporation of ketoprofen was found to increase with increasing
volume of the organic phase and decreasing pH of the aqueous phase, but was
independent of the acidity and the inherent viscosity of the PLGA used.
Formulations involving solvated ȕ-estradiol (especially using ethyl acetate)
showed maximum encapsulation of hormone within PLGA microparticles when
compared with formulations without ethyl acetate. Also, the organic phase used
was a mixture of dichloromethane/methanol, as the methanol quickly partitioned
to the aqueous phase [147]. The ratio of dichloromethane / methanol played an
important role in the encapsulation of the drug. The ȕ-estradiol is considerably
more soluble in the co-solvent system than just methanol. Thus, relatively large
quantities of drug could be dissolved in the co-solvent that otherwise would not
dissolve in methanol alone. Encapsulation of solid ȕ-estradiol was also enhanced
by making the dispersed phase more viscous. Reducing the volume of the
organic solvent used (DCM) would serve to increase the viscosity of the
dispersed phase as well as decrease the microparticle hardening time. Both
factors result in enhancing the encapsulation of the solid drug [147]. Molecular
weight and concentration of polymer used can also affect the encapsulation
efficiency of drugs. The molecular weight of the polymer has contradictory
effects on nanoparticle size and encapsulation efficiency. Smaller size
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nanoparticles can be prepared with lower molecular weight polymer, but, at the
expense of reduced encapsulation efficiency. On the other hand increase in
polymer concentration increases encapsulation efficiency and size of
nanoparticles [88, 148].
Thus, we can see from the literature review that over the last 20 years, increasing
attention has been paid to synthetic aliphatic polyesters derived from lactones,
lactides, and glycolide for applications in medicine and surgery. Nevertheless the
shortage of polyester chains bearing functional pendent groups is a severe
limitation to further progress in the field. Indeed, the availability of functional
pendant groups is highly desirable for enhancing drug incorporation and
lowering burst release especially for water soluble drugs along with the fine
tuning of properties in view of, e.g., attachment of drugs, improvement of
biocompatibility, and promotion of bioadhesion. However, chemistry involved in
the synthesis of the functional monomer is most often complex and / or tedious,
whereas the subsequent polymerization is generally out of control [133].
We have investigated poly (glycerol adipate) polymers synthesised by a lipase
catalysed reaction to provide a polymer backbone with pendant hydroxyl groups.
It is the presence of these free pendant hydroxyl groups on the backbone that
allows for substitution of different functional groups and thus modifies the
properties of the backbone. NPs were prepared using a combination of various
substituted polymers. The drugs used were mainly anticancer drugs and
belonging to different classes; water soluble Dexamethasone phosphate, Cytosine
arabinofuranoside, Etoposide phosphate and water insoluble Etoposide and
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Paclitaxel. Results presented in this study are of the polymer backbone in its
unsubstituted form along with a library of substituted polymers namely acyl
substituted and aromatic amino acid substituted polymers. These were evaluated
for drug incorporation and release. Thus, besides investigating the potential of
this polymer for use as a promising drug carrier system this study also helps to
obtain a deeper understanding of the physicochemical phenomena involved
during nanoparticle formation.
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CHAPTER 2. EXPERIMENTALMETHODS
2.1. Synthesis of polymer backbone and acylated polymers
The Poly (glycerol- adipate) polymer backbone and backbone substituted with
acyl groups with chain lengths from C2 to C10 and in varying (20, 40 and 100%)
was provided by Dr. S.Higgins, Dr.G.Hutcheon, Liverpool John Moores
University, UK as a part of BBSRC grant no. E 19350.
The Polymer backbone is a polyester of glycerol and adipic acid linked together
by esterification (Fig. 2.1). The polymers have pendant hydroxyl groups which
were then further substituted by fatty acyl / amino acid groups. The polymer is a
readily hydrolysable polymer, synthesis of which is enzyme catalysed. The
enzyme used is Novozyme435, which is a lipase derived from Candida
Antartica.
Fig. 2.1. Structure of Poly (glycerol adipate) backbone.
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Synthesis of the polymer is a single step reaction and takes place as shown
above. Details of reaction mechanism and polymer synthesis reaction conditions
are described in detail by Kallinetri et al [72].
2.2. (B) Acylation of backbone polyester
The polymer backbone was substituted with acyl groups by a reaction between
the pendant hydroxyl groups and various linear aliphatic acid chlorides. The
chain lengths of the acyl groups varied from 2 to 10 carbon atoms depending
upon the parent carboxylic acid. They were then coupled to the backbone using
Pyridine as a catalyst and acid scavenger [72].
2.3. Synthesis of amino acid substituted polymers
2.3.1. Synthesis of 5% tryptophan substituted polymer
The number of reactive hydroxyl sites per gram of polymer with average
molecular weight 12 kDa was calculated to be 5 mmoles. Hence polymer
backbone (200 mg corresponding to 1 mmole) was dissolved in 5 ml DMF and
added to a dry pre weighed round bottomed flask. To this was added 1.5 mmole
equivalent EDAC (14.38 mg) and N-Acetyl tryptophan (0.05 mmole = 12.32 mg)
under positive pressure followed by addition of 2 ml DMF making the total
reaction volume to 7 ml. The reaction mixture was then stirred with gentle
magnetic stirring at 4°C for an hour following which 2.5mg of dimethypropyl
aminopyridine (DMAP) was added as a catalyst. The mixture was again placed
in a cold room at 4°C overnight. Product was obtained by removal of DMF using
a rotary evaporator. Excess unreacted tryptophan was removed with a simple
washing of 25 ml each of water and methanol. The polymer was then freeze
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dried for 2 days till a constant weight was recorded. The resulting product was
characterised using NMR and FTIR. Polymer solution (10 mg/ml in acetonitrile)
approximately 10 to 12 ml was then passed through a calibrated sephadex LH-
20 column for purification and the fractions corresponding to the void volume
were collected. Eluent was mixture of ACN/MeOH (75:25).
Yield of the reaction mixture was 90-92 %.
Similarly polymers with 10, 20, 40 and 60% substitution were prepared using
24.68 mg, 49.26 mg, 100 mg and 147.76 mg N- acetyl tryptophan respectively.
2.3.2. Synthesis of 5% tyrosine substituted polymer
Polymer backbone was substituted with N- acetyl tyrosine in a method similar to
that for tryptophan substitution using 11.16 mg tyrosine corresponding to 5%
substitution.
2.3.3. Synthesis of 40% C8 + 5% tryptophan substituted polymer
The number of reactive hydroxyl sites per gram of 40% C8 acylated polymer
with an average molecular weight 12 kDa was calculated to be 3 mmoles. Hence
330 mg of 40% acylated polymer (equivalent to 1 mmole) was allowed to react
with 12.32 mg N- acetyl tryptophan as described in section 2.2.1.
2.4. Preparation of Nanoparticles
2.4.1. Interfacial deposition method
(A) Polymer backbone and acylated polymers: Nanoparticle dispersions were
prepared using the interfacial deposition method of Fessi et al.,[91] Briefly, 20
mg of polymer was dissolved in acetone (2 ml) and this solution was added drop
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wise into 5 ml of aqueous solution with or without drug. The dispersions were
left overnight in a fume hood to allow acetone to evaporate. All particles were
made in the absence of surfactants. The particles were filtered through a 1.0 ȝm
filter (Whattman, cellulose nitrate membrane filters) to remove flocculated
particles and polymers, when it was necessary. This method was used for water
soluble drugs (DXMP, CYT-ARA, ETO-P) in a concentration of 4 mg/ml.
(B) Tryptophan / Tyrosine substituted polymers: 1 ml of polymer solution
(10mg/ml) in acetone was added drop wise to 5 ml aqueous solution of 10mM
HEPES with/ without drug. The solution was left under gentle magnetic stirring
overnight.
2.4.2. Simultaneous Emulsification solvent evaporation method
1 ml Polymer backbone and acylated polymers (10mg/ml) in DCM along with 5
ml polysorbate 80 (1%) was sonicated at 30 W for 30 seconds. Solution was left
under gentle magnetic stirring overnight. The emulsification method was only
used for the DXMP particles for method comparison purposes.
2.4.3. Interfacial deposition method with reconstituted matrix
This method involves a slight modification of the interfacial deposition method
and was used only for the hydrophobic drugs Etoposide and Paclitaxel.
Powdered drug (2 mg) was dissolved in the polymer solution (10 mg/ml) in
acetone. The organic solvent was allowed to evaporate and the dried mixture was
reconstituted in 1 ml of acetone which was then added drop wise to 5 ml water /
HEPES solution depending upon the polymer used followed by gentle magnetic
stirring overnight.
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2.5. Separation of unincorporated drug from drug loaded
particles
(A) Particles prepared using backbone and acylated polymers (3-4 ml) were
passed through a glass Gel chromatography column (C2.5/40, Pharmacia, bed
volume 147 ml) packed with Sepharose CL-4B gel. Fractions, 2 ml per tube,
were collected by a fraction collector. Water was used as the eluent. Particles
eluted in the earlier fractions were collected and concentrated to 6 ml total
volume using vivaspin concentrators in a CENTAUR 2 centrifuge and
centrifuged at 3000 rpm for 15 minutes.
(B) For particles prepared using amino acid substituted polymers samples were
passed through a column packed with Sephadex G-25 gel. A peristaltic pump
was used to maintain the flow of eluent at 1 ml/min, through the column.
Fractions, 2 ml per tube, were collected by a fraction collector. HEPES (10nM,
pH 7.35) was used as the eluent. Particles eluted in the earlier fractions were
collected and concentrated to 6 ml total volume using vivaspin concentrators and
centrifuged at 3000 rpm for 15 mins.
2.6. Physicochemical characterization
2.6.1. Particle size
The particle size was determined by dynamic light scattering, using a Malvern
system 4700 instrument, with vertically polarised light supplied by an argon-ion
laser (Cyonics) operated at 40 mW. All experiments were performed at a
temperature of 25.0 ± 0.1
0
C at a measuring angle of 90
0
to the incident beam.
The analysis mode was CONTIN and 30 readings were taken for each sample.
Principle of working: The PCS method consists in determining the velocity
distribution of particle movement by measuring dynamic fluctuations of intensity
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of scattered light. The disperse particles or macromolecules suspended in a liquid
medium undergo Brownian motion which causes fluctuations of the local
concentration of the particles, resulting in local inhomogeneities of the refractive
index. This in turn results in fluctuations of intensity of the scattered light. The
line width of the light scattered spectrum (defined as the half-width at half-
maximum) is proportional to the diffusion coefficient of the particles D (Eq.1):
2
Dk * Equation 1
where,
)2/sin()/4( 4 SS nk
n is the refractive index of the medium, the laser wavelength, and the
scattering angle. With the assumption that the particles are spherical and non-
interacting, the mean radius is obtained from the Stokes-Einstein equation:
DTkR B SK6/ ,
where kB LV WKH %ROW]PDQQ FRQVWDQW 7 WKH WHPSHUDWXUH DQGȒ WKH VKHDU
viscosity of the solvent.
Information about the light-scattering spectrum can be obtained from the
autocorrelation function G (Ĳ) of the light-scattering intensity. For the simplest
case of spherical monodisperse non-interacting particles in a dust-free fluid, the
characteristic decay time of the correlation function is inversely proportional to
the linewidth of the spectrum. Therefore, the diffusion coefficient and either
particle size or viscosity can be found by fitting the measured correlation
function to a single exponential function.
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This method is also referred to as dynamic light scattering and quasi-elastic light
scattering. It is applicable to particles suspended in a liquid, which are in a state
of random movement due to Brownian motion (i.e. particles generally of 2 -3 µm
diameter and smaller). The speed of the movement is inversely proportional to
particle size (the smaller the particles are, the faster they move, or diffuse), and
the speed can be detected by analyzing the time dependency of the light intensity
fluctuations scattered from the particles when they are illuminated with a laser
beam.
2.6.2. Surface charge measurement
7KH ȗSRWHQWLDO RI WKH QDQRSDUWLFOHV ZDV GHWHUPLQHG E\ ODVHU GRSSOHU
anemometry using a Malvern Zetasizer also called Doppler Electrophoretic Light
Scatter Analyzer. The instrument is a laser-based multiple angle particle
electrophoresis analyzer. Using Doppler frequency shifts in the dynamic light
scattering from particles, the instrument measures the electrophoretic mobility
(or zeta potential) distribution together with the hydrodynamic size of particles
(size range 10 to 30 µm) in liquid suspensions by photon correlation
spectroscopy
Measurements were performed at 25 ± 0.1
0
C, on samples appropriately diluted
ZLWKWKHPHGLXPGHVFULEHGHDFKWLPH)LYHPHDVXUHPHQWVRIWKHȗSRWHQWLDOIRU
each sample were made.
2.6.3. Transmission Electron Microscopy
Morphology of the particles was examined using TEM. A sample of particle
suspension was diluted with 3% w/v phosphotungstic acid adjusted to pH 7.5
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with potassium hydroxide corresponding to a 1:1 ratio before examination. One
drop of sample was placed for 1 minute on a copper grid coated with a formvar
carbon film. The excess of sample was wicked away with the aid of filter paper.
The sample was then ready for analysis by TEM.
2.7. Differential Scanning Calorimetry
The thermal behaviour of the particles was analyzed using a DSC2920 TAINS
instrument. Approximately 10 mg of nanoparticle suspension was accurately
weighed into a 40-ȝL hermetic aluminium pan and sealed. A temperature range
of 0° C to 200° C was scanned using a heating rate of 10° C /min. Indium was
used as the standard reference material to calibrate the temperature and energy
scale of the apparatus.
2.8. Nuclear Magnetic Spectroscopy (NMR)
Polymer samples (2 mg) were dissolved in 0.86 ml deuterated acetone, while
pure amino acids (2 mg) were dissolved in 1 ml deuterated methanol and
subjected to NMR analysis. The NMR spectra were recorded on a Bruker 400
MHz spectrometer. The data was processed using the Omnispin software
2.9. Fourier Transformed Infrared Spectroscopy (FTIR)
Fourier transform infrared (FT-IR) spectra were obtained on a Nicolet AVATAR
360 FT-IR spectrometer. Samples of pure drug or nanoparticles (with or without
drug) were prepared in KBr disks (2 mg sample in 200 mg KBr). The scanning
range was 450–4000 cm
í1
and the resolution was 1 cm
í1
. Sample analysis were
carried out by the E2 OMNIC software for analysis
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2.10. Determination of drug loading
Indirect Estimation: Encapsulation of DXMP was first determined using an
indirect method. From the calibrated Sepharose column, fractions corresponding
to free drug were collected together and concentrated. The total amount of free or
unincorporated drug was determined using UV spectroscopy at 240 nm and a
calibration curve for DXMP. The amount of drug incorporated in the particles
was determined after subtracting unincorporated drug amount from total known
amount of drug added.
Direct estimation: Nanoparticle suspension was freeze dried and from the
lyophilised material drug was extracted by addition of Acetone / MeOH (1:2) for
hydrophobic drugs and acetone / Phosphate buffer saline (0.01%) for hydrophilic
drugs, followed by evaporation of acetone and centrifugation in a MSE
microcentrifuge at 13500 rpm for 5 mins. The supernatant was analysed
depending on the drug used by UV or HPLC.
The drug loading (%) was calculated using the following formula:
Drug loading (%) = Amount of drug in nanoparticles (mg) X 100
Polymer mass (mg)
2.11. Drug release studies
Nanoparticle suspension (2ml) was placed in a dialysis membrane (Spectra Pore
MWCO 1000) and immersed in 4 ml water or 10mM tween in HEPES for 30
days at 37 °C in an agitating water bath.
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Sampling was carried out at predetermined time points, 1 ml of aliquot taken for
analysis (UV/ HPLC); remaining media was replaced with fresh distilled water at
each time point
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CHAPTER 3. INCORPORATIONAND RELEASE OF
DEXAMETHASONE PHOSPHATEAND CYTOSINE
ARABINOSIDE FROM POLYGLYCEROLADIPATE
NANOPARTICLES.
3.1. Introduction
Glucocorticoids can be highly effective in treating joint inflammation, but their
systemic application is limited because of a high incidence of serious adverse
effects, especially related to long term treatment. Dexamethasone has been used
to reduce brain tumour-associated vascular permeability and cerebral oedema,
reduce intracranial pressure, improve accompanying symptoms, and provide
palliation of patients with malignant gliomas by prolonging useful neurologic
function and life span [149]. PLGA-nanosteroid for intra-articular preparation
has been reported but the encapsulation rate of steroids is low and their size is not
suitable for intravenous administration. Ishihara patented the preparation of
PLGA and PLA nanoparticles with water soluble steroids where they reported
the encapsulation of steroid salts to be between 0.5 and 2% w/w Also the release
rate has been reported to be associated with a high burst release for most steroid
salts [150]
Cytosine arabinoside has been reported to be widely used in chemotherapy for
sporadic primary central nervous system lymphoma. Depofoam is one of the
currently marketed products containing Cytarabine. It is a liposomal intrathecal
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formulation, where cytarabine is formulated inside small particles of a synthetic
lipid material called DepoFoam. This dosage form slowly releases the drug and
provides a sustained action.
In this study we present size, zeta potential, drug loading and release studies
using the water soluble drugs Dexamethasone phosphate ( DXMP), an anti
inflammatory agent, and Cytosine arabinoside (CYT-ARA), an anti cancer drug,
in functionalised poly (glycerol adipate) nanoparticles. The presence of free
pendant hydroxyl groups on the backbone introduces synthetic flexibility in the
backbone as they are available for substitution with different functional groups
and different chemistries. Dexamethasone phosphate was chosen as a model anti
inflammatory, low toxicity drug for initial studies in order to establish the
potential of poly (glycerol adipate) polymers for drug incorporation within
nanoparticles. Since we aim to introduce these polymers for nanoparticle
formulations in cancer therapy, CYT-ARA was chosen as an example of a water
soluble anti cancer drug. From literature it has been proved that steroid hormones
interact with fatty acyl groups of cholesterol and sphingomyelins [151]. We
hypothesised that on addition of acyl groups to the backbone a similar interaction
could occur between the steroidal nucleus of DXMP and polymer backbone acyl
groups. The steroidal nucleus is believed to be oriented parallel to the
phospholipid groups of the bilayer membrane and stacked between them. Hence,
we introduced within the backbone, acyl groups of varying chain lengths from C2
to C10 and in varying degrees of acylation from 20% to 100% substituted
polymer. The lack of a steroidal nucleus in the structure of CYT-ARA provided
an excellent example for comparison with the steroid containing DXMP.
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Particles were prepared using two different methods reported in the literature for
nanoparticle formulations namely: The Interfacial deposition [91] and the
simultaneous emulsification methods [86]. Extensive studies were carried out
using DXMP in order to identify the optimum chain length of acyl group,
method of preparation and MW of backbone polymer based on physicochemical
properties of particles and drug incorporation. The polymer was also assessed for
cytotoxicity and was found to be non toxic to HepG62 cell lines. From the in
vivo biodistribution studies of radiolabelled samples intavenously, around 15%
of the particles were found in the blood after 3 hours which is better than the
PLGA particles [72].
In this study, results with DXMP were compared with results obtained using
another water soluble drug CYT-ARA under similar formulation conditions and
polymer specifications. The nanoparticles manufactured using various recipes
and under various conditions were characterized by Photon correlation
spectroscopy (PCS) for size and size distribution, Transmission electron
microscopy (TEM) for morphological properties, and zeta-potential for surface
charge. The drug encapsulation efficiency and the drug release kinetics under in
vitro conditions were measured by high performance liquid chromatography
(HPLC). Also, during the study we compared the drug loading and encapsulation
efficiencies determined using an indirect method and a direct method of analysis.
Aims of the Chapter:
x To determine the optimum chain length of the acyl groups for maximum
loading of DXMP.
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x To evaluate the methods of nanoparticle preparation and select the
method for best drug incorporation.
x To study the influence of polymer functionalisation and degree of
acylation on DXMP and CYT-ARA incorporation.
x To compare the drug loading and release profile of DXMP and CYT-
ARA within various polymers.
3.2. MATERIALS ANDMETHODS
3.2.1. Materials
Polymer backbone and acylated polymers were synthesised as described in
Chapter 2.
n = 2 to 10
x/ x + y = 20%, 40% and 100% substituted.
Fig. 3.1. Structure of poly glycerol adipate backbone substituted with acyl
groups.
Dexamethasone Phosphate and Cytosine Arabinoside were purchased from
Sigma Aldrich (UK). Sepharose 4B-CL gel was purchased from Pharmacia UK.
All organic solvents were of HPLC grade. Water used in the experiments was
ELGA water (18 kȍ resistivity).
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Chemical name: fluoro-11(beta), 17-dihydroxy-16(alpha)-methyl-21-
(phosphonooxy)pregna-1, 4- diene-3, 20-dione disodium salt.
Molecular Formula: C22H28 FNa 2O8 P
Molecular Weight: 516.41
Fig. 3.2. Molecular structure and identity of DXMP
Chemical name : 4-Amino-1-ȕ –D- arabinofuranosyl- 2 (1H pyrimidinone)
Molecular formula : C9H13N3O5
Molecular weight: 243.22
Fig. 3.3. Molecular structure and identity of CYT-ARA.
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3.3. Methods
3.3.1. Preparation of nanoparticles
Nanoparticles were prepared using methods described in 2.4.1 and 2.4.2 in
Chapter 2.
3.3.2. Separation of free drug from nanoparticles
The nanoparticle suspension was passed through a Sepharose 4B-CL column (32
cm x 2.5 cm) using water as eluent at a flow rate of 1 ml /min. Particles eluted in
the earlier fractions were collected, concentrated using vivaspin ultrafiltration
tubes in a CENTAUR 2 centrifuge and subjected to characterisation.
3.3.3. Measurement of Particle size and Zeta Potential
Measurement of particle size was carried out using PCS (Malvern Instruments
Ltd., Malvern,UK). The analysis mode was CONTIN. The nanoparticle
suspension (200 ȝL) was diluted with ultrapure water in a cylindrical glass cell to
give 500-600 kcps. The particle size was expressed as the mean particle
hydrodynamic diameter +/- standard deviation of 30 readings. Measurements of
surface charge were performed using a Malvern Zetasizer IV (Malvern
Instruments Ltd., UK) at 25° C. Results are expressed as the mean ± standard
deviation of 6 readings.
3.3.4. Transmission Electron Microscopy (TEM)
Morphology of the particles was examined using TEM (Jeol Jem 1010 electron
microscope, Japan). A sample of particle suspension was diluted with a solution
of phosphotungstic acid (3% w/v, pH 4.7) and observed under TEM.
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3.3.5. Determination of entrapment efficiencies
Drug loading for DXMP nanoparticles was determined using both indirect and
direct estimation methods described in Chapter 2.
Direct method: Particles loaded with either DXMP or CYT-ARA were
lyophilized. To the freeze dried product acetone and Phosphate buffered saline
0.01M (1:2) were added, the mixture was centrifuged in a MSE Microcentaur
centrifuge at 13500 rpm for 10 min and the supernatant was analysed. For CYT-
ARA the supernatant was analysed using UV spectroscopy at 271 nm and the
concentration of the solution was assessed from a calibration line based on the
Beer Lamberts law [152]. For DXMP the supernatant was analysed by HPLC.
3.3.6. HPLC method for DXMP determination
High-performance liquid chromatography (HPLC) analyses were performed with
a Gilson Model 600 pump equipped with a Gilson photodiode array detector (set
at the wavelength of 240 nm), a 20 ȝl loop injection autosampler and Empower
software. For analysis, a reversed phase Lichrosphere 100 RP-18
(25 cm × 4.6 mm; 5µ) endcapped column in conjunction with a precolumn C18
insert was eluted with Phosphate buffer (0.1 M) pH 3.5: Methanol : Acetonitrile
50:36:14 in isocratic mode. The flow rate of 1 ml/min was maintained and the
column eluent was monitored continuously at 240 nm. Quantitation of the
compounds was carried out by measuring the peak areas in relation to those of
standards chromatographed under the same conditions. DXMP was eluted with a
retention time of 5.02 minutes and monitored at 240 nm [153].
3.3.7. In vitro Drug release studies
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Nanoparticle samples (2ml) enclosed in dialysis bags (Spectra Pore, MWCO
12000) were placed in 4 ml water at 37°C under mild agitation in a water bath.
At pre-determined time intervals, 1 ml samples were withdrawn from the release
medium and analysed with UV-Vis spectroscopy for CYT-ARA and by HPLC
for DXMP using the conditions as described in section 3.3.6. After sampling the
entire medium was removed and replaced with same amount of fresh media.
3.4. RESULTS
3.4.1. Particle size and zeta potential
In order to study the influence of degree of acylation on particle formation, size
and zeta potential of various drug loaded and empty polymers were examined.
The effect of the nature of drug and its correlation with degree of substitution on
particle sizes and zeta potential were also studied.
Table 3.1 shows the sizes and zeta potential of particles prepared using various
series of polymers and different drugs. Empty particles were particles formed
without the drug. Among the polymer backbone series with different molecular
weights no specific trend could be observed for the empty particles. Backbone
with MW 6 kDa formed the largest particles. The sizes of the empty particles
were larger than those containing drugs. No distinct correlation could be
observed between the particle sizes and the degree of acylation in the absence of
drugs. Particles formed with the polymer backbone were the smallest and those
formed with the 40% acylated polymer were the largest.
Between the two different formulations, the sizes of DXMP and CYT-ARA
particles in the backbones of 2 kDa and 6 kDa were almost the same. The only
significant effect was observed in the 12 kDa backbone where CYT-ARA
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particles were larger than the DXMP particles. For the acylated polymers,
DXMP loaded particles were smaller in size than the CYT-ARA loaded particles.
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Table 3.1 Particle size and Zeta potential of particles prepared from various polymers by the Interfacial deposition method. Polymer type is
designated by % of acylation (20, 40, 100%), acyl group chain length (C8) and molecular weight (2, 6, 12 kDa). Results are mean of 3 readings,
SD standard deviation, PB polymer backbone.
POLYMER TYPE EMPTY PARTICLES (+) CYT-ARA (+) DXMP
SIZE nm
(SD) [polydispersity]
ȟ327(17,$/P96' SIZE nm
(SD) [polydispersity]
ȟ327(17,$/P96' SIZE nm
(SD)[polydispersity]
ȟ327(17,$/P96'
Polymer backbone 169.6(2.2)[0.57] -20.2(0.4) 159.2(1.8)[0.041] -27.3 (1.0) 150.6(1.3)[0.206] -32.1(0.6)
20%C8-12 211.1 (6.8) [0.30] -30.1(0.1) 217.5(5.9)[0.07] -30.8 (0.45) 124.3(1.037)[0.41] - 36.9(6.01)
40%C8-12 267.5 (3.09) [0.33] -29.75(3.7) 200.8(0.63)[0.28] -28.6 (1.5) 147.3(9.68)[0.35] -34.4 (0.5)
100%C8-12 201.3 (0.57) [0.23] -27.3(0.3) 196.35(2.5)[0.1] -28.9 (0.62) 152.5(1)[0.25] -29.4(2.2)
PB-6kDa 221.7(2.7)[0.41] -25.8(4.5) 128.2(0.9)[0.073] -29.2 (0.5) 132.9(3.1)[0.05] -33.7(2)
PB-2kDa 172.9(1.1)0.72] -28.7(0.2) 129.3(1.1)[0.103] -31.4 (0.8) 127.3(3)[0.14] -33(0.5)
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Amongst the acylated series, an increase in polymer acylation increased the
particle size for DXMP while it decreased for CYT-ARA. However, acylated
DXMP loaded particles were still smaller than the unloaded particles made from
the same polymers.
Sizes of the DXMP particles prepared by the emulsification method were
between 200 and 250 nm. (Data not shown). No significant trend could be
observed between degree of acylation and particle size. However, empty
particles were larger in size than drug loaded particles.
Zeta potential for all empty and CYT-ARA particles was around -30 mV while it
was between -30 and -37 mV for the DXMP particles. For the empty polymer
backbone particles zeta potential became less negative as the MW increased and
was within an overall range from -20 mV to -28 mV. Acylation and DXMP
incorporation slightly increased negative zeta potential values. CYT-ARA
incorporation into the 12 kDa polymer backbone also increased the negative zeta
potential of the particles to a small extent.
3.4.2. TEM Images
Fig. 3.4. TEM Image of CYT-ARA nanoparticle in 40% acylated PGA, MW
12kDa.
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Fig. 3.5.TEM Image of DXMP nanoparticle in 40% acylated PGA, MW 12kDa
From Figs. 3.4 and 3.5, particles appeared to be spherical with smooth rounded
surfaces. DXMP and CYT-ARA particles appeared similar in size in the 40%
acylated polymer and also had similar polydispersities. The drug loaded particles
had a higher polydispersity compared to empty particles (Table 3.1).
3.4.3. Drug Incorporation
A number of studies have reported drug incorporation using an indirect method
of estimation based on determination of free drug after encapsulation compared
to total amount of drug used [154]. Initial studies carried out in the group
focussed on this method of determination of described in Chapter 2 for drug
loading and encapsulation efficiency [72]. Based on the results obtained by this
method we saw substantial amount of loading within the particles (Fig. 3.6).
However, during the course of this study, the method for direct estimation of
drug loading in particles was developed and compared with results for similar
polymers using the previous method.
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DXMP Incorporation in various polymers (Indirect estimation)
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Fig. 3.6. Influence degree of polymer acylation on Dexamethasone phosphate
analysed using indirect method of estimation
Based on the results obtained from indirect estimation, increase in acylation led
to an increase in drug loading within the particles. Around 30% drug loading was
observed in the 100% C8 acylated polymers and 9% loading was observed in the
polymer backbone.
3.4.3.1. Validation of DXMP determination
In the new method, the amount of drug loaded directly within the particles was
determined after extraction from the nanoparticles followed by its analysis by
HPLC. Results obtained for validation of the direct method and HPLC analysis
of the drug loaded nanoparticles are presented below.
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Fig. 3.7. Determination of retention time for standard solutions of DXMP and
DXM using conditions as described in 3.3.6
3.4.3.2. (B) Calibration curve
Due to its highly unstable nature, some DXMP is degraded to DXM as evident
from the HPLC curve for the standard solution of DXMP (Fig. 3.7). Hence, in
order to account for the total amount of DXMP present in the samples it is
essential to quantify the amount of DXMP present in the form of DXM. In order
to estimate the amount of DXMP and DXM present in the samples calibration
curves was prepared with known amounts of DXMP and DXM and analysed by
HPLC (Figs. 3.8 and 3.9).
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Standard curve for DXM-Pin water
y=43015x+601.11
R2 =0.9981
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Fig. 3.8. Calibration curve for DXMP in water.
.
†
total free volume
Table 3.2. Extraction efficiency for control samples of DXMP (100ȝg) using
conditions as described in 3.3.6
Sample
(DXMP)
Area Conc.(ng/ml)
(*100 dilution
factor)
ȝg/tot.fr.v
ol
†
(2ml)
Total (ȝg)
(DXMP+DXM)
Efficiency
(%)
Avg.
efficiency
(SD)
Control-1 21659 47.54 95.07 95.5233 95.5233
Control-2 20370 44.71 89.41 89.6191 89.6191
Control-3 19998 43.83 87.75 88.3658 88.3658
91.2%
(3.82)
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Fig. 3.9. Calibration curve for DXM in MeOH
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Table 3.3. Extraction efficiency for control samples of DXM using conditions as
described in 3.3.6
.
The above method illustrates analysis of both DXM and DXMP from the
samples treated as described for extraction in section 3.3.6.
Sample
(DXM)
Area Conc.(ng/ml) ȝg/tot.fr.vol.†
(2ml)
Control-1 23321 0.125 0.22
Control-2 30280 0.228 0.46
Control-3 35125 0.3 0.63
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Fig. 3.10. HPLC analysis of DXMP loaded samples within the 20, 40 and 100%
acylated polymers along with a standard DXMP solution (10ng/ml)
As can be seen from the standard chromatogram (Fig. 3.7) standard samples of
DXMP are contaminated with some amount of DXM. This is due to the inherent
instability of the phosphate group in DXMP. Retention time for DXMP and
DXM was 5.02 minutes and 15.5 minutes respectively using mobile phase ACN/
Phosphate buffer (pH 3.5)/ MeOH: 14/50/36. As a control, 100 ȝg pure drug was
added to a suspension of empty nanoparticles. Its recovery was determined in
order to assess the efficiency of the analytical procedure (Table 3.2, Table 3.3).
The calibration curves for DXMP in water (Fig. 3.8) and DXM in MeOH (Fig.
3.9) were used to calculate the amount of DXMP and DXM in the samples. The
amount of DXM present was taken into consideration while calculating total
amount of DXMP in the samples. Fig. 3.10 shows the analysis of drug loading of
some samples compared with the standard solutions.
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The average efficiency of the extraction procedure was 91% for DXMP (Table
3.2) and the results obtained for drug loading were divided by 0.9 to obtain the
final amount of DXMP loaded in the samples.
3.4.3.3. Validation of CYT-ARA determination
CYT-ARA was analysed spectroscopically. Standard solutions of known
concentrations of CYT-ARA in water were analysed at 271 nm on a UV-Vis
spectrophotometer and a calibration curve was prepared (Fig. 3.11). Samples
were extracted using the method described in Chapter 2. Control samples
containing a known amount of CYT-ARA (200 ȝg) were added to the empty
nanoparticles (4 ml) and analysed to determine the efficiency of the method.
Standard curve of CYT-ARAind.H2O
y=0.0298x+0.0012
R2 =0.9702
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Fig. 3.11. Calibration curve for CYT-ARA in water
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† total free volume
Table 3.4. Extraction efficiency for control samples of CYT-ARA
As it can be seen from Table 3.4 around 76% of the control amount was
recovered. Average extraction efficiency was calculated and results obtained for
drug loading were divided by 0.239 to calculate the drug loading of the samples.
3.4.3.4. Effect of chain length of Pendant acyl groups on loading
In order to observe to influence of acyl chain length on drug incorporation, a
model drug DXMP was incorporated within completely acylated polymer
backbone with varying acyl group chain lengths ranging from 2 to 10 carbon
atoms.
Sample
(CYT-ARA)
ABS.
(271nm)
Conc.(ng/ml)
*10 (dilution
factor)
ȝg/tot.fr.vol†
(2.2ml)
Efficiency
(%)
Avg.
efficiency
(SD)
Control-1 0.21 69.84 153.65 76.823
Control-2 0.209 74.12 163.06 81.533
Control-3 0.188 63.63 139.98 69.994
76.1%
(5.8)
CHAPTER 3 DXMP AND CYT-ARA
75
0
2
4
6
8
10
12
100%C10 100%C8 100%C6 100%C4 100%C2
Chain length
dr
u
g
lo
ad
in
g
(%
)l
Fig. 3.12. Dexamethasone phosphate incorporation in nanoparticles made from
100% acylated polymers with varying acyl group chain lengths.
From Fig. 3.12, it can be clearly seen that acyl chain length of 8 carbon atoms led
to maximum drug entrapment, 10% w/w drug loading being observed. Drug
loading within the lower chain length polymers (C2 to C6) was minimal and not
influenced by change in acyl group chain length. A substantial drop in drug
loading was observed when the chain length was increased to 10 carbon atoms.
3.4.3.5. Effect of degree of acylation on drug loading
Next, the effect of change in degree of substitution on drug incorporation was
investigated. C8 chain length polymers were acylated to an extent of 20%, 40%
and 100% and incorporation of DXMP and CYT-ARA within these polymers
was studied.
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Fig. 3.13. Influence degree of polymer acylation on Dexamethasone phosphate
and Cytosine Arabinoside loading in nanoparticles.
As can be seen in Fig 3.13, an increase in acylation led to increase in drug
loading for DXMP. However, the exact opposite trend is observed for CYT-
ARA. With increase in acylation CYT-ARA incorporation decreased with all the
acylated series incorporating around 1% of drug. Incorporation of CYT- ARA
was highest (2%) in the polymer backbone (Fig. 3.13) and it decreased as
acylation increased. Incorporation of DXMP was highest in the 100% acylated
polymer. 10.5% DXMP was encapsulated within this polymer. Comparing
DXMP results with that obtained using the indirect estimation (Fig. 3.6), it can
be seen that although the trend is similar for both methods the amount of drug
loading estimated previously within the 100% acylated polymer using the
indirect estimation was 30% which is 3 times greater than the direct estimation
shown above.
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3.4.3.6. Effect of Polymer backbone molecular weight
Polymer backbone was synthesised in various molecular weights and drug
incorporation within them was studied.
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Fig. 3.14. Influence of backbone M.W on DXMP and CYT-ARA loading in
nanoparticles
From Fig 3.14, for either drugs, backbone with highest molecular weight gave
maximum incorporation. CYT-ARA was encapsulated to a significant extent
within the 12 kDa polymer particles and minimum loading was observed in the 2
and 6 kDa polymers. Similarly, for DXMP, loading within the 2 and 6 kDa
polymers was to a similar extent and considerably lower than for the 12 kDa
polymer. Both DXMP and CYT-ARA were incorporated to a similar extent in
the polymer backbone of different molecular weights.
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3.4.3.7. Effect of nanoparticle production method
DXMP particles were prepared using two different methods, the interfacial
deposition method (IPD) and emulsification method.
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Fig. 3.15. Influence of method of preparation and degree of polymer acylation on
Dexamethasone phosphate loading in nanoparticles.
The particles showed better incorporation in the particles prepared using the IPD
method. (Fig. 3.15). Particles prepared using either the emulsification or ID
method showed maximum incorporation in the 100% acylated polymer.
With the emulsification method 5.8% DXMP was incorporated within 100%
acylated polymer while with the ID method 10.5% loading was observed. There
was no significant difference in incorporation within the polymer backbone, 20%
or 40% acylated polymers using the emulsification method. It was also
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interesting to observe that the polymer backbone particles prepared using the two
different methods had comparable incorporation of DXMP.
3.4.4. Drug Release
Drug release from nanoparticles is usually a biphasic phenomenon although on
some occasions a triphasic profile is also seen. Firstly there is an initial rapid
removal of the drug from nanoparticles possibly related to loss of drug associated
loosely on the surface of the nanoparticle. This initial release is rapid and
uncontrolled and is termed the burst release [155]. Most particles reported in the
literature prepared using either ID or emulsification methods show this initial
release. The drug loosely associated with the surface may occur due to the escape
of drug during the organic solvent evaporation phase towards the external
medium [11], and once the organic solvent evaporates there is re-adsorption of
the drug on the nanoparticle surface. After the surface component release is
complete, there is a slower much more controlled release of drug through the
nanoparticle matrix. This latter release has been characterised by zero order
release kinetics for biodegradable polymers like PLGA.
Change in morphology of polymer surface from being most porous to non porous
has also been suggested as an important factor contributing to burst release [156].
The rapid initial drug release is also reported to be affected by hydrophobicity of
polymer [157].
3.4.4.1. Effect of polymer acylation
Particles loaded with either DXMP or CYT-ARA in various polymers were
studied for their drug release profiles in water. Effect of nature of drug and
degree of polymer acylation on its release was determined.
CHAPTER 3 DXMP AND CYT-ARA
80
-20
0
20
40
60
80
100
120
0 5 10 15 20 25
Time (days)
%
C
u
m
u
la
tiv
e
R
e
le
a
se
Polymer backbone12KDa
20%C8-12KDa
40%C8-12KDa
100%C8-12KDa
FREEDRUG
.
Fig. 3.16. Influence of degree of polymer acylation on Dexamethasone phosphate
release from nanoparticles. Drug release studies were carried out in water at 37
qC for 25 days.
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Fig. 3.17. Influence of degree of polymer acylation on Cytosine Arabinoside
release from nanoparticles. Drug release studies were carried out in water at 37
qC up to 25 days.
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From Fig. 3.16, it can be seen that for the steroid ring containing drug DXMP,
polymer with 100% acylation showed controlled drug release without burst
effect with 70% of initial drug released at the end of 25 days. The 40% acylated
polymers also showed around 71% release at the end of 25 days however, initial
release was faster with 40% drug released at the end of 5 days while only 11%
drug was released from the 100% acylated polymer at the end of 5 days. The
polymer backbone had the greatest burst followed by the 20% acylated polymer.
However, total drug released at the end of 25 days was 85% with the 20%
acylated polymer and only 40% from the polymer backbone.
For CYT-ARA which is also a hydrophilic drug but without steroid ring, release
from the acylated polymers was rapid. The drug release from these polymers can
be seen in Fig. 3.17. The fully acylated polymer showed a rapid and complete
release. All the other polymers had a slower and comparable rate of release. The
only difference between the other formulations was the increased release rate
seen in the 40% C8 polymer after 12 days resulting in a complete release by 20
days. Around 80% drug was released from the backbone and the 20% C8
acylated polymers at the end of 25 days.
3.4.4.2.Effect of polymer backbone molecular weight
Rate of DXMP release was similar for both 6 and 12 kDa molecular weight
polymers (Fig. 3.18). Fast initial release of 40% drug occurred with both
polymers followed by a sustained release
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Fig. 3.18. Influence of Polymer backbone MW on DXMP release from
nanoparticles. Drug release studies were carried out in water at 37 qC for 25
days.
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Fig. 3.19. Influence of Polymer backbone M.W on Cytosine Arabinoside release
from nanoparticles. Drug release studies were carried out in water at 37 qC for 25
days.
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The polymer backbone of 12 kDa molecular weight released 61% drug while the
2 kDa backbone released 44% drug after 12 days.
Rate of CYT-ARA release was rapid and complete from the 6 kDa molecular
weight polymer (Fig. 3.19). Release from the 12 kDa and 2 kDa polymers were
slower but similar. Between 40 to 50% drug was released rapidly followed by a
slow sustained release from either polymer. However, the retention of drug was
greater from the 12 kDa polymers compared to the lower molecular weight (2
kDa) polymer.
3.4.4.3. Effect of nanoparticle preparation method
Fig. 3.20 shows the influence of method of preparation on DXMP release profile.
Particles prepared by the emulsification method showed a higher rate of drug
release compared to the particles prepared using the IDP method after 5 days.
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Fig. 3.20. DXMP release from 100% C8 particles prepared using different
techniques.
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Both particles showed no burst release. However, release from the particles
prepared from the IDP method was slower and more controlled. After 15 days,
particles prepared using the emulsification method released 85% drug while
particles prepared using the IDP method released around 65% drug.
3.4.5. Analysis of drug release kinetics
Several theories/kinetic models describe drug dissolution from immediate and
modified release dosage forms. There are several models to represent the drug
dissolution profiles where ft is a function of t (time) related to the amount of drug
dissolved from the pharmaceutical dosage system. The quantitative interpretation
of the values obtained in the dissolution assay is facilitated by the usage of a
generic equation that mathematically translates the dissolution curve into a
function of some parameters related to the pharmaceutical dosage forms.
3.4.5.1. Higuchi Model
Higuchi [158] developed several theoretical models to study the release of water
soluble and low solubility drugs incorporated in semi-solid and/or solid matrixes.
Mathematical expressions were obtained for drug particles dispersed in a
uniform matrix behaving as the diffusion media. To study the dissolution from a
planar system having a homogeneous matrix, the relation obtained was the
following:
tCCCDQft ss )2(   
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where Q is the amount of drug released in time t per unit area, C is the drug
initial concentration, CS is the drug solubility in the matrix media and D is the
diffusivity of the drug molecules (diffusion constant) in the matrix substance.
This relation was first proposed by Higuchi to describe the dissolution of drugs
in suspension from ointment bases, but is clearly also related to dissolution from
other pharmaceutical dosage forms. For these dosage forms a concentration
profile, which may exist after application of the pharmaceutical system, can be
represented. In a general way it is possible to reduce the Higuchi model to the
following expression, generally known as the simplified Higuchi model:
tKft H 
where KH is the Higuchi dissolution constant treated sometimes in a different
manner by different authors and theories. Higuchi describes drug release as a
diffusion process based on Fick’s law, which is square root of time dependent.
This relation can be used to describe the drug dissolution from several types of
modified release pharmaceutical dosage forms, as in the case of some
transdermal systems and matrix tablets with water soluble drugs [159].
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Fig. 3.21. Higuchi plots for DXMP particles
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Fig. 3.22 . Higuchi plot for CYT-ARA in PB-12kDa
In Figs. 3.21 and 3.22 the cumulative release of drug (%) against square root of
time for DXMP and CYT-ARA respectively has been plotted. Only the plot for
DXMP particles in the 100% acylated polymer was linear indicating a diffusion
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controlled mechanism. The release profile from the 100% C8 polymer had a
correlation coefficient of 0.9555). For the remaining series the correlation
coefficient was poor although it is interesting to see that the plot shows two
separate linear portions but overall do not obey ficks law of diffusion. Usually,
the Higuchi plotting applies to the situation when the amount of drug release
does not exceed 60%. Thus the plot for DXMP was calculated for just 4 days.
For CYT-ARA, all particles except polymer backbone showed a burst of more
than 50% in 24 hours. Hence, these plots have not been calculated. The plot for
polymer backbone is linear with a correlation coefficient of 0.969.
3.5. DISCUSSION
3.5.1. Particle size and zeta potential
The size of the empty particles was found to be larger than the drug loaded
particles for the backbone as well as the acylated polymers. There could be two
main possible explanations for these changes in particle size in the presence of
drugs: change in the aggregation number of polymer molecules or change in the
particle density due to increased interactions between drug and polymer. In this
case, it is more likely to be due to the interactions between drug and polymer.
Some interaction between the polymer and the drugs may cause them to form
more compact and condensed particles. Also, since the drugs are water soluble
they may also play a role at the interface; there could be steep concentration
gradient at the interface or transfer of solute from higher viscosity phase, both
leading to a decrease in interfacial tension and turbulence leading to rapid
diffusion of acetone from organic phase and more condensed particles. Thus,
presence of water soluble drugs may play a role in particle formation.
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All the empty particles formed with the acylated polymers were larger in size
than the 12 kDa polymer backbone. This could be the effect of the presence of
acyl groups on the polymer as particle size also depends upon the packing which
is influenced by the nature of chemical groups present on the polymer and drug
(Fig. 3.1, 3.2). A larger substituent requires more space, but this may be offset by
a greater packing efficiency. The increase in size of particles with increase in
acylation and increase in molecular weight could also be attributed to increased
lipophilicity i.e. increase in hydrophobic interactions within the particles. This
would have the opposite effect. The increased lipophilicity may cause a
subsequent increase in the aggregation number of polymer molecules leading to a
rapid precipitation of the polymer thus increasing the size of the particles rather
than the number of particles formed.
Comparing the two drugs, DXMP formed particles of smaller size compared to
CYT-ARA for all polymers. Larger sizes of the CYT-ARA particles indicate
possibly a more loosely packed arrangement compared to DXMP. This again
could be attributed to the nature of interaction between the drug and polymer.
We expect a better interaction between the steroid ring of DXMP and the acyl
groups on the polymer that may have led to a more densely packed arrangement
of the molecules (Fig. 3.1, Fig. 3.2.) In a majority of studies on nanoparticle
formulations, particle sizes have been correlated to either the polymer or the drug
physicochemical characteristics but not their combined effect.
Piskin et al reported that assembly of particles is largely dependant on
hydrophobicity of polymer and the nature of the drug used. An increase in the
number of hydrophobic domains was found to be associated with larger
nanoparticles [160]. Some studies showed a decrease in chain length of the
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polymer causes increase in hydrophilicity resulting in loosely packed
nanoparticles [161]. Lin et al observed an increase in the size of indomethacin
loaded PEG polylactone micelles with an increase in chain length of the lactones
(L-lactide, į-valerolactone and į-caprolactone) [162].
For particles prepared by Emulsification in presence of surfactant Giannone et al
suggested that size can be varied by modifying molecular weight and monomer
stereochemistry [163]. Yoo et al studied DNA incorporation within hydrophobic
glycol chitosan. Chitosan and its derivatives were complexed with DNA by ionic
interactions between anionic phosphate backbones of DNA and primary amine
groups of chitosan. The sizes of these particles were mainly dependent on the
number of polymer nitrogen per DNA phosphate (N/P). They reported that upon
increasing the hydrophobic glycol chitosan/glycol chitosan ratio, the
encapsulation efficiency of DNA slowly increased with a decrease in a particle
size and this was attributed to a hydrophobic interaction between 5ȕ-cholanic
acids of hydrophobic glycol chitosan and DNA complexes [164]. Govender et al
studied the effect of procaine hydrochloride loading on the particle size of
nanoparticles made from PLA–PEG diblock copolymers with a fixed PEG block
(5 kDa) and a varying PLA segment (3–110 kDa). The sizes of drug free
nanoparticles increased from 27.6 to 152.4 nm with an increase in the molecular
weight of the PLA block of the polymer from 3 to 110 kDa. The PLA–PEG
nanoparticle size remained unchanged with incorporation of drug into the 3:5;
15:5 and 30:5 series, while a slight increase was observed for the 75:5 and 110:5
series [165]. This has been explained on the basis of the polymer micelle
assembly theory where PLA blocks associate as linear chains within the particle
core. In the lower pegylated series PEG blocks would exert a weaker influence
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during particle formation. As the molecular weight of the PLA block was
increased the PLA–PEG 75:5 and 110:5 copolymer behaved more like PLA
homopolymer itself where the PLA blocks agglomerated as entangled chains
following precipitation into the aqueous phase. There is more free space amongst
the linear core-forming PLA chains of the micellar type PLA–PEG 3:5, 15:5 and
30:5 nanoparticles than in the 75:5 and 110:5 series and this would thus be
responsible for accommodating the drug without increasing particle size in the
3:5, 15:5 and 30:5 series [166]. There are some studies where increased size with
addition of drug was assigned to be due to the expansion of the polymer matrix
by the drug [166]. However, this seems highly unlikely to be an important factor
influencing increase in particle size as the amount of drug loaded within the
particles and its subsequent volume within the matrix is negligible compared to
the polymer mass. There are some studies reporting no difference between the
sizes of the empty and the drug loaded particles thus indicating a lack of
significant influence of drug-polymer interactions in particle formation. In a
study by Gomez-Gaete on DXM incorporation within PLGA polymers of various
LA/GA ratios, it was found that NP size and zeta potential were not modified in
the presence of drug and both empty and drug loaded particles had a similar size
of around 230 nm [154]. Similarly, Zhang et al studied incorporation of DXM in
poly (trimethylene carbonate) polymers. Particles were between 70 to 200 nm in
size and there was no difference between the drug loaded and empty
nanoparticles [167]. From these previous studies where interaction between drug
and polymer was not expected, little difference in particle size has been seen on
drug incorporation. However, from our results, the most important factor
influencing particle size appears to be the nature of interactions between drug
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and polymer. With our polymers an increase in molecular weight of the
backbone and substitution with acyl groups led to an increase in size of the drug
free particles thus suggesting that the assembly of polymer chains in the aqueous
phase changes with polymer substitution and the acyl groups could cause an
increase in free volume between the polymer chains, however in presence of
drug this assembly is altered and the interactions between polymer and drug
predominate over the effects caused by the substituents alone suggesting that the
result was either a compact and closely packed particle or more loosely packed
arrangement.
Zeta potential of the empty particles was most likely to be due to the presence of
terminal ionised carboxyl groups of the polymer present on the nanoparticle
surface. Increase in polymer molecular weight is associated with an increase in
the relative amount of pendant hydroxyl groups in the polymer and a decrease in
carboxyl groups present on the surface [161]. In the case of our polymer,
acylation led to a decrease in the amount of pendant hydroxyl groups. Both of
these groups are hydrophilic so will either try to arrange themselves on the
surface or alternatively will provide hydrophilic spaces/channels in the particle
matrix. The zeta potential of empty particles did not vary much on acylation
which could be an indication of the nature of assembly of particles. As there was
no significant deviation in the zeta potential it could probably mean that the side
chain groups orient facing the core of the particles and not on the surface.
In the presence of drugs, Zeta potential of CYT-ARA particles did not differ
much from that of the empty particles. The reduction in negative charge for
DXMP formulations as acylation increased could be the effect of DXMP
interaction with the polymers thus influencing the assembly of polymer
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molecules and appearance of carboxyl and hydroxyl groups present on surface.
The only exception was the 20% C8 polymer incorporating DXMP where a slight
increase in the negative values of zeta potential was observed. Here, there could
be a possibility of surface localisation of drug [168], and presence of ionised
phosphate groups of DXMP in addition to the ionised carboxyl groups.
3.5.2. Drug incorporation
Drug loading estimated using the indirect method was significantly higher than
the direct extraction method. Although the exact reason for this false high
loading is not exactly clear it seems that there may be some loss of drug by its
adsorbtion on the column during separation which could lead to a lower
concentration of the anaylsed free drug fraction. Drug loading within polymers
substituted with acyl groups of varying chain lengths from C2 to C10 was
investigated (Fig. 3.12). From C2 to C6, increase in chain length was not
accompanied with any increase in drug incorporation. This indicates that loading
of DXMP within the polymers was not influenced by hydrophobic interactions
alone. On the contrary, increase in chain length of acyl groups from C8 to C10
was accompanied by substantial drop in drug loading. Interaction between the
steroid nucleus and the acyl groups seemed to be very specific for the number of
carbon atoms and C8 polymers could be most favourable for enhancing drug
incorporation by promoting interaction with the drug and decreasing diffusion
from the organic to aqueous phase during particle formation. Poor incorporation
within the C10 polymers could be accounted by considering the marked increase
in hydrophobicity of the polymer core which probably did not allow for
sufficient encapsulation of the water soluble drug in the aqueous phase.
However; this seems unlikely to be a complete explanation as previous studies
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by the group on C18 substituted polymers did show good incorporation. Also, it is
worth noting that batches of C10 showed heavy aggregation after complete
evaporation of organic phase. The nanoparticle suspension had to be filtered
before analysis. This could have led to substantial loss of drug entrapped in the
precipitated polymer causing substantial decrease in amount of drug incorporated
into the nanoparticles. Hence among the acylated polymers, C8 acylated polymers
were chosen for further studies.
DXMP is a hydrophilic drug containing a steroidal ring (Fig. 3.2). We expect the
acyl groups on the acylated polymers to interact with the steroidal nucleus of the
drug thus retaining it within the particle core [151]. The polymer drug interaction
could be envisioned as the steroid nucleus occupying the space between the acyl
chains of the polymer similar to the orientation of steroids within the
phospholipid bilayer. The results from particle size support this theory, as more
compact and condensed particles were formed with DXMP than the empty
particles (Table 3.1). The higher the number of acyl groups, the greater the
expected interactions between drug and polymer. Hence the polymer with 100%
acylation showed maximum incorporation compared to the lower acyl substituted
polymers (Fig. 3.13).
Panyam et al. have reported greater Dexamethasone loading in PLGA/PLA
polymers with high lactide content (100%) compared to that with polymer
containing a fraction of glycolide and for lower molecular weight PLGA (12,000
Da) than higher molecular weight PLGA [169]. The incorporation and release of
the water insoluble dexamethasone (DXM) from nanoparticles of poly (lactic-co-
glycolic acid) (PLGA) embedded in alginate hydrogel (HG) matrices was
investigated by Kim et al [170]. DEX-loaded PLGA nanoparticles were prepared
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using a solvent evaporation technique. The amount of DXM loaded in the
nanoparticles was approximately 13 wt. %. In a study on incorporation of water
soluble corticosteroid Beclomethasone phosphate within PLGA polymers,
Horisawa et al found that drug content in the particles depends upon polymer
molecular weight and LA/GA ratio [171]. The highest incorporation of 5.8% was
reported within PLGA containing LA/GA 75/25 and MW 19,500. In order to
enhance encapsulation of the water soluble steroids beclomethasone phosphate
and hydrocortisone succinate into PLGA nanoparticles, Ishihara et al. used metal
ions like zinc in order to precipitate the water soluble steroids into their
hydrophobic forms by forming water insoluble metal steroid complexes with the
phosphate or succinate groups on the steroid rings. Incorporation of
Beclomethasone phosphate and hydrocortisone succinate in the presence of zinc
ions was only 5% and 1% respectively [172].
The acylated polymers did not seem to have a significant influence on CYT-
ARA incorporation (Fig. 3.13). The unsubstituted hydrophilic backbone was
more suitable for a highly polar drug like CYT-ARA thus further strengthening
the hypothesis of increased interaction between steroid nucleus (DXMP) and
acyl groups on the backbone. CYT-ARA binding is enhanced in presence of
more hydroxyl groups (lower acyl substitution, higher MW) on the polymer
indicating a possibility of hydrogen bonding as the main mechanism of
interaction (Fig. 3.2) This hydrogen bonding could also involve the terminal
carboxyl groups. At pH 7, Cytarabine is present in the 100% ionised state. The
positively charged cytarabine molecules may however interact better with the
negatively charged carboxyl groups of the polymer via electrostatic attraction
[173]. Although there is little information on CYT-ARA nanoparticles within
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polymers with fatty acyl groups, results obtained from a study of CYT-ARA
encapsulation in dipalmitoylphosphatidylcholine: cholesterol: dicetylphosphate
(DMPC) liposomes coated with O-palmitoylpullulan (OPP) can be compared
with our results using acylated polymers. It was found that coating with OPP
increases the stability of the liposomes as a drug delivery system in harsh
environments such as encountered after oral administration. However, the
reported encapsulation efficiency of CYT-ARA decreased from 27% in the
uncoated liposomes to 15% after coating with fatty acyl groups [174]. Thus,
presence of acyl groups could be responsible for either decreased interaction with
the polymers or interference in affinity of the drug into the polymer core.
However, this seems to be in contrast to the study by Stamp on factors affecting
Cytarabine encapsulation within liposomes where it was reported that Cytosine
arabinoside seems to interact with liposomal membranes at physiological pH and
ionic conditions with high efficiency [175]. In a study by Gomez et al.,
Cytarabine-loaded albumin microspheres were synthesized and were then
included in poly (lactide-co-glycolide) to obtain a comatrix that showed a good
drug loading [176]. The amount of cytarabine included in albumin microspheres
was between 46-50 ȝg of drug/mg of microspheres depending on the
composition of the disperse phase (i.e. 4.6 to 5.0% loading). The high solubility
of cytarabine in aqueous medium (148 mg/ml) was reasoned to be responsible
for some of the drug to be eliminated in the washing process after synthesis.
Influence of polymer molecular weight on drug loading showed that an increase
in MW led to increase in drug loading (Fig. 3.14) for both drugs. This is in
accordance with reported data showing that generally with increase in molecular
weight there is an increase in drug incorporation [130, 132].
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Labhasetwar et al. reported increased DNA loading within higher molecular
weight PLGA polymer [177]. However, these results seem to be in contrast to the
results of Panyam et al., who reported a higher DXM loading in PLGA with
12,000 Da molecular weight compared to PLGA of higher molecular weight
(143,000 Da) [169]. They concluded that drug is present in crystalline state
within the lower molecular weight polymer and that must have led to increased
solid state solubility of the drug in the polymer matrix. Studies with Poly lactide-
co-glycolide polymers and their derivatives show decreased entrapment of
Huperzine A with higher molecular weight polymers [178]. This has been
attributed to the decreased hydrophilicity of high MW polymers as they contain
fewer carboxylic acid terminal groups [178, 179]. However with our polymers
the presence of pendant hydroxyl groups in addition to the terminal hydroxyl /
carboxyl groups determines their hydrophilicity and hence the 12 kDa polymer
backbone contains more OH groups per polymer chain that enhances counter ion
interactions with DXMP and CYT-ARA leading to better incorporation of these
drugs as compared to the 2 kDa and 6 kDa backbone units.
On comparing the drug loading in particles prepared by the IDP and
emulsification methods, higher loading was seen in particles prepared using the
IDP method (Fig. 3.15). The nanoprecipitation (IDP) method is more flexible
and can be modified to achieve incorporation of drugs of varying
physicochemical properties [180]. Emulsified particles were prepared in the
presence of Tween 80. When the surfactant is present at a concentration
exceeding its Critical Micelle Concentration, there is a formation of micelles of
surfactant in the external phase. The Critical Micelle Concentration of Tween 80
solution is 13 mg/ml or 0.35% [181], while we have used a 1% solution in this
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study. This may be responsible for solubilisation of drug into the external phase
as the organic solvent used to prepare the polymer solution diffuses towards the
external phase taking the drug along with it [182].
3.5.3. Drug release
DXMP particles prepared from the 100% acylated polymers showed a controlled
release profile without burst release. Decrease in acylation resulted in a more
rapid release along with a significant burst effect (Fig. 3.16). Similarly, the
polymer backbone with a higher MW had a lower burst and greater retention of
DXMP compared to the 6 kDa polymer (Fig. 3.18). These results may be due to
strong hydrophobic interactions between hydrophobic domain of polymer and
drug. The steroid - acyl interaction discussed in section 3.5.2 could also be
responsible for the better retention of drug within acylated polymers. Thus,
enhanced interaction between drug and polymer contributed to both sustained
drug release and increased drug loading (Fig. 3.13). Also, the more hydrophobic
domain of polymer should lead to a stronger hydrophobic interaction. Surface
localisation of DXMP may have occurred with the lower percentage acylated
polymers (Table 3.1) that led to rapid release of bound drug. Release from the
100% acylated polymer was probably due to diffusion of entrapped drug through
polymer matrix and surface erosion of polymer [183]. The Higuchi analysis of
DXMP release from the 100% acylated polymer (Fig. 3.21) suggests diffusion
was a significant mechanism of drug release.
It has been reported that the lower molecular weight polymer fractions easily
escape from the nanoparticles during the release conditions especially in the
initial phase from PLA particles [86]. Low molecular weight PLGA particles in
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the absence of a surfactant showed a great burst release of drug [176]. This was
due to the presence of shorter hydrophobic blocks that are more water soluble
and degrade faster.
Soo et al. studied the effect of PCL block length on the release of estradiol from
polycaprolactone-block-poly (ethylene oxide) (PCL-b-PEO) micelles [184]. The
drug was released more slowly from PCL151-b-PEO44 than PCL23-b-PEO44
because presumably it had a larger core due to the longer hydrophobic block
(151 units of PCL), compared to the shorter hydrophobic block (23 units of
PCL). The drug had a longer diffusion distance when in a core with a longer
hydrophobic block. Jeong et al. showed that for poly ( -benzyl L-glutamate)-b-
poly (ethylene oxide) (PBLG-b-PEO) micelles with different PBLG contents, but
similar loadings of adriamycin, the release was slower from the copolymer with
higher poly ( -benzyl L-glutamate) content [185]. The increased hydrophobic
interactions between the drug and the micelles with higher PBLG content were
responsible for the slower release. However, all micelle samples were associated
with an initial burst of around 20 to 30% in the first hour. Similarly, Nah et al.
incorporated norfloxacin and clonazepam into poly ( -benzyl L-glutamate)-b-
poly (ethylene oxide) micelles and observed that the drug release was slower
from the longer PLBG chains [186]. Gorshokova et al. found that over a 15 day
period, the release rate of daunomycin was reduced from 16% to 4% due to the
introduction of hydrophobic blocks (decylamine) [187]. In an attempt to decrease
the rate of release of DXM from NPs of PLGA, Kim et al. entrapped the PLGA
NPs into alginate hydrogels at 1% and 3% concentrations [170]. Free NPs in
PBS solution showed an initial burst of 60% during the first two days followed
by gradual reduction of release. NPs entrapped in alginate hydrogels at both
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concentrations showed a marked decrease in the burst with 20% drug being
released after 24 hours. Song et al. reported a 25% release of DXM from PLGA
particles in the initial 24 hours [88].
For CYT-ARA, as evident by the drug loading results, drug loading in the
acylated polymers is low (Fig. 3.13). The polymer backbone had minimum initial
release (20%) after 24 hours and there was no significant difference in the initial
release rates from the 20% and 40% acylated polymers (Fig. 3.17). Also, there
was no significant difference in the release from the 2 kDa and 12 kDa polymer
backbones except that for the latter greater retention was observed and 90% of
the drug was released by 24 days. The 6 kDa polymer released the drug rapidly
(Fig. 3.19). The fully acylated polymer had a rapid and uncontrolled release.
Incorporation of CYT-ARA was highest in the 12 kDa polymer backbone with
no acylated groups (Fig. 3.14). This indicates that for CYT-ARA, the hydroxyl
and carboxyl functions were important not only for enhancing the drug loading
but also for retaining the drug within the core for a longer period. With an
increase in polymer MW an increased loading was observed. Surprisingly,
loading within the 2 and 6 kDa polymers was similar, yet retention and release
was better with the lower MW polymer. Thus, it is evident that the water
solubility of the lower MW fractions did not seem to be important for amount of
drug loaded. Surface localisation of the drug could have occurred with the 6 kDa
polymer resulting in its rapid release (Fig. 3.14). With an increase in acylation of
the polymer the number of hydroxyl groups available was lower compared to the
backbone and this could be responsible for the slight increase in the initial
release rate. However, all three polymers (backbone 12 kDa, 20% and 40%
acylated) retained the drug for a longer period of time compared to the 100%
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acylated polymer. Solubility of DXMP in water is 500 mg/ml while that of CYT-
ARA is 300 mg/ml. Both are highly water soluble drugs yet DXMP was retained
best by the most hydrophobic polymer. CYT-ARA release was uncontrolled
from the same polymer thus strongly suggesting an altered ability of the polymer
to retain the drug depending upon the structure of drug and its interaction with
the polymer.
When the drug-loaded hydrophilic polymeric carrier contacts water, swelling of
the polymer might occur as a result of diffusion of water molecules into the
polymer network and relaxation of macromolecular chains. Both of these
processes result in a release of the entrapped drug. It is known that drug release
may be diffusion controlled or dissolution controlled, depending on the
parameters such as permeability of the polymer to water, the solubility of the
drug in the polymer and in water, and size of the drug [173]. In the present case,
release by dissolution is not applicable as both DXMP and cytarabine are water
soluble. Thus, the mechanism of drug release is most likely to be diffusion or
Fickian controlled.
Most studies have reported a higher initial rate of release and lower retention of
water soluble drugs from hydrophilic polymers. Other factors contributing to
high initial burst release are large surface area, high diffusion coefficient and low
viscosity of matrix [188].
In a study of CYT-ARA release from gelatine nanoparticles it was found that
drug release rate was more controlled with increasing percent of drug loading.
This was attributed to decrease in the pore size of nanoparticles due to
accumulation of drug molecules within the nanoparticles. The diffusion of water
molecules into the loaded nanoparticles would hence be restrained resulting in a
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lower release of cytarabine [173]. Ameri et al. reported sustained release of Ara-
C from matrices prepared from triblock copolymers C17EmC17 (where C denotes
methylene or methyl, E denotes oxyethylene, and m is either 227 or 454) [189].
The particular copolymers were chosen as representatives of the class of
copolymers which form elastic, cross-linked gels through association
(micellisation) of their alkyl end blocks. The release of cytarabine from the
copolymer matrices was predominantly by a Fickian diffusion mechanism and
attributed to increase in matrix gel layer thickness as water diffused into the
matrices. The release rate was dependent on drug loading and independent of co
polymer molar mass. In our studies, for either drug, polymers with the highest
drug loading had slowest release.
The release kinetics of Ara-C from Albumin-PLGA co matrix microspheres took
place via swelling and showed a hyperbolic profile [176]. The maximum drug
release from Ara C – PEG conjugates took place in the first 7 h, and a burst
effect was observed in the first hour, where 29 to 37% of the drug was released.
These conjugates of Ara-C with PEG release drug by a different mechanism
compared to PGA or PLGA particles however, it is worth noting that even
conjugated drug showed 60 to 80% release within 8 to 10 days at pH 7.4 [173].
Studies incorporating flurouracil in PLA-PEG-PLA triblock polymers showed
that the rate of drug release was high (60%) in the initial period. Most drug was
released within 2 to 3 days by diffusion and burst release. This was correlated
with the hydrophilic nature of the drug which does not permit encapsulation in
the micelle core [190]. In a study performed by McCarron et al. on release of 5-
FU from PLGA particles, an initial burst effect of 50% drug was seen in the first
hour followed by a slower release of 66% drug released over 24 hours [183]. As
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evident from our results, for our polymers, drug release is not influenced by
hydrophobic characteristics of the polymer or properties of the drug in isolation.
Rather, it is a combined effect of both drug and polymer properties that influence
their interactions and hence retention within the polymer core.
Most commonly it is reported that particles with a higher drug loading have a
fast release rate mainly attributed to surface localisation [191]. The amounts of
lidocaine released in PBS from PLA nanoparticles in the initial phase were
related to the nanosphere size [29]. Their DSC and infrared studies showed that
no strong chemical interaction between drug and polymer occurred. Release
kinetics of praziquantel from PLGA particles was governed not only by actual
drug loading but also by the particle size. The higher the drug content and the
smaller the particle size, faster was the drug release [192].
Nah et al. correlated clonazepam release from block copolymers consisting of
SRO\ȖEHQ]\O/JOXWDPDWH3%/*DVWKHK\GURSKRELFSDUWDQGSRO\HWK\OHQH
oxide) (PEO) as the hydrophilic part to drug loading contents [186]. They found
that the polymer with a longer PBLG length had a greater drug loading and
slower rate of release. In a study of Fluorescein isothiocyanate-dextran
encapsulation within cross linked polyvinyl pyrolidone NPs, a 3.2% w/w loading
of Fluorescein isothiocyanate–dextran in polyvinyl pyrolidone polymer released
nearly 95% of drug in 10–12 days while about 60% release occurred from the
nanoparticles during the same period when the dye loading was 6.4% w/w in the
same polymeric material [193]. It was hypothesised that a larger population of
dye (6.4%) within the same volume of nanoparticles may lead, at least partly, to
the association of dye molecules as dimers, trimers, etc. or even to the formation
of solid clusters inside the matrices of the nanoparticles [194]. When the
CHAPTER 3 DXMP AND CYT-ARA
103
concentration of dye inside the core of the particle is very high, a part of it is
associated or clustered, which has to be dissolved and released more slowly out
of the nanoparticles. At low loadings of the compound, it may remain in the form
of a molecular dispersion inside the polyvinyl pyrolidone nanoparticles.
For a number of polymer systems studied it has been reported that particles with
the largest size have more controlled release compared to the particles with
smaller sizes [89, 194, 195] and factors like increase in particle size, increase in
polymer MW inhibit drug diffusion. This has been explained based on the fact
that small sized nanoparticles have increased total nanoparticle surface area
resulting in larger drug fraction exposed to leaching medium molecules. Thus,
decrease in particle size may lead to increased diffusion from organic to aqueous
phase during solvent evaporation causing low drug loading and fast release.
Smaller nanoparticle size also leads to a shorter average diffusion path of
entrapped drug. From our studies, we observed that difference in particle sizes
cannot be considered as a predominant factor influencing drug release. Although,
for DXMP particles it was found that the 100% acylated polymer forming
particles with largest size had slowest release compared to polymer backbone
that formed particles with smallest size. In presence of CYT-ARA, the 20 and
40% acylated polymers formed particles that were similar in size to the 100%
acylated polymers; however, only the release rate from the 100% acylated
polymers differed significantly from the others and was rapid.
The difference in release profile of DXMP prepared using the emulsification
method may be due to the presence of Tween 80 as explained by Niwa et al.
[86]. An increase in the concentration of Tween 80 led to enhanced release (Fig.
3.20). When the surfactant is initially present in the aqueous phase there is the
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possibility of anchoring of the surfactant molecules to the polymer matrix. This
surface bound fraction of the surfactant may contribute to the solubilisation of
the drug molecules reaching the nanoparticle surfaces and facilitating their
dissociation to the leaching medium. This may then be responsible for enhanced
drug release and lower drug encapsulation [86, 190].
Surfactants also contribute to the burst release by promoting a more porous
structure [190]. Arica et al. prepared betamethasone particles using surfactants
PVA (8 -18%) or sodium cholate (25-35%). They observed an initial burst
release followed by sustained release delivering 15 to 40% entrapped drug within
48 hrs [196]. Various other studies have also shown that increase in surfactant
concentration leads to an increase in drug release [90, 194, 196].
3.6. CONCLUSIONS
PGA polymer backbone and its substituted acylated series can form stable
nanoparticles in the presence and absence of drugs and in the absence of
surfactants.
DXM-P loaded particles are smaller in size than CYT-ARA particles suggesting
a possible role of drug polymer interactions in particle formation. Drug loading
increases with acylation and molecular weight of polymer for DXMP, while
CYT –ARA shows maximum incorporation within polymer which is non
acylated and of maximum molecular weight. The degree of polymer acylation
has less effect on drug loading of CYT-A than that of DXM-P. Burst release for
DXMP decreased as acylation increased. Thus, increase in polymer acylation
contributes to an increase in drug loading and decrease in rate of cumulative drug
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released. Increase in Polymer acylation increased drug release for CYT-ARA
with the most controlled release occurring from the polymer backbone particles.
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CHAPTER 4. SYNTHESIS AND
CHARACTERISATION OFAMINOACID
SUBSTITUTED POLYMERS
4.1. Introduction
The polymer backbone substituted with acyl groups has been investigated
extensively for drug incorporation and release in the previous chapter. The
backbone was further substituted with amino acids viz. N- acetyl tryptophan and
N- acetyl tyrosine in order to study the influence of aromatic rings and ring
stacking as a non covalent bond on the polymer characteristics, incorporation and
release characteristics of hydrophilic and hydrophobic drugs. The polymer was
substituted to a similar extent as the acylated polymer series (Chapter 3). The
degree of substitution ranged from 1% to 60% substitution. In addition to the
above, a combination polymer containing 40% acyl and 5% tryptophan side
chains together was synthesised and investigated. The drugs included in the
study were anti cancer drugs containing aromatic heterocycles (Etoposide,
Paclitaxel) with an aim to study the effect of aromatic ring stacking between the
polymer and the drugs and their influence on drug loading and release.
Aims of the chapter:
x Synthesis of amino acid and combined acyl-amino acid substituted
polymers.
x Characterisation of the substituted polymers.
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x Optimise degree of substitution for assembly into stable nanoparticles.
4.2. MATERIALSAND METHODS
4.2.1. MATERALS
Polymer backbone and the C8 acylated polymers were obtained as described in
Chapter 2. The amino acids N-Acetyl-tryptophan, N- acetyl tyrosine, Deuterated
acetone, Methanol, EDAC, DMAP were purchased from Sigma. All solvents
used were of HPLC grade.
4.2.2. METHODS
Tryptophan, tyrosine and the combination polymer were synthesised using the
EDC mediated conjugation as described in sections 2.3.1, 2.3.2 and 2.3.3.
The reaction mechanism is illustrated in Fig. 4.1. Molecules with reactive amino
or carboxyl groups can be coupled to polymers with reactive sites under gentle
conditions using water soluble carbodiimides; example 1-ethyl-3-(3-
dilethylaminopropyl) carbodiimide hydrochloride (EDAC) to form covalent
conjugates via amide/ester bonds. The reaction involves the intermediary
formation of the activated o-acylurea derivative of the carbodiimide. A
subsequent nucleoplilic attack by the activated hydroxyl group on the polymer in
the presence of dimethylaminopyridine as a catalyst brings about the formation
of the ester linkage with the release of the soluble substituted urea [197]. The
reaction was simple and straightforward and went smoothly without any
difficulties.
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Fig. 4.1. Reaction mechanism of EDAC mediated (A) Tryptophan (B) Tyrosine
(C) Acyl-tryptophan conjugation to backbone/acylated poly (glycerol adipate).
(A)
(B)
(C)
CHAPTER 4 Characterisation Of Amino Acid Polymers
109
4.3. RESULTS
The synthesised polymers were then characterised by NMR. Following are the
NMR scans of the polymer backbone, 40% tryptophan substituted polymer, 5%
tyrosine and 40% C8 + 5% tryptophan substituted polymers.
Fig. 4.2. NMR spectrum for poly (glycerol adipate) backbone
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Fig. 4.3. NMR spectrum for poly (glycerol adipate) backbone substituted with
tryptophan (40%)
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Fig. 4.4. NMR spectrum for poly (glycerol adipate) backbone substituted with
tyrosine (5%).
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Fig. 4.5. NMR spectrum for 40% C8 acylated polymer substituted with
tryptophan (5%)
CHAPTER 4 Characterisation Of Amino Acid Polymers
113
Fig. 4.6. FTIR of poly (glycerol adipate) substituted with tryptophan (40%).
(Polymer backbone ---, Polymer + Tryptophan ---).
4.4. DISCUSSION
The NMR for the polymer backbone is presented in Fig. 4.2.
Due to the random polymeric nature of these systems the NMR interpretation
becomes somewhat complicated. The area between į (4.5-3.5) appears cluttered.
It could possibly indicate that the hydroxyl proton must be involved in hydrogen
bonding which would account for the large number of peaks in this area due to
the varying conformations viz intra and inter- molecular hydrogen bonding. The
peaks for the 4 methylene protons –CH2-O-CO- appear at į( 3.9-4.1) and the –
CH2-CO- are detected at 1.63 ppm while –CH2-CO-O- at 2.09 ppm. The pendant
hydroxyl group appears at 5 ppm.
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However, for the tryptophan substituted polymer peaks at į (7-7.5), characteristic
to the benzene ring of tryptophan/ tyrosine and the peak at 10 ppm corresponding
to the indole proton confirm the presence of amino acid attachment to the
polymer. The spectrum in Fig. 4.3 is of a 40% substituted polymer in order to
demonstrate the benzene protons with clarity. The degree of substitution was
calculated by calibrating the 4 methylene protons of the protons. The integral of
the protons of the benzene group correspond to the degree of substitution.
Around 2 to 3 % substitution occurred for the tryptophan substituted polymers.
(For NMR of pure tryptophan and tyrosine refer Appendix 16 and Appendix 17
respectively).
Similarly, with the addition of tyrosine (Fig. 4.4) the benzene ring protons are
visible although they appear slightly downfield compared to tryptophan. The
phenolic proton was detected at 8.2 ppm. The methylene protons from tyrosine
were also visible between 3.5 and 4 ppm although the signal was very weak as it
is a 5% substituted polymer. Also, since no protecting group was used for the
hydroxyl groups on tyrosine before its conjugation with the polymer there might
be some intramolecular hydrogen bonding and cross linked product although it
cannot be distinguished distinctly in the NMR. However from the integral values
of the benzene protons resulting in around 1 % substitution it could indicate cross
linking in the product.
From Fig. 4.5, for the polymer substituted with both acyl and tryptophan groups
the presence of methylene protons in the alkyl groups and the methyl proton in
addition to the tryptophan protons were detected upfield at 1.02 and 0.9 ppm.
The FT-IR of the polymer substituted with 40% tryptophan further confirmed the
presence of ester bonds at 1659 and 1556.50 cm
-1
, which was absent in the scan
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of the unmodified polymer. The peaks for the hydroxyl groups shifted from
3448.2 in the polymer backbone to 3307.64 cm
-1
probably due to involvement of
some protons in esterification reaction (Fig. 4.6).
4.5. CONCLUSIONS
Polymers were successfully substituted with tryptophan and tyrosine in varying
degrees.
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CHAPTER 5. INCORPORATIONAND RELEASE OF
ETOPOSIDEAND ETOPOSIDE PHOSPHATE FROM
FUNCTIONALISED POLY (GLYCEROLADIPATE)
NANOPARTICLES
5.1. Introduction
Podophyllotoxin is an antimitotic natural product. Its inhibitory activity on cell
growth led to the development of the clinically valuable anticancer agents,
etoposide, teniposide and the water-soluble prodrug, etoposide phosphate. The
cytotoxic mechanism of these drugs is the inhibition of topoisomerase II [198].
Etoposide is a highly hydrophobic molecule with lipophilic properties, and the
formulation of etoposide is quite challenging. The major limiting step in the
formulation of etoposide is its lipophilicity, and vehicles Cremophor® EL,
(CrmEL) or polysorbate 80 (Tween® 80) used as solubilizers are associated with
adverse side effects such as hypotension, anaphylaxis, bronchospasm,
nephrotoxicity and cardiotoxicity, some of which can even be life threatening
[199-201]. Commercial Etoposide formulations are eliminated rapidly from the
blood circulation upon intravenous administration and produce
myelosuppression. Etoposide Phosphate on the other hand, is water soluble and
is converted to etoposide in vivo. No reported literature exists to date on
Etoposide phosphate formulation into colloidal drug delivery systems. The
nanoparticles containing ETO and ETO-P in functionalised poly glycerol adipate
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nanoparticles were characterized by Photon correlation spectroscopy (PCS) for
size and size distribution, Transmission electron microscopy (TEM) for
morphological properties and zeta-potential for surface charge. We aim to
investigate the influence of chemistry of drug and polymer on their interaction
and retention within nanoparticles.
Aims of chapter:
x To assess the ability of poly glycerol adipate and its modifications to
encapsulate ETO and ETO-P into stable nanoparticles.
x To study the influence of polymer functionalisation and nature of side
chain functional groups on drug incorporation and release of ETO and
ETO-P.
x To compare encapsulation and release of a hydrophobic drug (ETO) and
its hydrophilic prodrug (ETO-P) with similar chemical structure, from
various polymers with different properties.
5.2. MATERIALSAND METHODS
5.2.1. MATERIALS
Etoposide and Etoposide phosphate were obtained from Sigma UK. Polymer
backbone, acyl substituted and amino acid substituted polymers were synthesised
as described in Chapter 3. All organic solvents were of HPLC grade.
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4'-demethyl-epipodophyllotoxin 9-[4, 6-O-(R)-ethylidene-beta-D-
glucopyranoside]
Formula: C29H32O13
Mol. Weight: 588.557g/mol
Fig. 5.1. Molecular structure and identity of Etoposide (ETO).
4'-Demethyl-epipodophyllotoxin 9-[4, 6-O-(R)-ethylidene-ß-D-
glucopyranoside], 4'-(dihydrogen phosphate).
Formula: C29H33O16P
Mol. Weight: 650.557g/mol
Fig. 5.2. Molecular structure and identity of Etoposide phosphate (ETO-P).
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5.2.2. METHODS
5.2.3. Preparation of Etoposide nanoparticles
Etoposide loaded nanoparticles using polymer backbone, acylated and amino
acid substituted polymers were prepared using both the interfacial deposition
method and the interfacial deposition method with preformed matrix as described
in section 2.4.3, Chapter 2.
5.2.4. Preparation of etoposide phosphate nanoparticles
Etoposide phosphate nanoparticles were prepared using the interfacial deposition
method described in section 2.4.3, Chapter 2.
5.2.5. Separation of free drug from nanoparticles
Nanoparticles were separated from unincorporated drug using methods 2.3 A and
B described in Chapter 2.
5.2.6. Physicochemical Characterisation
Size, surface charge and external morphology of the nanoparticles were
determined using methods detailed in Chapter 2.
5.2.7. Determination of drug loading
Drug loading was determined by extraction of drug from the nanoparticles
followed by quantitation of drug extract.
Etoposide: The freeze dried nanoparticle powder was weighed and dissolved in a
mixture of acetone/ MeOH (1:2), followed by centrifugation at 13500 rpm for 3
mins. Acetone was then allowed to evaporate and methanolic solution was
analysed by HPLC. Samples were passed through a Lichrosphere 100 RP-18
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(5µ) endcapped column Mobile phase MeOH: Water: Acetic acid 54:45:1, flow
rate was 1 ml/min and the operating pressure was 2800 psi.
Etoposide phosphate: The freeze dried nanoparticle powder was weighed and
dissolved in a mixture of acetone/ PBS (1:2), followed by centrifugation at a
speed of 13500 rpm for 3 mins. The supernatant was then analysed using UV
spectroscopy at 281 nm.
5.2.8. Drug Release
Drug release studies were performed with distilled water as the external media
for Etoposide phosphate and with 0.1% Tween in HEPES for Etoposide at 37°C
for 25 days.
5.3. RESULTS
5.3.1. Particle size and zeta potential
The effect of polymer substituents and properties of drug on particle size and
surface charge were examined.
Table 5.1 compares the size and zeta potential of particles loaded with either
Etoposide or its phosphate prodrug within various substituted polymers.
With the amino acid substitution, particle size decreased compared to size of
particles produced with backbone and with the acylated polymers. The polymer
substituted with both acyl and tryptophan groups produced particles which were
larger than the tryptophan or tyrosine substituted polymer and smaller than the
40% acylated polymer. Comparing the size of drug loaded particles with empty
particles; it was observed that the acylated polymers in the presence of either
drug produced slightly smaller particles compared to the amino acid substituted
polymers.
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Table 5.1 Particle size and Zeta potential of ETO and ETO-P loaded nanoparticles using various polymers by the Interfacial deposition method.
Polymer type is designated by nature and degree of substitution, MW. Results are mean of 3 readings, SD standard deviation.
POLYMER TYPE
EMPTY PARTICLES (+) ETO (+) ETO-P
SIZE nm
(SD) [polydispersity]
ȟ327(17,$/P96' SIZE nm
(SD) [polydispersity]
ȟ327(17,$/P96' SIZE nm
(SD)[polydispersity]
ȟ327(17,$/P96'
Polymer backbone 169.6(2.2)[0.57] -35.3 (0.9) 130.2 (0.56) [0.2] -25.3 (0.9) 125.1 (1.5) [0.4] -31.3 (0.32)
40%C8-12 267.5 (3.09) [0.33] -31.3 (0.3) 141.2 (1.4)[0.013] -31.3 (0.3) 139 (2.1) [0.11] -33.9 (2)
100%C8-12 201.3 (0.57) [0.23] -39.3(0.8) 126.1 (0.2) [0.03] -31.3(0.8) 141.8(1.1)[0.048] -34.3 (0.5)
5 % Tryptophan 132.3 (0.3) [0.05] -40.1 (2.9) 165.45 (0.16)[0.04] -43.8 (2.5) 159.3 (0.53) [0.23] -39.4 (1.2)
5 % Tyrosine 145.2 (2.9) [0.15] -34.2 (1.87) 177.12 (0.67)[0.06] -39.6 (0.5) 168.2 (0.5)[0.01] -31.4 (3.5)
40%C8 + 5 %
Tryptophan
190.7 (1.9) [0.35] -35.9 (0.9) 184.1 (1.0) [0.08] -29.9 (2.1) 149.3 (0.61) [0.09] -34.5 (0.7)
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The 40% C8 + 5% tryptophan substituted polymer produced particles smaller in
size than in the absence of drug. For ETO these particles were larger than either
the tryptophan or 40% C8 drug loaded particles, but for ETO-P were of
intermediate size.
Between the two different drug formulations it can be seen that the nature of the
drug appears to influence particle size. Increase in acylation increased the size of
ETO-P particles while particles produced using the acylated polymers were
smaller in size than the amino acid substituted polymers. For ETO-P, the largest
particles were produced using the polymer substituted with tyrosine moieties
while for ETO the combination polymer produced particles larger is size
compared to the other substitutents. The size of ETO-P particles with the amino
acid substituted polymers was smaller than the empty particles with the same
polymers. ETO, on the other hand did not follow a definite trend for acylated
polymers although the smallest particles with ETO were produced with 100%
acylated polymers. However, for amino acid substituted polymers, particle size
was larger than the acylated polymers and the empty particles and was the largest
with polymer containing both acyl and tryptophan substitutions.
Zeta potential of ETO-P loaded polymers was in the range of -31 to -35 mV with
the exception of the 5% tryptophan polymers which was around -40 mV. For
ETO the zeta potential was higher, in the range of -25 to -31 mV with the
exception of the amino acid substituted polymers with values around -40 mV.
Zeta potential of tyrosine substitution was more negative for ETO than ETO-P.
In presence of either drug, zeta potential of the combination polymer became less
negative than the tryptophan polymers alone.
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5.3.2. TEM Images
Fig. 5.3.TEM Image of ETO-P nanoparticle in 5% tryptophan substituted
polymer, MW 12kDa
Fig. 5.4. TEM Image of ETO nanoparticle in 5% tryptophan substituted polymer,
MW 12kDa
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Fig. 5.5. TEM Image of ETO nanoparticle in 100% C8 polymer, MW 12kDa
Particles prepared using the acylated polymers were spherical and homogenously
dispersed for both drugs as can be seen with the TEM images in Figures 5.3.
However, within the 5% tryptophan substituted polymers, particles prepared
using ETO were larger than ETO-P particles. Polydispersity was higher for ETO-
P loaded particles (Figs. 5.4, 5.5).
5.3.3.Determination of Drug Loading
5.3.3.1.Method validation for ETO (HPLC Assay)
Standard solutions of ETO in MeOH were analysed on the HPLC using the
method described in section 5.2.7 and a calibration curve was prepared (Fig. 5.6).
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Fig. 5.6. Calibration curve for Etoposide standard solutions in MeOH using
HPLC.
Fig. 5.7. HPLC chromatogram for ETO determination. Standard solutions of
ETO in MeOH were analysed to determine retention time on the column.
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Retention time of ETO under operating conditions described earlier was 4.23
minutes’. Empty particles do not show any peak at elution time of drug (Fig.
5.7). As a control, 200 ȝg of pure drug was added to a suspension of empty
nanoparticles and their recovery was analysed in order to estimate the efficiency
of the procedure (Table 5.2).
† total free volume
Table 5.2. Extraction efficiency of known amount of control ETO.
As it can be seen from Table 5.2, ETO from controls was recovered in a range
from 78 to 84% efficiency. Average drug loading was calculated and results
were divided by 0.773 to give the final amount of drug in the samples.
5.3.3.2. Method Validation for ETO-P
ETO-P was analysed spectroscopically. Standard solutions of known
concentrations of ETO-P in water were analysed at 281 nm on a UV-Vis
spectrophotometer and a calibration curve was prepared (Fig. 5.8). Samples were
extracted using the method described in Chapter 3. Control samples containing
known amount of ETO-P (200 ȝg) was added to the empty nanoparticles and
analysed to determine efficiency of the method.
Sample Area Conc.(ng/ml)
(* 100)
ȝg/tot.fr.vol.†
(4ml)
Efficiency
(%)
Avg.
Efficiency
(SD)
Control-1 5899 47.32 169.25 84.63
Control-2 4788 34.45 137.62 68.79
Control-3 5456 39.2 157.58 78.28
77.3%
(7.97)
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Fig. 5.8. Calibration curve for Etoposide phosphate standard solutions in water
using UV spectroscopy.
† total free volume
Table 5.3. Extraction efficiency of control ETO-P
As it can be seen from Table 5.3, around 68% of the control was recovered.
Average extraction efficiency was calculated and the average drug loading result
was divided by 0.68 to calculate the final drug loading of the samples.
Sample Abs.
(281nm)
Conc.(ng/ml)
*100
ȝg/tot.fr.vol.†
(4ml)
Efficiency
(%)
Avg.
Efficiency
(SD)
Control-1 0.0153 33.93 135.68 67.84
Control-2 0.0175 39.12 156.06 78.03
Control-3 0.0157 34.77 139.15 69.57
67.9%
(5.45)
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5.3.3.3. Effect of method of preparation on ETO loading
Fig. 5.9 shows the incorporation of ETO achieved using the original IDP method
compared with a modified method. Using the standard method resulted in a small
increase in ETO incorporation with increasing acylation and maximum drug
(0.74%) incorporated by the 100% acylated polymer (Fig. 5.9).
Fig. 5.9. Comparison of ETO loading using IDP and Modified IDP methods.
Modified IDP increased the loading within the polymers.
There was a very low drug incorporation using the original ID method as
compared to results obtained previously using water soluble drugs (DXMP,
CYT-ARA(500 ȝg/ml)>ETO(150 ȝg/ml). Hence, a modified ID method was
investigated. Here a matrix of the polymer was first prepared with the drug in a
common solvent followed by its addition into the aqueous phase as opposed to
adding the drug and polymer directly into the aqueous phase. Drug loading
increased substantially and followed a similar trend with increase in acylation.
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5.3.3.4. Effect of polymer substitution
Fig 5.10 compares incorporation of Etoposide in various substituted polymers
using the modified ID with Etoposide phosphate; a water soluble prodrug
incorporated by the standard IDP method. Among the acylated polymers increase
in acylation led to increase in incorporation of both Etoposide and Etoposide
phosphate (3% and 1.7% respectively in the 100% C8 polymers).
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Fig. 5.10. Influence of Polymer substitution on ETO and ETO-P incorporation
Polymer backbone substituted with acyl, amino acid or combination of acyl and
tryptophan were analysed for drug loading.
.
ETO incorporation in the amino acid substituted polymers was reduced
substantially compared to the 100% acylated polymer. Among these amino acid
substituted polymers, maximum incorporation was 1.8% in the tryptophan
substituted polymer. A combination of tryptophan and acyl groups gave a lower
ETO loading than either substituent alone (1.1%) and was comparable to the
loading in tyrosine substituted polymer.
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Incorporation of ETO-P was similar to ETO incorporation in the tryptophan
substituted polymer. Maximum ETO-P incorporation was found in the polymer
containing both C8 and tryptophan substitutions while ETO loading was
maximum in the 100% acylated polymer and minimum in the combination
polymer. Also, ETO loading in this combination polymer was comparable to that
in the tyrosine substituted polymer. Surprisingly, encapsulation of both drugs
was reduced markedly with the tyrosine substituted polymer to that seen in the
backbone polymer alone.
5.3.4. Determination of Drug Release
Effect of nature of polymer substitution on the drug release profile was
investigated. Etoposide release from the polymer backbone and substituted
polymers is compared in Fig. 5.11.
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Fig. 5.11. Influence of polymer substitution on ETO release from various
polymers. Drug release studies performed in 0.1% tween in HEPES (pH 7) for 10
days
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ETO release from the acylated polymers seemed to occur faster than from the
tryptophan substituted polymers (Fig. 5.11). Release from the tyrosine
substituted polymer was similar to the acylated polymer in the first 5 hours
following which a much slower release rate was observed. There was a very
small burst release for all the formulations. After the initial rapid release, the
acylated polymers had a slower rate of drug release than the backbone. The
slowest release was observed from the 5% tryptophan substituted polymer
followed by the 5% tyrosine substituted polymer. Drug release was slower in the
presence of all the substituted polymers compared to the polymer backbone.
Fig. 5.12. Influence of polymer substitution on ETO-P release from various
polymers Drug release studies performed in 0.1% tween in HEPES (pH 7) (5
days).
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Fig. 5.13. Influence of polymer substitution on ETO-P release from various
polymers (25 days).
Drug release profile of hydrophilic ETO-P is described in Figs 5.12 and 5.13. In
Fig. 5.12 drug release for only the initial 5 days has been presented. All the
formulations except the combination polymer showed fast initial release which
varied in extent with the formulation. The polymer substituted with acyl and
tryptophan groups together did not show a burst release and only 10% drug was
released after 5 hours. Both polymer backbone and 100% acylated polymer had a
similar slow rate of release which was incomplete. Only 30% drug was released
at the end of 5 days (Fig.5.12). Compared to the results obtained from acylated
polymers, the rate of ETO-P release from the tyrosine and tryptophan substituted
polymers was high. The fastest release was observed from the tryptophan
substituted polymer contrary to ETO release profile where tryptophan substituted
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polymer had the slowest release. Polymer with 40% acylation had faster rate of
release compared to backbone and other acylated series and was similar to
release from the tryptophan substituted polymer. The polymer substituted with
tyrosine showed greater retention after the initial burst and complete release was
seen at the end of 25 days followed by the combined acyl-tryptophan substituted
polymer that released 60% drug by the end of 20 days.
5.3.5. Analysis of drug release kinetics
In Fig. 5.14 (A) and (B) we plotted the cumulative release of drug (%) against
square root of time.
For ETO, only the Higuchi plots from the 5% tyrosine and 40% C8 polymers had
correlation values greater than or equal to 0.95 (Fig. 5.14 A) and these plots were
visibly linear curves. Hence, only these polymers follow Fick’s law of diffusion
for ETO release. All the plots were linear for ETO-P (Fig. 5.14 B) indicating a
diffusion controlled mechanism. Usually, the Higuchi plot applies to the situation
when the amount of drug release does not exceed 60%. Thus the plot was only
performed for data over 24 hours for the ETO-P particles.
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5.4. DISCUSSION
5.4.1. Particle size and zeta potential
Etoposide being a hydrophobic drug would be expected to interact strongly with
the more hydrophobic polymers. The 100% acylated polymer produced particles
of smallest size amongst the acylated series of polymer (Table 5.1). This
observation was similar to the DXMP incorporation by the 100% acylated
polymer (Chap 3, Table 3.1). Particles from the 100% acylated polymers were
either more condensed or had a lower aggregation number compared to the less
substituted polymers. Here we expect this to be due to a more compact
arrangement of molecules forming a particle due to drug polymer interactions as
discussed in section 3.5.1. The influence of method of preparation where size is
largely controlled by interfacial tension between the aqueous and organic layers
cannot be applied here as the drug is water insoluble.
Polymers with tryptophan and tyrosine substitution on the other hand were larger
in size compared to the acyl substituted polymers which could be attributed to
less efficient packing of the polymer’s bulky substituents and the etoposide
molecules. Alternatively, there could be a further increase in the number of
molecules associating to form a particle leading to greater increase in size
compared to the acylated polymers. Also, the method of preparation of these
particles differed from the method of preparation for previously investigated
drugs and ETO-P particles. Polymer and drug were allowed to interact before
adding into the aqueous phase thus allowing for greater chances of drug polymer
interactions.
Etoposide phosphate is highly water soluble and could best be solubilised in the
more hydrophilic polymers. Increase in acylation led to an increase in the size of
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particles. Although ETO-P is water soluble it did not follow the trend for DXMP
(Table 3.1) thus further strengthening the influence of drug and polymer
functional chemical characteristics on their interaction and hence particle size.
With the amino acid substituted polymers, particle size increased further
compared to acylated polymers. The only exception was the polymer containing
40% acyl and 5% tryptophan substitutions together, where particle size decreased
compared to the individually substituted polymers. In general, particles produced
with ETO-P were smaller than those produced by ETO. This could indicate
influence of the density of the side groups that influences size and packing
arrangement of molecules and was more compact in the presence of water
soluble drug compared to the hydrophobic drugs.
Zeta potential did not vary significantly between different polymer substitutions
and drugs although there was a tendency to form particles with a less negative
zeta potential values with ETO than with ETO-P. This indicates that surface
charges on the particles are not influenced by substituents present on the polymer
but there may have been some ETO on the surface. Probably, when molecules
assemble to form particles, the side groups and drug orient towards the core and
not on the surface. The charge is mainly due to presence of ionised carboxyl
group of the polymer matrix. With a charge of -30 mV all particles were
inherently stable to aggregation or precipitation in absence of the surfactant
[202].
5.4.2. Drug incorporation
The nanoparticles prepared with the ID method showed very little drug
incorporation (Fig. 5.9). This could be due to insufficient opportunity for
interaction between the polymer chains and the drug when added to the aqueous
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phase. Hence, in order to promote interaction between the drug and polymer, we
first prepared a mixture of both drug and polymer followed by its addition into
the aqueous phase. Also, this may be due to stronger interaction between the
drug and polymer matrix than the solvent drug interaction when allowed to
interact before adding to the aqueous phase. This simple modification led to a
marked increase in drug incorporation in all the polymer series for the
hydrophobic drug. A similar extraction method for comparing the loading was
designed in a study by Wang et al. wherein, Etoposide incorporation was carried
out by two different methods and compared. In the solid extraction method a
measured volume of a methanol solution of etoposide was added to a vial, and
the solvent was removed under vacuum, leaving a solid film of Etoposide. A
polymer micelle solution was agitated with etoposide for 24 hours. After
filtration, the total etoposide concentration in the micelle solution was
determined by UV spectroscopy. While in the solution extraction method, a stock
solution of etoposide (19.2 mg/mL) in 1:1 (vol) acetonitrile/methanol was added
slowly with agitation to the polymer solutions of various concentrations. They
reported 6% and 22% drug loading using the solution and solid extraction
methods respectively [202].
Aromatic interaction (or ʌ-ʌ interaction) is a noncovalent interaction between
organic compounds containing aromatic moieties. ʌ-ʌ interactions are caused by
intermolecular overlapping of p-orbitals in ʌ-conjugated systems, so they
become stronger as the number of ʌ-electrons increases. Other noncovalent
interactions that could be acting are hydrogen bonds, van der Waals forces,
charge-transfer interactions, and dipole-dipole interactions. ʌ-ʌ interactions act
strongly on flat polycyclic aromatic hydrocarbons such as anthracene,
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triphenylene, and coronene because of the many delocalized ʌ-electrons [203].
This interaction, which is slightly stronger than other noncovalent interactions,
may be responsible for increased association of ETO-P within the tryptophan
substituted polymer (Fig. 5.10). Although we would expect a similar interaction
to take place between Etoposide and tryptophan we found that the incorporation
of etoposide is higher with the acylated polymer which indicates that
incorporation of drug is also influenced by a number of other factors such as, its
structure, hydrophobicity, stereochemistry and more importantly solubility in the
solvent (water). These are responsible collectively for influencing precipitation
of the drug and its association with polymer chains and hence its retention within
the particles. Tyrosine however did not incorporate either of the drugs to a
significant extent and was lowest of all other polymers. This could probably be
due to the presence of the phenolic group of tyrosine that may have interfered in
the rate of precipitation of the polymer during particle formation compared to the
polymer backbone. Tyrosine lacks the indole group of tryptophan that could be
responsible for greater interaction with the drugs.
In order to study the combined effect of both these substituents simultaneously,
we substituted the 40% acylated polymer with 5% tryptophan and studied drug
loading of ETO-P and ETO in it. This new polymer slightly increased
encapsulation of ETO-P while it decreased ETO encapsulation to an extent lower
than the individually substituted polymers. Contrary to most studies where it has
been reported that water soluble drugs are difficult to incorporate in hydrophobic
polymers; ETO-P was best incorporated in the acyl-tryptophan combination
polymer which was the most hydrophobic compared to the other polymers. Also,
its loading within the most hydrophilic polymer backbone was lower than that of
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ETO (water insoluble). There may be a steric influence of both acyl and
tryptophan groups when present in combination that did not allow for sufficient
accommodation of hydrophobic ETO into the polymer. Better ETO-P loading by
the combination polymer suggests the influence of water solubility of the drug
due to the presence of ionised phosphate groups that led to an electrostatic
interaction in addition to the ring stacking interaction with the polymer and
hence its better incorporation. There could also be some influence of the method
of preparation as in case of ETO-P, drug was present in the aqueous phase and
had a better opportunity to accommodate into the polymeric matrix as opposed to
ETO which was present in the organic phase.
ETO-P loading within the acyl-tryptophan combination polymer was comparable
to that of the tryptophan substituted polymer which probably means that the ring
stacking is more predominant than other non covalent interactions between drug
and polymer and degree of acylation does not influence this interaction to a great
extent. However for ETO where we would expect both these substitutions to
enhance drug incorporation, it was found to be lowered significantly. ETO
consists of a bulky, extended fused ring with several hydrophobic substituents
and hence proved highly hydrophobic when present with acylated and tryptophan
substituted polymer. The increased hydrophobicity could lead to precipitation of
the drug before the polymer and hence its low entrapment. Both acyl and
tryptophan chains when present together may have interfered in their association
with the drug causing a marked decrease in drug encapsulation. It appears that
the presence of acyl groups favoured ETO incorporation better than ETO-P. The
polymer backbone and 40% acylated polymers did not show any difference in
drug loading while the 100% acylated polymer showed a marked increase in
CHAPTER 6. Paclitaxel
140
ETO loading. This also indicates that the acyl groups are significant only when
the polymer is fully acylated or in other words does not contain any hydroxyl
groups. Probably interference from the residual hydroxyl groups could have led
to the displacement of the drug towards the external aqueous phase. For ETO-P,
the combination of acyl and tryptophan may have rendered sufficient solubility
characteristics to both the drug and the polymer leading to their co precipitation
when added to the solvent and enhanced loading within this polymer.
Wang and co workers synthesised an amphiphilic block copolymer of PCL and
PEG [196]. The feasibility of using star-PCL-PEG copolymer as a delivery
carrier for lipophilic drugs was evaluated using indomethacin, doxorubicin and
etoposide as the drug candidates. They found that there is little dependence of
etoposide solubility on the polymer concentration in the range studied, when the
solution extraction method was used. This was explained on basis of studies
carried out on solubilization of aromatic compounds within polymers [204]. The
solute partition coefficient in the polymer was shown to have a strong
dependence on the solute concentration for all polymers. The amount solubilized
was at its highest for the high mol. weight, hydrophobic polymers. For the less
hydrophobic or lower molecular weight polymers, it was determined that
solubilization capacity was a function of the polymer concentration.
In a study on ETO loading in Glycerol Monostearate, Distearate, Tripalmitin and
HSPC (Human serum) in presence of sodium tauroglycholate, maximum
incorporation was found in tripalmitin [205]. Around 4% incorporation within
particles of around 390 nm size and zeta potential -46 mV was reported. Particles
were prepared by melt homogenisation and in the presence of surfactant.
Etoposide loading was related to solubilisation capacity of the drug into the lipid
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portion thus correlating hydrophobicity with encapsulation. However, from our
studies we showed that incorporation of etoposide does not depend only on
polymer hydrophobicity. Increased drug loading was observed with the 100%
acylated polymer; however substitution of amino acids like tryptophan and
tyrosine made the polymer more hydrophobic but did not lead to a corresponding
increase in drug loading. This could suggest that binding of etoposide is more
specific with the acyl groups and higher than amino acids.
Lo Prete et al. reported association of etoposide to cholesterol rich nanoemulsion
(LDE) and evaluated its antitumoral action and toxicity [206]. ETO-LDE
demonstrated reduced drug toxicity; however it does exhibit stability problems
which are very important in colloidal drug delivery systems. Studies on
interaction of Etoposide with Dipalmitoylphosphatidyl choline liposomes have
proved Etoposide localization at C1-C9 methylene region of the bilayer [152].
This could be responsible for the enhanced incorporation of ETO in the 100%
acylated polymer. Valduja et al. reported synthesis of ETO-LDE complex with
improved stability when ETO is attached to oleoyl groups [207]. Patlolla et al.
synthesised ETO in lipid emulsions. These were stable at 4 °C for 25 days and
are being developed to obtain ETO therapeutic levels in brain and thus targeting
brain tumour [208].
No existing literature is available on ETO-P encapsulation within polymeric
nanoparticles. From our studies it is evident that the presence of phosphate group
on ETO nucleus changes its affinity towards polymers to a great extent. Amongst
the acylated polymers, it shows greater incorporation with the 100% acylated
polymer similar to ETO; however the loading is half of that obtained with ETO.
The presence of tryptophan enhances encapsulation to some extent. Both acyl
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and tryptophan moieties act in conjunction to retain highly water soluble drug
within its core and this enhanced interaction works better to retain a hydrophilic
drug than a hydrophobic drug.
5.4.3. Drug Release
Although incorporation of Etoposide is highest in 100% acylated polymer (Fig
5.10) release from this polymer occurs faster compared to the amino acid
substituted polymers. Interestingly, it was observed that both 40% and 100%
acylated polymers had similar rate of release. From the tyrosine substituted
polymer, 50% of drug was released at the end of 9 days. However this polymer
had minimum drug incorporation. Between the acyl and amino acid substitutions,
the amino acid substituted polymers had a better ability to retain the drug within
the core and provide more controlled and slower release. Faster rate of release
with the acylated polymers could be due to the location of drug. It could be
possible that ETO localisation occurred at / near the surface of the particles,
which could be attributed to the nature of association of the polymer and drug
molecules. Although the tyrosine substituted polymer had the least drug loading
it had a better retention capacity compared to the acylated polymers. This
highlights the influence of aromatic substituents on drug release. Probably
tryptophan and tyrosine groups held the drug towards the core of the polymeric
matrix and decreased its movement towards the external phase thus providing
controlled release.
From Table 5.1, Zeta potential of the ETO particles with the tryptophan
substituted polymers was more negative than with the 100% acylated polymers.
Also, increased size of the particles could indicate that the tryptophan and
etoposide molecules are present at the surface rather than towards the core thus
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enhancing its diffusion outwards. However, slow drug release from this
combination could suggest possible role of drug polymer interactions that delay
rapid drug removal from the surface.
In a study on ETO incorporation by Glycerol Monostearate, Distearate,
Tripalmitin and human serum all formulations showed an initial burst release of
approximately 20% within the first five hours [205]. Tripalmitin showed more
prolonged release of ETO compared to other formulations and this could be due
to a greater retention of drug within the more hydrophobic polymer. In case of
our polymers, the amino acid substituted polymers provided a better retention
than the acylated polymers. There could be also be a possibility that in the
presence of amino acids on the polymer the ability of the dissolution medium to
penetrate the polymer matrix is less than the acylated polymers. A number of
studies have reported a direct correlation between drug loading and release.
Higher drug loading would increase the concentration gradient of the drug at the
interface thus enhance its diffusion towards the external phase [154]. This is
possible only for the water soluble drugs. Most formulations with faster rate of
release also had a higher incorporation. In our study, although the acylated
polymers could incorporate more drug, release from these polymers was faster.
Drug loading of ETO-P in 100% acylated polymer was similar to that in the 5%
tryptophan polymer (Fig. 5.10) but release from the 100% acylated polymer was
slower. Although the drug loading trend is similar to ETO, the release profile is
exactly opposite as the 100% acylated polymer provided slowest ETO-P release
but fastest ETO release (Fig. 5.13). Similarly, ETO-P release from tryptophan
polymers was fastest while ETO release was slowest. Thus, the presence of a
phosphate group on ETO-P is responsible for its better interaction with the acyl
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groups on polymer and hence better retention compared to ETO, whereas the
lack of phosphate group makes it difficult for such an interaction and retention
(Fig. 5.1, 5.2). The polymer substituted with both acyl and tryptophan groups
further enhanced ETO-P incorporation and retention within the core providing a
slow and more complete release. It does not follow the general correlation of
higher loading and fast release. It is interesting to observe that the polymer
backbone and the 100% acylated polymer had a comparable rate of release.
There could be localisation of the drug towards the surface. An increase in
acylation led to an increase in loading however for drug retention and release rate
the acyl groups were not very significant in comparison to the hydroxyl groups
of the unsubstituted polymer. ETO-P particles in the acylated polymers were
smaller than the amino acid substituted polymers. The correlation between small
size and faster release is hence not applicable for these particles. Thus, the
difference in chemistry of drug influences its affinity and interaction with the
polymer along with its retention within the core matrix. ETO release only from
the 5% tyrosine and 40% acylated polymers obeyed Fick’s law of diffusion while
all the plots for ETO-P were linear as seen in the Higuchi plots in Figs. 5.14 (A)
and (B). It is highly unlikely that PGA dissolves under existing experimental
condition and hence drug release is not due to the erosion of the matrix. TEM
images of particles observed after 25 days of studies showed no disintegration or
loss of shape of the particles (Appendix 18) and hence probably its
biodegradation starts at a time longer than that taken into consideration. Dunne et
al observed the SEM of the PLGA particles after 28 days of drug release studies
and reported a gradual loss of shape of the microparticles. At 22 days some
pitting of the surface of the larger particles was observed while after 28 days
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these larger microspheres developed a porous outer surface. The smaller particles
only showed a fusion at the earlier time points [209]. It was concluded that
particle size could influence their degradation behaviour
5.5. CONCLUSIONS
Particles were formed using both ETO (water insoluble) and ETO-P (water
soluble) and were stable in the absence of surfactants. A preformed matrix of
drug and polymer enhanced drug loading to a significant extent. Drug loading
varied according to the polymer type and the nature of drug. Etoposide was best
incorporated in the 100% acylated polymer, and its incorporation decreased in
the lower acylated polymers. Amino acid substitution increased hydrophobicity
of polymer compared to the backbone and acylated polymers but decreased drug
loading. Thus, Etoposide interaction was greater with the acyl groups compared
to the amino acid side chains indicating loading did not depend upon
hydrophobicity of polymer alone.
ETO-P, with similar chemical structure but water soluble, showed decreased
incorporation in acylated polymers. However, it followed a similar trend
compared to ETO, with increase in acylation increasing loading. Maximum drug
loading was found with the polymer having a combination of acyl and
tryptophan substitution. Drug release from this polymer was the slowest and
most complete compared to all other polymer substitutions. Thus, for a water
soluble drug like ETO-P better drug loading and slow release rate could be a
contribution of enhanced interaction with tryptophan by formation of ionic
bonds, aromatic groups may on the other hand be responsible for better retention
of water insoluble aromatic ring containg drugs within particle matrix by
aromatic ring stacking.
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CHAPTER 6. INCORPORATIONAND RELEASE OF
PACLITAXEL FROM FUNCTIONALISED POLY
(GLYCEROLADIPATE) NANOPARTICLES
6.1. Introduction
Taxol is a novel antitumor alkaloid that has shown clinical activity against
several tumours especially prostate, ovarian and breast cancers. However, due to
its low aqueous solubility, Cremophor EL (polyoxyethylated castor oil) and
ethanol are used as excipients in the pharmaceutical drug formulations. These
agents are implicated in hypersensitivity reactions as described in section 5.1,
Chapter 5. In addition to the hypersensitivity reactions to Cremophor® EL, the
multiple dosing of the drug, required to maintain the therapeutic drug
concentration in the tumour, causes nonspecific toxicity [210]. To increase the
therapeutic efficacy of anticancer agents, polymeric-, micellar- and liposome-
based delivery systems conjugated to tumour-specific ligands have been
investigated.
Paclitaxel nanoparticles produced using a range of functionalised polymers were
characterized by Photon correlation spectroscopy (PCS) for size and size
distribution, Transmission electron microscopy (TEM) for morphological
properties and zeta-potential for surface charge. The aim is to achieve a better
understanding of various aspects of drug polymer interactions and based on this
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identify formulations that could provide high encapsulation and controlled
release.
Aims of chapter:
x To assess ability of poly glycerol adipate and its modifications to
encapsulate PTx into stable nanoparticles.
x To study the influence of polymer functionalisation, nature of side chain
functional groups and formulation parameters on drug incorporation and
release of PTx.
6.2. MATERIALSAND METHODS
6.2.1. MATERIALS
Paclitaxel was obtained from Sigma, UK. All other chemicals were of analytical
grade and organic solvents of HPLC grade.
Chemical name: ȕ-(benzoylamino)-Į-hydroxy-,6,12b-bis(acetyloxy)-12
(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-
4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-
9-ylester,(2aR-(2a-Į,4-ȕ,4a-ȕ,6-ȕ,9-Į(Į-R*,ȕ-S*),11-Į,12-Į,12a-Į,2b-Į))-
benzenepropanoicacid.
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Formula: C47H51NO14
Mol.Weight: 853.906 g/mol
Fig. 6.1. Molecular structure and identity of Paclitaxel
6.2.2. METHODS
6.2.3. Preparation of Paclitaxel nanoparticles
Paclitaxel nanoparticles were prepared using the modified IPD method described
in Chapter 2.
6.2.4. Separation of free drug from nanoparticles
Nanoparticles were separated from unincorporated drug using methods 2.5 A and
B described in Chapter 2.
6.2.5. Physicochemical Characterisation
Size, surface charge and external morphology of the nanoparticles were
determined using methods detailed in Chapter 2.
6.2.6. Method validation and Drug loading
The freeze dried nanoparticle powder was weighed and dissolved in a mixture of
acetone/ ACN (1:2), followed by centrifugation. The ACN solution was analysed
by HPLC. Samples were passed through a Lichrosphere 100 RP-18 (5µ)
endcapped column Mobile phase 0.01% Acetic acid: ACN 35:65, flow rate was 1
ml/min and operating pressure 1280 psi.
6.2.7. Drug Release
Drug release studies were performed as described for Etoposide in Chapter 5,
section 5.2.8.
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6.3. RESULTS
6.3.1. Particle size and zeta potential
Table 6.1 shows the influence of polymer substitution on size and zeta potential
of PTx nanoparticles. In the presence of PTx, increase in acylation led to an
increase in size of the particles. Tyrosine substituted particles were smaller than
the tryptophan substituted polymers. However, a combination of acyl and
tryptophan groups on the polymer reduced the size significantly compared to
presence of 5% tryptophan on the polymer alone. In the presence of PTx, most
loaded particles were larger than the empty particles with the exception being
40% C8 acylated particles. Overall, the particles were in the size range of 190 to
240 nm with most particles around 200 to 220 nm in size.
Zeta potential varied between -27 to -37 mV for drug loaded particles and did not
change much with polymer substitution. Values for the 40% acylated and
tryptophan polymers were slightly less negative compared to the other polymers.
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Table 6.1 Particle size and Zeta potential of empty and PTx loaded nanoparticles using various polymers by the Interfacial deposition method.
Polymer type is designated by nature and degree of substitution, MW. Results are mean of 3 readings, SD standard deviation
POLYMER TYPE
EMPTY PARTICLES (+) PTx
SIZE nm
(SD) [polydispersity]
ȟ327(17,$/P96' SIZE nm
(SD) [polydispersity]
ȟ327(17,$/P96'
Polymer backbone 169.6(2.2)[0.57] -20.2(0.4) 188.2 (2) [0.45] -32.9 (1)
40%C8-12 267.5 (3.09) [0.33] -31.3 (0.3) 195.65(2.6)[0.03] -26.9(1.8)
100%C8-12 201.3 (0.57) [0.23] -29.3(0.8) 216.0(1)[0.04] -37.2 (0.55)
5 % Tryptophan 132.3 (0.3) [0.05] -43.8 (2.5) 240.3 (2.5) [0.37] -28.9 (0.02)
5 % Tyrosine 145.2 (2.9) [0.15] -34.2 (1.87) 205.7(0.9)[0.58] -32.5 (1.5)
40%C8 + 5 % Tryptophan 190.7 (1.9) [0.35] -35.9 (0.9) 202.7 (0.56)[0.6] -30.1 (0.4)
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6.3.2. TEM images
(A) (B)
(C)
Fig. 6.2. TEM Images of PTx nanoparticles in (A) 100% C8 (B) 5% tryptophan
and (C) 40% C8 + 5% tryptophan polymers.
Particles were spherical in shape with well rounded surfaces. The 100% acylated
polymers produced particles smaller in size than the tryptophan substituted
polymer (Table 6.1, Fig. 6.2A) and with low polydispersity. Particles in the
tryptophan and combined acyl-tryptophan substituted polymers appear larger in
size and aggregated.
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6.3.3. Method validation (HPLC analysis for PTx)
The determination of the calibration curve for PTx was performed in ACN (Fig.
6.4), as PTx undergoes rapid trans esterification in methanolic solutions.
The retention time for PTx under the operating conditions and mobile phase as
described in 6.2.6 was 4.5 minutes (Fig. 6.3). Control drug (100 ȝg) was added to
empty particles and 92% extraction efficiency was obtained. The average drug
loading was divided by 0.92 to obtain to final amount of drug in the samples
(Table 6.2).
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Fig. 6.3. (A) Chromatogram for std. solutions of PTx in ACN, (B) PTx particles
in ACN
A
B
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Std. Curve for PTxinACN
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Fig. 6.4. Calibration curve for PTx in ACN
† total free volume
Table 6.2. Extraction efficiency for control PTx samples using HPLC
Sample Area Conc.(ng/ml)
(*10)
ȝg/tot.fr.vol.†
(4ml)
Efficiency
(%)
Avg.
efficiency
(SD)
Control-1 1387820 21.78 87.13 87.13
Control-2 1554879 24.38 97.52 97.52
Control-3 1485125 23.29 93.18 93.18
92.6%
(5.22)
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6.4. Drug Loading
6.4.1. Effect or organic/aqueous phase ratio
Effect of organic/aqueous phase ratio on loading of PTx within various polymers
is described in Fig. 6.5.
From previous studies on our polymers, we optimised the ratio of organic to
aqueous phase at 2:5 to produce particles within the desired size range and zeta
potential that were stable and prepared in the absence of surfactant. However
with PTx as the drug, the 100% acylated polymer and the amino acid substituted
polymers did not form particles. After evaporation of organic solvent, polymer
aggregated and formed a separate layer.
0
0.5
1
1.5
2
2.5
3
PB 40%C8 100%C8
Polymer substitution
dr
u
g
lo
a
di
n
g
(%
)lo
Organicphase/Aqeous
phase1/2
Organicphase/ Aqeous
phase2/5
Fig. 6.5. PTx loading within various polymers under different conditions.
When this ratio was increased to 1:2, all polymers formed stable particles. It is
however, interesting to observe a significant drop in drug loading within the 40%
acylated polymer under these conditions (Fig 6.5). Loading decreased from 2.5%
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to 1.5% when the Organic/Aqueous (O/A) phase ratio was changed from 2/5 to
1/2.
6.4.2. Effect of polymer substitution
Fig. 6.6 shows loading of PTx within various polymers formulated using O/A
1/2. 1.5% incorporation was seen in the 40% acylated polymer, and higher
incorporation (2.5%) was observed with change in O/A ratio from 1/2 to 2/5
(Fig. 6.5).
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Fig. 6.6. PTx incorporation within various substituted polymers, organic/aqueous
phase 1:2
Further increase in acylation decreased incorporation. For tryptophan substituted
polymer, incorporation of Paclitaxel was higher than that obtained using acylated
polymer (2%). Tyrosine and a combination of acyl and tryptophan substitutions
led to a significant drop in drug loading.
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6.5. Drug Release
The Paclitaxel release profile from various polymers is shown in Fig. 6.7. The
slowest release occurred from the 5% tryptophan polymer and the 40% acylated
polymer followed by polymer backbone, while further increase in acylation led
to a larger burst release and comparatively faster rate of release.
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Fig. 6.7. PTx release from various polymers
The tryptophan substituted polymer had the slowest rate of release followed by
the 40% acylated polymer. Approximately 30% drug was released after 15 days.
Drug incorporation within the tyrosine polymer was negligible and hence drug
release was not carried out from this polymer. Drug release from the polymer
with combined acyl and tryptophan groups was similar to the 100% acylated
polymer. PTx release from backbone, 40% acylated polymer and tryptophan
substituted polymers did not show the typical burst release profile.
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6.6. Analysis of drug release kinetics
A plot of Cumulative drug release Vs ¥T gave an almost linear plot for most
particles indicating that the drug release followed Fick’s law of diffusion (Fig.
6.8). Higuchi plot for particles prepared from the 5% tryptophan polymers gave a
correlation coefficient less than 0.95 and hence may not be following Fick’s law
of diffusion for drug release. Usually, the Higuchi plotting applies to the
situation when the amount of drug release does not exceed 60%. Thus the plot
was performed for 24 hours. The plot for 40% C8 + 5% tryptophan was omitted
since the initial burst reached about 55%.
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Fig. 6.8. Higuchi plot for PTx in various polymeric NPs
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6.7. DISCUSSION
6.7.1. Particle size and zeta potential
PTx particles prepared using the acylated polymers produced smaller particles
than the amino acid substituted polymers. On comparing the sizes of empty and
drug loaded particles only the 40% C8 polymer showed a reduction in particle
size on drug loading while those of the backbone and 100% C8 particles were
only slightly larger in size. However, the tryptophan and tyrosine substituted
polymers produced particles of larger size. The presence of drug and aromatic
rings probably led to a loosely packed structure suggesting a difference in the
mechanism of interaction of PTx with various polymers. This largely depends
upon the properties of the different functional groups attached to the polymers
discussed in Chapter 3, section 3.5.1. It is also worth noting that the formulation
conditions had to be changed for the amino acid substituted polymers in order to
form stable particles after complete evaporation of the organic phase. The
organic/aqueous phase ratio had to be reduced to 1:2 from 2:5. The exact reason
for the failure of 100% C8, tryptophan and tyrosine substituted polymers to form
nanoparticles when the phases are in a ratio of 2:5 is not completely understood.
It might be due to the influence of the aqueous phase on particle formation. Since
the hydrophobicity of the drug was the highest (aqueous solubility only 3 ȝg/ml
at 37°C) among the drugs investigated previously in this project. It could be
possible that in the presence of more hydrophobic polymers excess water
interferes with the process of drug – polymer co-precipitation. Hence, particles
do form initially but on evaporation of the organic phase the polymer aggregates.
With the acylated polymers, PTx probably encouraged a closely packed
arrangement of the molecules and hence formation of more condensed particles
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with a very narrow polydispersity. With the amino acid substituted polymers the
combination of the aromatic rings in both the drug and the polymer could have
led to a less efficient packing of molecules associating to form a particle with
more free volume between the polymer chains and hence a larger size.
Hydrophobicity of the polymer alone is not a criterion influencing particle size,
as can be seen from our results with the tryptophan substituted polymers.
Particles were larger in size than those produced by the more hydrophobic
polymer viz. 40% acyl + 5% tryptophan substituted polymer.
Some authors have reported drug loaded particles to be larger in size than empty
particles due to the presence of drug in polymeric matrix based on the
assumption that presence of drug in the matrix is responsible for expansion of
matrix volume and hence size [166]. However, comparing the % drug loading in
the particles with the % increase in size this seems highly unlikely. There is no
indication towards the influence of drug and polymer structures which are the
main factors influencing association of polymer molecules into particles. As can
be seen from Table 6.1, drug loaded particles using polymer backbone and 40%
acylated polymers produced smaller particles while amino acid substituted
polymers produced larger particles for the same drug. Thus polymer–drug
chemistry seems to be an important parameter in governing particle size by
influencing the packing arrangement, density and interactions of molecules.
Zeta potential values changed only very slightly between formulations and
overall indicated good stability of the nanoparticle dispersion.
Venkartaraman et al. studied incorporation of PTx in PLA (x)-PEG91- PLA x of
different molecular weights. They reported an increase in particle size with
increase in length of PLA segments. A longer PLA chain length was associated
CHAPTER 6. Paclitaxel
161
with larger hydrophobic cores and hence a larger size. However, in presence of
PEG 45, there was no significant effect of PLA chain length on particle size
[195].
6.7.2. Drug incorporation
The ratio of Organic/Aqueous phases seems to be important for PTx loading
using the modified IDP method (Fig. 6.5). Stable drug loaded particles by the
100% C8 acylated, tryptophan, tyrosine and the combined substituted polymers
could only be formed when this ratio was increased to 1:2. This could be an
influence of the amount of aqueous phase on particle formation or due to the
difference in the interaction of the various side groups with the drug as discussed
in section 6.7.1. With the 40% acylated polymer this interaction was best when
the aqueous phase is double the organic phase. When the more hydrophobic
polymers were used, PTx being a bulky hydrophobic molecule probably did not
encapsulate well within the polymeric particles when the O/A phase ratio was
2/5. When added to the aqueous phase, polymer precipitation did not favour drug
entrapment leading to aggregation. Failure of the nanoprecipitation method (IDP)
has been reported to occur when the viscosity of the polymeric solution is
enhanced significantly. Addition of bulky drug PTx to the polymeric phase thus,
may hamper diffusion of solvent towards non solvent. It was found that the
interaction with the acyl groups was more specific with the 40% acylated
polymer under the conditions employed. It is worth noting that despite the
hydrophobicity of the complex and bulky drug, there are a number of hydroxyl
groups and a secondary amine function as well. It is possible that these groups
may either undergo hydrogen bonding with the free hydroxyl groups on the
polymer, or that these polymer hydroxyl groups allow some incorporation of
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water molecules favouring hydrogen bonding. A similar finding of the advantage
of 40% C18 polymer for incorporation of DXMP has previously been noted [72].
Comparable loading was obtained with the 5% tryptophan substitution; however,
the decrease in ratio of o/w from 1/2 to 2/5 did not allow particle formation and
led to complete precipitation of polymer (Fig. 6.6). Complete acylation of
polymer led to decrease in drug loading. Also, binding to the tryptophan
substituted polymer (2.1%) was favored compared to the tyrosine substituted
polymer (0.5%) (Fig. 6.6).
Fonseca et al. investigated the influence of various formulation parameters on
PTx incorporation efficiency within PLGA nanoparticles using the IDP method.
They observed that doubling the volume of the external aqueous phase while
maintaining constant the volume for the organic phase resulted in reduction of
the incorporation efficiency of the drug for all the copolymers tested by around
15 to 20% compared to the formulations obtained with organic/aqueous phase
ratio 1:1 [211].
Ruan et al. encapsulated PTx in PLA-PEG-PLA triblock polymers and studied
the effect of varying the length of the PLA segments [89]. The PLA chain length
had no significant effect on the drug loading. Rodrigues et al. reported greater
tolerance, therapeutic potential and reduced toxicity when PTx- oleate (chemical
conjugation) was complexed with LDE (cholesterol rich nanoemulsion) rather
than PTX alone. This finding provides some indication that attachment of the
oleate group to PTx increased affinity of PTx to interact with fatty acyl groups of
cholesterol [212]. Liang et al. prepared PTx particles with block co polymers:
SRO\ȖJOXWDPLFDFLGDQGSRO\ODFWLFDFLG3DUWLFOHVKDGDGUXJ ORDGLQJ
An increase in the ratio of PTx / polymer increased loading but decreased
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encapsulation efficiency. The optimum ratio between the drug and polymer
concentrations was found to be 1/10 [213]. Mu et al. studied incorporation of
PTx in PLGA using vitamin E TPGS (Alpha-tocopheryl polyethylene glycol
succinate) as an emulsifier due to its amphipathic nature or blended it with
PLGA in order to formulate a system that overcomes side effects of Cremophor
EL [214]. Varying the concentration of TPGS, a number of NPs were fabricated.
The mixture of PLGA and TPGS had a self emulsifying effect which resulted in
the formation of NPs without use of an additional stabiliser. Vitamin E TPGS in
a concentration of 0.03% produced particles with good yield and loading. The
high solubility of TPGS in water may be responsible for decreased yield when
the concentration of TPGS was increased above this level. A 2.4% loading was
reported with PLGA 50:50, 75:25 and 85:15. Dong et al. have reported a
decrease in the encapsulation efficiency of PTx with increase in initial drug
loading in the methoxy poly (ethylene glycol)-poly (lactide) nanoparticles. They
reported 21% encapsulation efficiency of 3mg PTx in 40 mg polymer equivalent
to 1.58% drug loading [94], while in our study we obtained 1.75% w/w PTx
loading using 2 mg drug and 10mg polymer. Cavallaro et al. conjugated poly (N-
2-hydroxy ethyl)-DL- aspartamide [PHEA], a freely water soluble plasma
substitute with PTx [215]. Lu et al. incorporated PTx in gelatine for
intravesicular bladder cancer. They reported a 0.7% drug loading within this
polymer [216].
Lundberg et al. synthesised a lipophilic derivative of PTx in a lipid o/w emulsion
covered with a hydrophilic polymer. They reported improved pharmacokinetics
of PTx in this system [217]. Many studies have reported a need for the presence
of hydrophobic surfactants in the formulation system for successful incorporation
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for paclitaxel [218]. Mu and Feng [141] reported enhanced drug loading (1.46%)
within PLGA microspheres with addition of surfactants like lecithin, DPPC or
cholesterol compared to microspheres without additives (1.3%).
However, Mitra et al. reported a lower encapsulation in the presence of
cholesterol and / or lecithin as surfactants [219]. They attributed this to the fact
that an increase in surfactant concentration results in a decrease in the particle
size and an increase in surface area per unit volume, which consequently
increases the possibility of drug loss by diffusion into the medium during the
fabrication process.
From our studies we have shown that paclitaxel forms stable particles with
appreciable drug loading in the absence of surfactants. A simple manipulation in
the formulation method allowed stable particle formation by all the polymers
investigated. The presence of fatty acyl groups on the polymer enhanced
paclitaxel incorporation. However, it is worth mentioning that unlike previous
studies where fatty acyl groups were added to enhance solubility of drug in the
aqueous phase here these groups did not act as surfactants. They probably helped
enhance drug interaction with the polymer by formation of hydrogen bonds
between the N and OH groups in the drug and the polymer (
Fig. 6.1).
Various literature studies have reported PTx binding to microtubuler proteins as
their main mode of antitumoral action. More specifically, the N terminus of ȕ
tubulin is the site of binding for most vinca alkaloids and taxol. This area was
sequenced by Rao et al. and found to be composed of 31 amino acid residues
that included tryptophan [220]. This was an important finding in the study of
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paclitaxel incorporation by the tryptophan substituted polymers. We could expect
a similar binding between paclitaxel and tryptophan and probably a substantial
drug loading. Panda et al. studied binding of Estramustine (EM), which is an
anticancer alkaloid with similar mode of action as taxol and other alkaloids, to
tubulin [221]. The extent of binding was studied by measuring the change in the
fluorescence intensity of a tryptophan solution equivalent to the tubulin
concentration in the presence of EM. They found that EM quenched the intrinsic
fluorescence of tubulin due to tryptophan residues in a concentration-dependent
manner.
Sackett et al. have also demonstrated quenching of tubulin tryptophan
fluorescence in presence of vinca alkaloids binding to tubulin. The quenching of
fluorescence is due to the fact that the vinca-site occupancy results in the
conformational changes on the tubulin structure [222]. Also, the interaction of
taxol with human serum albumin (containing tryptophan residues) has major
biochemical importance and has been used as a model for elucidation of the
taxol–protein complexation [223].
6.7.3. Drug Release
PTx release was controlled and was slowest from the 5% tryptophan and the 40%
acylated polymer (Fig. 6.7). Even for the other polymers 30 to 40% drug release
is observed in the initial phase which is lower than the burst effect shown by
various other researchers [94]. Although the polymer backbone is more
hydrophilic than the substituted polymers it retained the drug for a longer time.
Hydrophilic polymers have been associated with a significant burst and fast rate
of release. A number of reports on particles prepared using surfactants have
attributed burst release to the enhanced erosion of the polymer matrix due to
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surfactants as they may promote water penetration or reduce hydrophobic
interactions between polymer and drug [93]. The polymer substituted with
tryptophan had the slowest release while the 100% acylated polymer was
associated with a significant burst and the fastest rate of release. The rate of
release from the tryptophan and 40% acylated polymer were similar to each
other. Drug loading was also highest in the 5% tryptophan substituted polymer
(Fig. 6.6). From results with ETO we found that the tryptophan substituted
polymers also have a better retention of aromatic ring containing groups and
provide a slower and sustained release compared to the other polymers. The 40%
acylated polymer had the highest drug incorporation within the acylated series
thus indicating the possible influence of acyl and hydroxyl groups on the
polymer solubility profile and on the location of the drug either at / near the
surface or within the core. In a 40% acylated polymer the drug could have
interacted better with the acyl and the residual hydroxyl groups or could be
present in the interior of the particles thus showing a controlled release from the
matrix. However, when all the hydroxyl groups were acylated, this arrangement
was altered and made the drug easily accessible to the external media thus
explaining the significant burst with the 100% acylated polymer.
For the combination polymer the mechanism of interaction between drug and
polymer is different from the acylated polymers and probably the strength of this
interaction is weaker than with the tryptophan or the 40% acylated polymer. This
is reflected in the drug release profile as the drug release is fastest compared to
all other polymers. Another explanation could be the effect of the hydroxyl
groups on the polymer which seemed to be important for both loading and
retention within the interior or surface localisation of drug. With the combined
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acyl and tryptophan groups the polymer still had around 55% hydroxyl groups
however, the steric configuration and hence orientation of the drug was altered in
this polymer compared to the unsubstituted polymer such that the drug was
easily diffused towards the external medium. The particle sizes with the
combined amino acid - acyl substituted polymers were larger than the acylated
polymers (Table 6.1) and hence do not follow the trend of large size, slow
release rate. An interesting observation was the sudden increase in the amount of
drug released at the end of 6 days from all polymers. Studies on PTx
nanoparticles made from gelatin showed a rapid release of drug in PBS.
Approximately 90% release was observed after 2 hours. Release was rapid and
completed within 3 hours of the study [216].
Another problem associated with paclitaxel is extremely slow rate of drug
release, especially from more hydrophobic polymers. The conjugation of PTx to
PHEA showed no PTx release for up to 30 hours at pH 7.4 in the presence of
plasmin. This system is being developed for long term treatment with PTx. [215].
Less than 5% PTx was released from PLGA/MPEG films after 16 days [214].
From their previous studies, Ruan et al. reported only 50% PTx release from
PLGA particles at the end of 3 months. Hence, in an attempt to obtain faster and
more complete release they studied PTx release from PLA-PEG- PLA triblock
polymers. The paclitaxel-loaded PLA–PEG–PLA microspheres resulted in
significantly faster release of the drug from the microspheres compared with that
from PLGA samples [89]. Liggins et al. observed incomplete release and
slowing of release rate of paclitaxel after 12 days which led to the development
of the two compartment model for describing the release kinetics of paclitaxel. It
was assumed that release from the two compartments was independent.
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Compartment 1 was diffusion controlled while compartment 2 did not allow
paclitaxel diffusion at a measurable rate. It was also assumed that the first
compartment was depleted over the course of the 14 day release study and that in
the second compartment paclitaxel was essentially immobilised by the crystalline
domains in the matrix such that diffusion is almost negligible over the course of
time of these studies [224]. The release from the 5% tryptophan substituted
polymers also seems to have slowed down greatly after 8 days and this could be
attributed to the same reasons hypothesised by Liggins et al. in their study. This
drug polymer combination did not fit into the Higuchi model (Fig. 6.8) However,
the two compartment model could be reduced to the Higuchi model if a pore
density existed within a polymeric matrix sufficient to affect the polymer
domains of compartment 2 [224].
Various researchers have also correlated size of the particles to release rates. The
smaller the size of the particles greater is the surface area and hence the faster the
release [94, 225]. Some studies have also correlated the rate of drug release with
drug loading [30, 89]. PTx release from PLA-PEG-PLA triblock polymers
showed a decrease in the rate of release with an increase in drug loading.
Venkatraman, Liggins reported an exact opposite trend. They attributed the faster
rate of release to enormously decreased size of the particles i.e. 300 nm as
opposed to 20 microns in their previous work [195, 224]. However, with our
polymers the backbone and 40% acylated polymers also provided controlled
release and these were smaller in size than other PTx loaded polymers used in
this study (Table 6.1).
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6.8. CONCLUSIONS
Paclitaxel could be successfully incorporated within polymer backbone and
functionalised polymers using the modified Interfacial deposition method in the
absence of surfactant. Particle sizes were between 200 to 240 nm and surface
charge around -30 to -32 mV. Drug loading was influenced by the ratio of
organic to aqueous phase and type of polymer. The tryptophan substituted
polymer had highest drug loading (2.1%) at an organic / aqueous phase ratio 1:2.
The maximum loading of 2.5% was observed with the 40% acylated polymer
when the organic to aqueous phase ratio was 2:5. Drug release from various
formulations varied depending upon the type of polymer used. Slowest,
controlled drug release was observed from the tryptophan and the 40% acylated
polymer followed by polymer backbone, while the combined acyl tryptophan
substituted polymer demonstrated the highest burst release followed by the 100%
acylated polymer. Thus, paclitaxel interaction was greatest for tryptophan
substituted polymer and 40% C8 polymer under different formulation conditions,
indicating that the drug loading was influenced significantly by both of these
factors. The drug release profile indicates the influence of chemistries of
different functional groups on the ability of the polymer matrix to retain drug and
release it in a controlled manner. Again, this ability seemed to be best with the
5% tryptophan polymer which is less hydrophobic than the 40% acylated
polymer, of intermediate hydrophobicity, and is slower than the most hydrophilic
polymer i.e. the polymer backbone. Increase in hydrophobicity (combination
polymer) led to an increase in the burst release. Drug release thus, does not
depend upon hydrophilic – hydrophobic properties of polymer alone and it can
be concluded that particle properties are specific for drug and side group
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interactions. In this case, polymers with either acyl or tryptophan substitution
provided good drug incorporation and a controlled release profile and were
specific depending upon the degree of acylation and the formulation parameters.
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CHAPTER 7. PHYSICOCHEMICAL
CHARACTERISATION OFDRUG POLYMER
INTERACTIONS IN NANOPARTICLES
7.1. Introduction
In order to assess whether or not interactions between various substituted
polymers and drugs did occur and to confirm the presence of drug in the NPs
either in its crystalline or amorphous form, FT-IR and DSC studies were
performed. Results from various drug polymer combinations were compared
with those obtained for NPs prepared using the polymer alone. Thus, to some
extent, the effect of the nature of drug and polymer functional groups on polymer
drug interactions could be investigated. These results could then be correlated to
drug loading and release characteristics from various drug-polymer formulations.
DIFFERENTIAL SCANNING COLORIMETRY (DSC)
Differential scanning calorimetry can be used to measure a number of
characteristic properties of a sample. Using this technique it is possible to
observe fusion and crystallization events as well as glass transition temperatures
(Tg). The change from a glassy to a viscous rubbery state defines the (Tg) of a
polymer and is a function of chain motility (Fig. 7.1). Glass transitions may
occur as the temperature of an amorphous solid is increased. These transitions
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appear as a step in the baseline of the recorded DSC signal and are due to the
sample undergoing a change in heat capacity; no formal phase change occurs.
As the temperature increases, an amorphous solid will become less viscous. At
some point the molecules may obtain enough freedom of motion to
spontaneously arrange themselves into a crystalline form. This is known as the
crystallization temperature (Tc). This transition from amorphous solid to
crystalline solid is an exothermic process, and results in a peak in the DSC
signal. As the temperature increases the sample eventually reaches its melting
temperature (Tm). The melting process results in an endothermic peak in the DSC
curve (Fig. 7.2)
The DSC also provides insight into morphology of drug loaded particles and how
this morphology changes under a range of conditions.
Fig. 7.1. DSC scan indicating Tg of a polymer
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Fig. 7.2. DSC scan indicating Tm for a polymer
Fig. 7.3. DSC scan indicating change in polymer state from glassy to rubbery
The glass transition is a second order phase transition in which a supercooled
melt yield, on cooling, a glassy structure and properties similar to those of
crystalline materials e.g. of an isotropic solid material. Phase transitions are
associated with the symmetry breaking. The translation-rotation symmetry in the
distribution of atoms and molecules is unchanged at the liquid-glass transition,
which retains the topological disorder of fluids. From Fig. 7.3, above the Tg, the
secondary, non-covalent bonds between the polymer chains become weak in
comparison to thermal motion, and the polymer becomes rubbery and capable of
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elastic or plastic deformation without fracture [226]. Polydisperse polymers of
the same mean molecular weight may differ in their tensile strength if their low
molecular weight fractions are substantially different. Plasticisers enhance chain
mobility and lower the Tg value. They are added to restore or maintain mobility
by interposing themselves between the chains like solvent molecules. A small
amount of entrapped or residual solvent could also have a pronounced effect on
the Tg of a polymer.
The assembly of nanoparticles and the way an active agent is dispersed in a
microparticle may affect the drug loading. This in turn is determined by the
interactions an active agent experiences with the solvent and polymer used to
form microparticles.
Crystalline solid particles that are insoluble in the casting solvent and
suspending medium often are unchanged by incorporation in a microparticle.
An active agent that is a crystalline solid which is completely soluble in the
casting solvent and insoluble in the continuous phase may do several things: It
may crystallise as removal of the volatile solvent progresses. Crystallisation
could occur inside the polymer nanoparticles, on the surface or in the
continuous phase or combinations of the above. Alternatively, it could be
molecularly dispersed in a nanoparticle, by forming a true solution with the
carrier or as a metastable dispersion because it is trapped in the carrier [119].
FOURIER TRANSFORMATION SPECTROSCOPY (FT-IR)
FT-IR spectroscopy is a very powerful method for the identification of
functional groups. The most important regions of the IR spectrum are >1650
cm
-1
, whereas the fingerprint region (600-1500 cm
-1
) of the spectrum cannot
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easily be used for identification of unknown compounds. Many references
exist which tabulate the IR frequencies for various functional groups and
organic compounds. In a molecule, the atoms are not held rigidly apart. Instead
they can move, as if they are attached by a spring of equilibrium separation Re.
This bond can either bend or stretch. If the bond is subjected to infrared
radiation of a specific frequency (between 300 and 4000 cm
-1
), it will absorb
the energy, and the bond will move from the lowest vibrational state, to the
next highest.
In a simple diatomic molecule, there is only one direction of vibration;
stretching. This means there is only one band of infra red absorption. Weaker
bonds require less energy, as if the bonds are springs of different strengths. If
there are more atoms, there will be more bonds, and therefore more modes of
vibrations. This will produce a more complicated spectrum. For a linear
molecule with "n" atoms, there are 3n-5 vibrational modes, if it is nonlinear, it
will have 3n-6 modes.
The graph obtained from an FT-IR analysis shows percentage transmission
against wave number. If no radiation is absorbed at a particular frequency, then
the line on the graph will be at 100% at the corresponding wave number.
Different types of bonds have characteristic regions of the spectrum where they
absorb (Fig. 7.4).
CHAPTER 7. DSC and FTIR
176
Fig. 7.4. Typical Interferogram with FT-IR spectroscopy
7.2. RESULTS
7.2.1. Effect of substitution on thermal behaviour of drug free
polymers
The DSC thermogram of the empty unsubstituted polymer backbone is compared
with the thermograms of the various substituted polymer particles in Fig. 7.5 in
order to study the influence of nature of substituted functional group on the DSC
profiles of the polymers.
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Fig. 7.5. DSC thermograms of polymer backbone and various substituted
polymers
Table 7.1. DSC thermograms of drug free polymer backbone and substituted
polymers. Tm 1 and 2 refer to the melting endotherms, ND= not detected.
POLYMER Tg °C Tm (1) °C -heat
flow (W/g)
Tm (2) °C -heat
flow (W/g)
Polymer Backbone ND 70 (-27.5) 101 (-35)
40% C8 35 45 (-4) 102 (-0.9)
100% C8 55 - 110 (-16.2)
5% Tryptophan 30 55 (-3) 100
5% Tyrosine ND 115 (-2.5) 135
40% C8 + 5%
Tryptophan
ND - 103 (-75)
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From Table 7.1, the polymer backbone without any substitution shows two
melting curves Tm1 and Tm2 at 70°C and 101°C respectively. On substituting
the polymer with acyl groups the Tg of the polymer was detected at 35°C and
55°C in the 40% and 100% acylated polymers respectively. There was an
increase in the Tg with increase in degree of acylation. The temperature and peak
height of Tm1 of the polymer backbone decreased in the 40% acylated polymer
while it completely disappeared in the 100% acylated polymer. There was no
significant difference in the Tm2 of the acylated polymers. Addition of
tryptophan to the polymer backbone lowered the Tg of the polymer compared to
the acylated polymers. Tm1 and Tm2 appeared at similar temperatures as the
acylated polymers; however the peak heights were reduced significantly. With
the attachment of tyrosine the Tg of the polymer was not clearly detected. Both
Tm1 and Tm2 increased and were higher than all the other polymers. For the
combination polymer, again the Tg could not be clearly distinguished. Tm1 was
absent while Tm2 appeared at the same temperature as in the polymer backbone,
acylated and tryptophan substituted polymers.
7.2.2. DSC thermograms of DXMP and CYT-ARA particles
In order to obtain a better understanding of possible effects of drug and polymer
interactions and correlate it with drug incorporation and release data, the thermal
behaviour of the particles was analyzed with DSC.
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Fig. 7.6. DSC thermograms of DXMP particles in various polymers. Tm 1 and 2
refer to the melting endotherms, ND= not detected.
Fig. 7.7. DSC thermograms of CYT-ARA particles in various polymers. Tm 1
and 2 refer to the melting endotherms, ND= not detected.
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Table 7.2. Peak temperature and heat flow for various nanoparticle formulations.
Tm 1 and 2 refer to the melting endotherms, ND= not detected.
From Figs. 7.6 and 7.7, for nanoparticles prepared using polymeric backbone
without functional side chains and in absence of drug, a broad endothermic peak
(Tm1) at 70° C and a sharp peak at 101°C (Tm2) were observed (Table 7.2).
Polymer backbone particles with DXMP significantly differed in peak heights
compared to the empty particles. The peak at 70° C (Tm1) of the empty polymer
became broader and shifted to 74°C (Tm1) while Tm2 appeared at the same
temperature, it was significantly smaller.
The thermograms of acylated polymers differed from that of the polymer
backbone.
The 100% acylated polymer particles in the absence of drug showed a main
endothermic peak at 110°C while in the presence of DXMP; this peak broadened
and appeared at a slightly higher temperature (115 °C).
From Fig. 7.7, in the presence of CYT-ARA for the 100% acylated polymer this
peak decreased from 110°C to 95°C. The thermograms for the polymer backbone
POLYMER Tg °C Tm (1) °C -heat
flow (W/g)
Tm (2) °C -heat
flow (W/g)
Backbone empty ND 70 (-28) 101 (-35)
Backbone + DXMP ND 74 (-8) 100 (-3.5)
Backbone+CYT-
ARA
38 55 (-28) 101 (-47.2)
100% C8 empty 55 - 110 (-17)
100% C8+ DXMP ND - 115 (-9)
100% C8 + CYT-
ARA
ND - 95 (-8)
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empty particles and particles containing CYT-ARA were similar in shape and the
Tm1 and Tm2 were recorded at 55°C and 101°C respectively. The peak heights
also decreased to a great extent compared to the empty particles for both the
backbone and the 100% acylated polymers (Table 7.2). The Tg of the polymer
backbone though not very distinct in the other formulations could be detected for
the CYT-ARA particles in the polymer backbone at around 38°C.
DSC of the pure drugs showed the melting peaks of DXMP at 260°C (Fig. 7.6)
or CYT-ARA at 212°C (not shown). However all the nanoparticle formulations
containing either drug did not show these peaks.
7.2.3. DSC Thermograms for ETO and ETO-P particles in various
polymers
Fig. 7.8 shows the physical state of ETO within nanoparticles made from the 5%
tryptophan substituted polymer. Etoposide free drug showed two endothermic
peaks at 190°C and 295°C respectively along with a small crystallisation peak at
around 220° C. However, these did not appear in the curves for the drug loaded
particles in any of the polymers investigated (Figs. 7.8, 7.9, 7.10).
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Fig. 7.8. DSC thermograms of ETO and ETO-P in tryptophan substituted
polymers. Tm 1 and 2 refer to the melting endotherms, ND= not detected.
Fig. 7.9. DSC thermograms of ETO in Tyrosine substituted polymers. Tm 1 and
2 refer to the melting endotherms, ND= not detected.
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Fig. 7.10. DSC thermograms of ETO and ETO-P in 100% C8 substituted
polymers. Tm 1 and 2 refer to the melting endotherms, ND= not detected.
Table 7.3. Peak Temperatures and heat flow for ETO and ETO-P in various
polymers. Tm 1 and 2 refer to the melting endotherms, ND= not detected.
POLYMER Tg °C
Tm (1) °C - heat
flow (W/g)
Tm (2) °C -heat
flow (W/g)
5% Tryptophan
empty
30°C 55°C (-3) 100 (-1.8)
5% Tryptophan +
ETO
80°C 101°C (-10) 126°C
5% Tryptophan +
ETO-P
50°C 75°C (-6.8) 100°C
5% Tyrosine empty ND 115°C (-2.6) 135°C (-1)
5% Tyrosine + ETO ND 124°C (-13.5) 147°C (-3.6)
100% C8 empty 58°C - 125°C (-16.2)
100% C8 + ETO 35°C - 68 (-16.2)
100% C8 + ETO-P ND - 200°C (-15)
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In the DSC curves for the empty nanoparticles formed using the 5% tryptophan
polymer alone, two endothermic peaks appeared at 55°C and 100°C respectively
(Table 7.3). The Tg of the polymer was around 30°C.
In the presence of ETO, the Tg increased to 80°C. Tg for the ETO-P particles
was around 50°C. For the ETO particles, endothermic peaks Tm1 and Tm2
increased to 101°C and 126°C respectively (Fig. 7.8). While for ETO-P loaded
particles in the same polymer, these peaks were recorded at 75°C and 100°C.
The Tm2 for ETO-P particles appeared at the same temperature as Tm2 for the
empty polymer particles. However the shape of Tm2 for ETO-P appeared
broader while Tm2 of the ETO loaded curve was steeper. Both drugs increased
the Tg and Tm of the polymer. Increase was greater for the ETO particles than
ETO-P.
The thermogram for ETO particles in the tyrosine substituted polymers is
illustrated in Fig. 7.9. Two melting endotherms were recorded at 115°C and
135°C for the empty particles. There was a slight increase in the Tm1 of the drug
loaded particles compared to the empty polymer. Tm1 appeared at 125°C and
Tm2 at 148°C (Table 7.3). The region between 60°C to 100°C was smoother in
the drug loaded particles. There appear to be the same number of peaks but they
are better resolved in the unloaded polymer because the peak heights are lower.
Also the curve for the drug loaded polymer was steeper.
For the 100% acylated polymer (Fig. 7.10), both Tm and Tg of empty polymer
particles decreased in the presence of ETO (Table 7.3). While Tm increased in
the presence of ETO-P, Tg was not very distinct.
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7.2.4. DSC Thermograms of PTx loaded nanoparticles in various polymers.
Fig. 7.11. DSC thermograms for PTx powder, PTx particles in 40% C8 polymers,
empty 40% C8 polymers. Tm 1 and 2 refer to the melting endotherms, ND= not
detected.
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Fig. 7.12. DSC thermograms for PTx particles in 40% C8, 40% C8 + 5%
Tryptophan. Tm 1 and 2 refer to the melting endotherms, ND= not detected.
Table 7.4. Peak Temperatures and heat flow for PTx in various polymers. ND
(not detected).
Fig. 7.11 compares the thermograms of PTx powder along with PTx loaded in
40% C8 polymer nanoparticles. PTx alone shows a small endothermic peak at
223°C (Tm) and a small exotherm around 247°C (Tc). The empty 40% C8
POLYMER Tg °C
Tm (1) °C -heat
flow (W/g)
Tm (2) ° C -heat
flow (W/g)
40% C8 empty 32°C 45°C (-0.8) 102°C (-3.5)
40% C8 + PTx 35°C 48°C (-1.5) 98°C (-2.4)
40% C8 + 5%
Tryptophan empty
ND - 103 °C (-75)
40% C8 + 5%
Tryptophan + PTx
ND - 73°C (-9.7)
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polymer particles showed two sharp endothermic peaks at 45°C (Tm1) and
102°C, while Tg of the polymer was around 32°C.
In the presence of PTx, the Tg increased slightly to 35°C and the melting
endotherms Tm1 and Tm2 appeared at 48°C and 98°C respectively. The shape of
the Tm2 for the PTx loaded melting curve was steeper than for the empty
polymer although there was no significant difference in the temperature of
appearance of the peaks.
Fig. 7.12 compares the profile of PTx within the 40% acylated + 5% tryptophan
polymers with the drug free polymer. A single endothermic peak for the empty
combination polymer particles was recorded at 103°C (Tm2) while in the drug
loaded particles the (Tm2) was recorded at a lower temperature (73°C).
Crystallisation peak for pure drug was absent for all drug loaded polymers. There
was a significant difference in the peak heights of drug loaded particles within
the 40% acylated polymer and in the polymer substituted with both acyl and
tryptophan groups. The latent heat of melting for the PTx particles with the 40%
C8 polymers seems negligible compared to that of the PTx loaded combination
polymer particles (Table 7.4).
7.3.(B) FTIR of particles
FTIR studies were performed on the drug loaded particles in order to obtain
some information regarding surface chemistry of the particles. Empty polymer
particles were chosen as a reference and compared to drug loaded particles.
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7.3.1. FT-IR for DXMP and CYT-ARA particles
Polymer Position Intensity
PB empty 3444.49 77.87
2950.99 78.12
1739.29 56.93
1455.93 81.42
1385.46 80.39
1174.43 67.26
Table 7.5. FTIR peaks for empty polymer backbone particles
Table 7.6. FTIR peaks for CYT-ARA loaded particles
7.3.2. ETO and ETO-P
FTIR peaks for ETO particles in the tryptophan substituted polymers are
presented in Tables 7.8 and 7.10. Interferograms for the pure drugs ETO and
ETO-P had a similar profile
Appendix 3, Appendix 4) and hence significant differences could not be detected
in the IR scans of their nanoparticle formulations.
Polymer Position Intensity
PB+ CYT-ARA 3358 31.54
2950.22 26.74
1735.45 5.984
1530.53 70.21
1489.53 80.39
1177.52 26.74
1650.44 30.952
1140.25 71.72
1062.69 41.39
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Table 7.7. FTIR peaks for 5% tryptophan empty nanoparticles.
Table 7.8. FTIR peaks for 5% tryptophan + ETO nanoparticles
Table 7.9. FTIR peaks for 100% C8 empty nanoparticles.
Polymer Position Intensity
5% tryptophan (empty NPs) 3318.48 34.97
2947.56 53.413
2844.07 57.397
2553.33 56.656
1737.25 50.085
1568.15 52.641
1215.84 21.977
765.90 56.311
588.89 46.236
543.72 49.508
Polymer Position Intensity
5% tryptophan + ETO 3444.16 87.289
2951.66 89.985
1737.65 63.848
1171.61 77.822
1140.94 80.175
1078.63 87.447
472.09 95.439
446.39 95.639
423.76 95.624
Polymer Position Intensity
100% empty NPs 2923.98 85.149
1736.90 84.933
1104.71 74.368
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Table 7.10. FTIR peaks for 100% C8 + ETO nanoparticles.
7.4. (A) DISCUSSION
7.4.1. DSC thermograms for polymer backbone and substituted
polymers
The polymer backbone is predominately rich in hydroxyl groups. The polymer
seems to be crystalline in nature with two melting curves Tm1 and Tm2 at 70°C
and 101°C respectively. Melting is a transition which occurs in crystalline
polymers. Melting happens when the polymer chains fall out of their crystal
structures, and become a disordered liquid. The glass transition is a transition
which happens to amorphous polymers. But even crystalline polymers may have
some amorphous portion. This portion usually makes up 40-70% of the polymer
sample. This is why the same sample of a polymer can have both a glass
transition temperature and a melting temperature. But the amorphous portion
undergoes the glass transition only, and the crystalline portion undergoes melting
only. The differences in the latent heat of melting and peak heights are indicative
of low and high energy melting components within the polymeric backbone. The
hydroxyl and carboxyl groups could most likely be the low melting components
while the adipate groups could be the higher melting components. There also
Polymer Position Intensity
100% C8 + ETO NPs 2929.06 67.793
1740.41 40.234
1484.60 77.146
1229.51 61.733
1115.60 57.852
1036.90 72.211
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exist intermolecular forces within the polymer molecules that could either melt at
low energy or high energy input depending upon the nature of interactions
(hydrogen bonding, or hydrophobic interactions) and the degree of disorder.
On substituting the polymer with acyl groups, the crystalline nature of the
polymer seems to have a less stable conformation and the appearance of the Tg
suggests the presence of both amorphous and crystalline regions within the
polymer. Thus acylation increases the disorder of the polymer and hence its
stability in terms of its conformation. The Tg increases with acylation thus
indicating the effect of the pendant groups on chain mobility. Increase in the
number of acyl groups serve to act as an anchor to the molecules in its vicinity
thereby restricting their flexibility and movement. The Tm1 of the polymer
backbone decreases with increase in acylation and completely disappears in the
100% acylated polymer which does not contain hydroxyl groups. The increase in
the Tm2 suggests that increase in hydrophobicity has affected the melting of this
hydrophobic domain.
Amongst the amino acid substituted polymers, tryptophan substitution showed a
Tg at 30 °C which was lower than the acyl substituted polymers. The Tm1 was
lower than the backbone but higher than the acylated polymers which would be
expected as the polymer still has 95% hydroxyl groups. However, the addition of
tyrosine showed a completely different profile. The Tg of the polymer could not
be detected. Both Tm1 and Tm2 were increased significantly compared to the
backbone and was higher than all other polymers. This could be attributed to the
phenolic group of tyrosine that contains an additional hydroxyl group. The
combination polymer again did not have a distinct Tg, Tm1 completely
disappeared from this polymer while Tm2 did not deviate from that of the
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polymer backbone, 40% acylated and tryptophan substituted polymer but had a
greater heat flow. Again this could be attributed to the combined effect of the
tryptophan and acyl groups that could have affected the appearance of the low
melting domains. The massive Tm2 of the combination polymer compared to the
40% C8 or the tryptophan substituted polymers suggests a great increase in the
hydrophobicity of the polymer. Also the Tm1 for the 40% acylated polymer
decreased greatly compared to the backbone and completely disappeared when
tryptophan was attached to it thus further strengthening the hypothesis of
predominating hydrophobic interactions.
7.4.2. DSC of Drug components
Crystallinity of any of the pure drugs could not be detected by DSC in any of the
polymers irrespective of the type of drug. This could be due to the small amount
of drug or the influence of method of preparation. It indicated the presence of
drug either in the form of a molecular dispersion or in an amorphous state. The
particles when observed under the TEM did not show the presence of grain
boundaries, instead, the particles were smooth with a uniform exterior (Figs. 5.3,
5.4, 5.5) indicating the amorphous structure of nanoparticles obtained.
Nanoparticles formed are amorphous due to rapid evaporation of organic solvent
[163]. In the amorphous structure, drug is solubilised by the polymer and the two
components form an amorphous solution [155].
7.4.3. DSC thermograms of DXMP and CYT-ARA particles
The DSC scans of the empty polymer backbone particles show two melting
endotherms. The Tg of the polymer is distinctly observed only with the 100% C8
polymer and when the backbone is loaded with CYT-ARA (Table 7.1)
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From the DSC scans of our polymers, it seems that some of the polymer drug
combinations show both amorphous and crystalline regions while some are
predominantly crystalline. Double or multiple melting endotherms are often
found in semi crystalline polymers crystallized isothermally from the melt at
selective crystallization temperature [126, 153]. The possible origin of the double
or multiple melting endotherms may be listed as follows: (1) melting,
recrystallization and remelting during the DSC heating process, (2) the presence
of more than one crystal modifications (polymorphism), (3) variation in
morphology (such as lamellar thickness, distribution, perfection or stability), (4)
physical aging or/and relaxation of the rigid amorphous fraction, (5) different
molecular weight species and so on. On the other hand, double or multiple
melting endotherms are also occasionally found in the polymers crystallized
nonisothermally from the melt at various constant cooling rates [227].
It is possible that the Tm1 for our polymers occurs as a result of the low melting
components such as the hydroxyl groups while Tm2 is a result of the divinyl
adipate and fatty acyl groups. DXMP particles produced by the backbone and the
100% acylated polymer led to a slight increase in the Tm while it decreased in
the presence of CYT-ARA. Peak heights for either drug loaded particles were
significantly smaller than the empty particles with the polymer backbone (Tm1
and Tm2, Table 7.1).
With the 100% acylated polymers there was a marked difference in the scans of
the empty polymers compared to the polymer backbone and in presence of the
two drugs; DXMP and CYT-ARA (Fig. 7.6 and 7.7). The empty 100% acylated
polymer showed only one main melting endotherm. This further strengthens the
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possibility that Tm2 could be due to the high melting components such as the
adipate or the fatty acyl groups. It was similar to the Tm2 of the unsubstituted
polymer backbone and the absence of Tm1 could correspond to the absence of
free hydroxyl groups. In the DSC analysis of palm stearin by Busfield et al., the
high melting component consisted mainly of triglycerides and higher fatty
groups [228]. In the presence of CYT-ARA, Tm1 of the empty particles at 110°C
decreased to 95°C and decreased in height significantly. In the presence of
DXMP this peak broadened and Tm increased to 115°C. This could suggest the
influence of acyl groups on interaction with the drug. As DXMP loading was
highest in the 100% C8 polymer, this could reduce the ability of the polymer
chains to reorganise and recrystallise during evaporation phase by interrupting
molecular interactions of polymer. This could be responsible for the increase in
Tm of DXMP nanoparticles. Also, the 100% acylated polymer and DXMP
combination did not show any burst release (Fig 3.15). The polymer might be
present in a glassy state that retards drug release [229]. Thus it could be
reinforced that the steroid nucleus of DXMP interacts best with the acyl groups
on the polymer forming smaller particles (Table 3.1), with a better drug
incorporation (Fig. 3.13) and a controlled drug release profile (Fig. 3.15).
Another possibility is that the crystallinity of the acylated polymer decreased in
the presence of CYT-ARA causing a decrease in Tm of the polymer. There could
also be an influence of the method of preparation [230]. Fast evaporation of the
organic solvent dissolving the polymer inhibits crystallisation of polymer; giving
it less time to organise into crystals [163]. The absence of DXMP and CYT-ARA
pure drug peaks in the particles indicates the drug might have been transformed
into an amorphous state either due to the method or the miscibility of the drug in
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polymer or the low amount of drug (4 mg) compared to polymer (20 mg). It was
interesting to observe that for the polymer backbone particles prepared using
either drug; there was no appreciable difference in the drug loading (Fig.3.13).
The DSC scans also seem to support this as the Tm1 values along with peak
heights for DXMP and CYT-ARA particles were similar (Fig. 7.5, 7.6)
Another important observation is the increase in the Tg of the polymer with
addition of pendant acyl groups on the backbone. Pendant groups have a big
effect on chain mobility. Even a small pendant group can act as a fish hook that
will catch on any nearby molecule when the polymer chain tries to move. But
bulky pendant groups can lower the Tg too as will be discussed in section 7.4.4.
Yoon et al. reported an absence of Tc for DXMP at 269°C in DXM scaffolds
with PLGA prepared by the salt leeching method [231]. Softening and thermal
degradation of polymer above 200 °C may also be a possible reason. In a study
on estradiol incorporation in PCL polymers of various block lengths, it was
reported that longer PCL blocks had a higher Tg and higher crystallinty that
retards estradiol release compared to shorter hydrophobic block lengths [184].
Liggins and Burt reported for PTx incorporation in microspheres of PLA, drug
miscibility in particles led to decrease in Tm of polymeric blend [224].
Eerikainen et al. observed an absence of signal attributable to a melting peak of
free ketoprofen in the Eudragit L nanoparticles when the drug amount was equal
to or less than 33% w/w and concluded that drug was incorporated in these
nanoparticles in the amorphous form [232]. Cavalier et al. reported for PLA
microparticles loaded with 12.6% hydrocortisone had an endothermic event at
208°C. This was attributed to the melting of HC crystal domains which is below
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the reported Tm for HC (228°C). This may reflect the formation of imperfect HC
crystal domains in the polymer matrix during particle formation [233].
Several studies have reported use of low molecular weight PLA (2000 Da) as an
additive to enhance release rates of several drugs from microparticles formed
from a high molecular weight sample [234].
7.4.4. ETO and ETO-P
An increase in Tm occurred in the 5% tryptophan and tyrosine substituted
polymers in the presence of ETO and in the 5% tryptophan polymer with ETO-P
(Table 7.2 and Table 7.3) compared to the Tm of the empty polymer. A greater
increase in Tm occurred in the presence of ETO compared to ETO-P in these
polymers.
Similarly an increase in Tg and Tm was recorded in the DSC scan of ETO-P in
the 100% acylated polymers. However, the exact opposite was observed when
the 100% acylated polymers were loaded with ETO. A decrease in Tg and Tm
was recorded compared to the empty polymers. ETO release from the 5%
tryptophan and tyrosine substituted polymers was slower than the acylated
polymers (Fig. 5.10), while ETO-P release was slowest from the acylated
polymer and rapid from the tryptophan substituted polymers (Fig. 5.12).
A number of authors have tried to correlate polymer crystallinity and its effect on
drug release. In the case of crystallinity, there are conflicting reports about its
effect: some report an increase in rate [235] while others report a rate reduction
[236]. From a study conducted by Ge et al. it was reported that, the higher the
crystallinity of the polymer matrix the faster was the nimodipine release from the
nanoparticles [237]. The high crystallinity could lead to formation of a
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microchannel structure and large surface area in the polymer matrix, making the
drug escape easily from the nanoparticles [238]. From these results, we could
also consider that the crystallinity of the polymer played an important role in the
drug release of the nanoparticles as the decrease in Tg and Tm of ETO in the
100% acylated polymer and ETO-P in the 5% tryptophan polymer correlated
with a fast release. The fastest release rate might be attributed to the lower
crystallinity of fully acylated matrix in presence of ETO.
Interactions between the drug and polymer molecules determine solubility of
these molecules in each other. When the drug polymer interactions are weaker
compared to drug – drug or polymer – polymer interactions, the drug and the
polymer have a preference to interact with similar molecules, leading to potential
drug or polymer crystallisation. A small amount of drug below its solubility limit
in the polymer can be solubilised in the matrix [239]. Crystallisation of drug
requires the diffusion of drug molecules and their arrangement into a crystal
lattice. Diffusion of drug in the polymer matrix is shown to be governed by drug
polymer interactions and size of the molecules. The stronger the interaction, the
slower the drug diffusion [240]. Izumikawa et al. have reported that the
crystallinity of the polymer matrices greatly affect the drug release rate [238].
When a high molecular weight polymer is exposed to a smaller molecule such as
a drug, the extent to which a Tg will change depends on the balance between the
loss of elastic energy and the gain in free energy due to solubilization [241]. It
would be expected that the incorporation of such molecules will generally lower
Tg because the small molecules allow the polymer chain segments to have
greater freedom. This phenomenon is known as plasticization and the diluent is
called as a plasticizer. A similar observation was reported by Benoit and Thies.
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They hypothesised a solid solution of the drug i.e. the drug molecules are
embedded between the macromolecular chains of the polymer in a solid solution.
By separating the polymer chains, it would tend to reduce the secondary
polymer-polymer bonds. The free volume available for each chain and hence its
degree of freedom, would accordingly increase. Therefore, the drug would act as
a sort of plasticizer for the polymer and apart from the absence of crystalline
regions in the polymer mass, Tg of the latter would be lowered [242].
However, there are some exceptions to this phenomenon. Due to strong
intermolecular interactions between the drug and the polymer, the Tg of the
mixture can be higher than either of the pure components. These intermolecular
interactions between drug and polymer decrease the free volume of the polymer
and increase the Tg which is commonly known as an antiplasticization effect
[243]. This decrease has been attributed generally to the size of particles or the
presence of surfactant. This seems to be in accordance with our results for drug
release studies. The ETO particles produced with the 5% tryptophan polymers
had an increased Tg and Tm and also showed slower release compared to the
100% acylated polymers where a lowered Tg was recorded. Similarly ETO-P
particles in the 100% acylated polymers showed an increased Tm compared to
the empty polymers and was associated with a slower rate of release from these
particles. Moreover, between the ETO and ETO-P formulations in the tryptophan
polymers, rate of ETO-P release was faster than ETO release. Incorporation of
either drug led to an increase in Tg and Tm. However, this increase was greater
in the ETO formulations than in ETO-P. Thus, ETO acts as a plasticizer in the
100% acylated polymer and may have maximum solubility within this polymeric
matrix compared to the other drug polymer combinations which also explains its
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highest drug loading in this polymer. In the 5% tryptophan particles ETO acts as
an antiplasticizer as described above.
Reddy et al. observed a decrease in the melting temperature of spray dried
etoposide nanoparticles prepared from various glycerol derivatives compared to
the endotherm of the bulk lipids alone [205].
7.4.5. Paclitaxel
Only a few studies have been reported on DSC characterisation of PTx NPs. The
DSC pattern varies for different polymer- drug particles based on the type of
polymer, physical state, presence of additives and method of preparation. For
example PLGA polymers are amorphous in nature; PLA is crystalline and PCL is
semi crystalline. The nanoprecipitation method lowers the crystallinity of
polymers [244]. The presence of drug may either promote an amorphous or a
crystalline state of the polymer. For the 40% C8 polymers, the Tm of the polymer
increased slightly in the presence of PTx, while it decreased in the 40% C8 + 5%
tryptophan polymer. This may indicate a difference in interaction between PTx
and polymer causing fast melting of the low melting component of the polymer.
Polymer does not show any crystallisation exotherm indicating it may be
crystalline. However, the absence of a drug crystallisation peak indicates that
drug may be present in an amorphous form or molecularly dispersed state in a
crystalline polymer.
The increase in the Tg of the acylated polymer on incorporation of PTx could be
due to the antiplasticization effect of drug on polymer. The pendant groups and
the bulkiness of the drug may limit how closely the polymer chains can pack
together and thus increase the free volume of this polymer drug combination.
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Hyoven et al. studied Beclomethasone diphosphate incorporation within
nanoparticles prepared from PLA polymers [230]. They observed an increase in
Tg of polymer in the presence of amorphous drug indicating that drug promotes
the amorphous form of polymer. A similar observation holds true for PTx in the
40% acylated polymer where a slight increase in polymer Tg was observed. For
the combination polymer drug acts as an impurity and decreases Tm of polymer
and hence decreases its crystallinity. Increase in Tg of polymer in the presence
of drug is also an indication of polymer drug interaction. Drug polymer
interactions may interrupt intermolecular interactions of the polymer during the
evaporation of the solvent [245]. When the DSC thermograms of PLA powder
and empty PLA nanoparticles were compared, a cold-crystallization exotherm at
about 100 °C appeared in the thermogram of nanoparticles. The exotherm
indicated that nanoprecipitation lowered the degree of crystallinity of PLA.
The disappearance of the drug-melting peak is explained by the miscibility of the
drug in the polymer rather than by, for example; transformation to an amorphous
state due to the preparation technique [246].
Liggins and Burt reported that PTx was miscible within PLA microparticles as
shown by increasing Tg, Tc and decreasing Tm of microparticles with various
MWs PLA blends with PTx [224]. Polymer Tg values can also provide some
indication as to drug release characteristics. Below the Tg, polymer is in a glassy
state where mobility of polymer is low and free volume available for diffusion
decreases. On the other hand, in the rubbery state polymer is more mobile, the
nanoparticle surface is easier to erode and drug release is accelerated. Although
the Tg of the combination polymer was not clearly distinguishable the Tm2 was
lowered significantly (Fig. 7.12). In accordance with results from Liggins and
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Burt, an increased Tg was associated with slower and controlled release from our
polymers as discussed in sections 7.2.2 and 7.2.3.
7.5. (B) FT-IR
7.5.1. DXMP and CYT-ARA
The FT-IR spectrum of the empty nanoparticles prepared using the polymer
backbone clearly indicates the hydroxyl group at 3444 cm
-1
. There is little else in
these spectra except the peaks for the various C-H and C-O stretches and
deformations (2950 cm
-1
, 1455 cm
-1
, 1385 cm
-1
, 1174 cm
-1
) and the large
carbonyl peak around 1735 cm
-1
(Table 7.5).
In addition to the peaks seen in the empty particles there was a new peak with the
CYT-ARA particles at 1650 cm
-1
which corresponds to the NH2 group of the drug
and the peak at 1734 cm
-1
corresponding to the ketonic group of the drug, thus
confirming the presence of CYT-ARA (Table 7.6). The peaks for the CH3, CH2
and O=C-O-C=O stretching appeared at a similar position as in the empty
polymer backbone particles but with lower intensities. This could probably
indicate the effect of polymer drug interactions leading to change in vibration
energies of free groups. Also, an additional peak appeared at 1062 cm
-1
in the
drug loaded particles corresponding to O=C-O-C groups that were not prominent
in the empty particles.
The decrease in intensity of the carbonyl group peak could also indicate its
deviation from the free state.
With the 40% acylated polymer particles, there was a decrease in intensity of the
hydroxyl peaks while these peaks disappeared completely in the 100% acylated
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polymers as expected (Appendix 1, Appendix 11). There was also a consistent
increase in peak for the carbonyl group with increase in amount of acylation.
Addition of CYT-ARA to 40% C8 polymers did not change the spectrum
significantly. The peak for NH2 and the one at 1062 cm
-1
was absent. It could be
related to amount of drug incorporation as well as interaction. The addition of
DXMP to 100% acylated polymers showed a new peak at 1161 cm
-1
which was
absent in empty particles and corresponds to a C-F (aromatic interaction) in
DXMP (Appendix 2). There was an increase in the peak heights at 1743, 2985
and 2926 cm
-1
.
Bajpai et al. studied the FTIR spectra of Cytarabine in gelatine nanoparticles
[173]. The presence of CH2 group at 2920 cm
-1
due to C H stretching
vibration of furane ring and ketonic group at 1637 cm
-1
due to C O stretching
vibration confirmed the presence of drug molecule in the nanoparticles.
Similarly, the peaks observed at 1464 cm
-1
due to C N stretching vibration of
pyrimidine and at 1031 cm
-1
due to O H stretching of primary and secondary
alcoholic group also provide evidence for the presence of cytarabine.
7.5.2. ETO and ETO-P
On comparing the IR spectrum of tryptophan substituted empty particles (Table
7.7) with ETO loaded particles, a significant difference was observed in the
regions between 2900 cm
-1
to 2400 cm
-1
and from 1500 cm
-1
to 500 cm
-1
(Table
7.8). Peaks at 1568 cm
-1
corresponding to the NH2 groups, peaks at 1274 cm
-1
,
1215 cm
-1
, 1234 cm
-1
corresponding to the C-O-C= O and C-OH stretching seen
in the empty polymer completely disappeared. The region between 1000 cm
-1
to
500 cm
-1
especially showed particularly high interference. The spectrum showed
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additional peaks at 1381 cm
-1
which was also seen in the spectra of the ETO
particles in the 100% C8 polymers corresponding to free OH groups.
The FT-IR peaks of 100% C8 acylated empty nanoparticles are presented in
Table 7.9. The spectrum showed a broad peak region at 3400 to 2400 cm
-1
due to
the hydroxylic group while a sharp peak at 1737 cm
-1
is characteristic of the
carbonyl group. However, in the presence of ETO (Table 7.10) a significant
reduction in the signal intensities in the region from 1500 cm
-1
to 1000 cm
-1
was
observed.
Additional peaks at 1613 cm
-1
and 1484 cm
-1
characteristic of a secondary amine
salt and at 1115 cm
-1
and 1036 cm
-1
corresponding to the C-O-C= O and O=C-O-
C=O respectively appeared (Appendix 5). On comparing this scan to the FT-IR
of pure Etoposide it could be confirmed that these additional peaks are a
contribution of the drug.
Ge et al. studied the FTIR spectra of nimodipine in PCL nanoparticles and
observed the peaks for both the drug and the pure polymer with little or no
significant changes and concluded that drug is only physically entrapped within
the particles without any interactions with the polymer [237].
7.5.3. Paclitaxel
The FT IR scan for PTx within the 40% acylated polymers did not show any
significant difference compared to the empty polymers (
Appendix 14).
7.6. CONCLUSIONS
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(A) For all drug-polymer formulations, drug was present either in the amorphous
state or as a molecular dispersion. DXMP incorporation by the polymer
backbone 100% acylated polymers increased the Tm of the polymer, while CYT-
ARA decreased it. However, ETO incorporation led to a decrease in the Tm of
the 100% acylated polymer whereas ETO-P produced an opposite effect.
For both the amino acid substituted polymers ETO and ETO-P increased the Tm
of the polymers. In the presence of PTx an increase in Tg of the polymer was
recorded.
Polymer drug formulations with a slow and controlled release profile showed
increased Tm and Tg of the polymers while the exact opposite trend was
observed for the rapid release formulation (ETO in 100% C8). Hence, these could
be correlated indicating enhanced polymer crystallinity in presence of drugs and
strong intermolecular interactions between drug and polymer led to increased Tg
and Tm of the formulations.
(B) Since for most drug loaded particles there were no additional functional
groups that were significantly different from the ones already existing on the
empty polymers, it was difficult to make a distinct identification of either
presence of drug in the polymers or the extent of drug polymer interactions on
the basis of their IR scans.
However in some cases, for example, the ETO particles with the tryptophan or
acyl substituted polymers, appearance of peaks specific to certain regions of the
pure drug were observed which could confirm presence of drug.
The influence of drug polymer interactions could also be clearly seen in the
spectra of ETO loaded within the tryptophan and 100% acyl substituted polymer
and the spectra for ETO-P in the acyl – tryptophan combination polymer. As an
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influence of drug polymer interactions, significant changes could occur in the
vibrational energy of certain groups of atoms resulting in a significant difference
in positions and intensities of certain peaks or regions or complete disappearance
of peaks specific for the pure compounds when compared to that of the empty
particles lacking the drug.
The FTIR scans provided evidence of presence of drug while the DSC was more
useful in terms of understanding the effect of polymer substitutions and drugs on
the particles which could then be correlated with the nature of interactions
existing within the drug loaded particles. For example the tryptophan substituted
polymers in the presence of ETO, showed the highest increase in the Tg of the
polymer compared to all other formulations while the FTIR scans of these
particles also showed significant high interference regions compared to the
particles prepared using only the polymer. This particular formulation had the
slowest release of ETO and satisfactory drug loading.
These studies are still in the initial stage and would require a more extensive
analysis in order to characterise the nature of drug polymer interactions.
Nevertheless, it helps to provide valuable information regarding confirmation of
presence of drug within the particles and to some extent its influence on
interaction with the polymer molecules.
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CHAPTER 8. SUMMARYAND CONCLUSIONS
8.1. SUMMARY
8.1.1. Objectives and background of study
This study was devised mainly with two objectives; firstly, to obtain a tool for
understanding in depth the influence of physicochemical properties of different
drugs and their interaction with polymers of various properties. Secondly, to
identify polymer drug formulations with good drug loading and slow release for
use in anticancer therapy. Through this study we are also trying to understand the
effect of these drug polymer interactions on the drug entrapment and release
profile from the polymeric matrix. Polymers such as PLA, PGA and their co
polymers (PLGA) have been extensively studied for nanoparticle formulations
however due to limited chemical functionality in their backbone, the
physicochemical properties of these polymers is nearly constant.
The block copolymers developed so far either contain no functional groups at all
in the hydrophobic block such as PCL, PLA or contain a functional group in
every monomer unit as in poly (aspartic acid) [247]. When functional groups are
not contained in the hydrophobic block of the polymer, no other interactions such
as hydrogen bonding, ionic interactions can be expected between the copolymer
and the drug. Consequently for many studies reported in the literature, drug is not
very well loaded into the particle or micelle and these polymers have a relatively
low drug loading efficiency. In the case of fully functionalised polymers the
polymers may be water-soluble and unable to form a micelle or a particle in an
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aqueous medium. Thus, the amphiphilicity of the polymer results in a problem—
that is, the chemical conjugation of a hydrophobic drug is needed with the
functional group of the core block. Hence, functionalisation of polymer blocks
has been attempted. For example PEO–PLA block copolymers containing a
small quantity of carboxylic acid in the PLA block were successfully synthesized
[248]. The nanoparticles prepared from the functionalized block copolymer had a
very low CMC value, which suggests good stability of the nanoparticles. The
drug loading efficiency of nanoparticles was dramatically increased with the
content of carboxylic acid in the block copolymers. This result may be attributed
to the hydrogen bonding between copolymer and drug. The release rate of drug
was much slower from nanoparticles containing higher amounts of carboxylic
acid in the copolymer, which might be associated with the enhanced interaction
between the carboxylic group of copolymers and the drug [248]. The nature of
drug polymer interactions may therefore significantly influence the drug loading
and release pattern.
The aims of this study were:
x To assess the potential of a novel Poly (glycerol Adipate) backbone and
various substituted variants of this polymer to assemble into
nanoparticles using a simple method and in the absence of a surfactant.
x To provide nanoparticle formulations for both, hydrophobic and
hydrophilic drugs with good drug loading and sustained drug release
profile compared to existing polymeric nanoparticles.
x To modify the properties of the polymer by attaching different functional
groups and to study their influence on drug loading and release for a
wide range of drugs with differing structures and chemistries.
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x Overall, to provide a better understanding of effect of drug polymer
chemistries on their interactions in nanoparticles.
The study began with the detailed investigation of DXMP, a water soluble
steroid which was chosen as the model drug, for drug incorporation and release
from backbone and various acyl substituted polymers. Influence of chain length
of acyl group substituent along with degree of substitution on drug incorporation
and release was studied. Further into the study, drugs such as CYT-ARA, ETO,
ETO-P and PTx were included. Along with the acylated polymers, amino acid
substituted polymers were also investigated. Drug release studies provided
significant insight into the influence of drug polymer interactions on the release
pattern as release from a dispersion of drugs in the presence of polymer matrices
was much faster than its release pattern from nanoparticles. DSC and FTIR were
also employed to obtain a better insight into the influence of drug polymer
interactions in NPs.
8.2. OVERALLDISCUSSION
The effect of polymer side chain functional groups and properties of the drug on
nanoparticle physicochemical properties such as size, shape and zeta potential
and their drug loading and release profile have been summarised in Tables 8.1
and 8.2.
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Table 8.1. Summary of particle size, drug loading and release of water soluble
drugs
Drug ReleaseDrug Polymer Size
(empty)
nm
Size (with
drug) nm
Drug
loading
% w/w % at 24 hours % at 10 days
PB-12kDa 169.6 115.6 2.35 38 50
20% C8 217.1 124.3 4 36 87
40% C8 267.5 147.3 8 17 60
D
X
M
P
100% C8
201.3 152.5 10.5 6.1 38.2
PB-12kDa 169.6 159.2 1.9 20 60
20% C8 217.1 211.5 0.33 37.3 58
40% C8 267.5 200.8 0.3 26 60
C
Y
T
-
A
R
A
100% C8 201.3 196.35 0.23 26 99
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Table 8.2. Summary of particle size, drug loading and release of water insoluble
drugs
Drug ReleaseDrug Polymer Size
(empty)
nm
Size
(with
drug) nm
Drug
loading
% w/w
% at 24
hours
% at 10
days
PB-12kDa
169.6 130.2 1.7
40 85
40% C8 267.5 141.2 1.95 41 87
100% C8 201.3 126.1 3.1 43 55
5% Tryptophan 132.3 165. 5 1.73 17 45
5% Tyrosine 145.2 177.1 1.1 29 55
E
T
O
40% C8 + 5%
Tryptophan
190.7 184.1 1.2 50 94
PB-12kDa
169.6 125.1 0.7 23 31
40% C8 267.5 139 1.48 47 63
100% C8 201.3 141.8 1.75 39 77
5% Tryptophan
132.3 159.3 1.8 45 80
5% Tyrosine
145.2 168.2 0.55 37 80
E
T
O
-P
40% C8 + 5%
Tryptophan
190.7 149.3 2 32 62
PB-12kDa
169.6 188.2 0.77 16 50
40% C8 267.5 195.6 1.43 10 25
100% C8 201.3 216 0.44 40 85
5% Tryptophan
132.3 240.3 1.8 11 23
5% Tyrosine
145.2 205.7 0.3 55 95
P
T
x
40% C8 + 5%
Tryptophan
190.7 202.7 0.48 37 80
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8.2.1. Particle size
Physicochemical characterisation of the various particles formed using different
drug polymer combinations revealed certain important changes that occurred in
the particles when drug was present within the polymers.
Fig. 8.1. Factors affecting particle formation and size.
According to existing literature reports, once the organic droplets contact water,
the diffusion of acetone from the organic to aqueous phase produces very small
droplets and makes the polymer molecules aggregate and precipitate
instantaneously. Furthermore, these small droplets will break up into smaller and
smaller ones until the polymer precipitates completely, which leads to the
formation of nanoparticles. As illustrated in Fig. 8.1, aggregation of the polymer
molecules is the main factor responsible for assembly into particles. Factors
leading to an increase in association number of the particles could form loosely
packed particles or a decrease in the interfacial free energy could lead to compact
or dense particles. While most studies have reported polymer or drug
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hydrophobicity influences the aggregation number of particles, this parameter
was not measured in our studies.
DXMP, CYT-ARA and ETO-P, all water soluble drugs prepared using the Fessi
method showed different trends for influence of particle size depending upon the
type of polymer used. Increase in acylation was accompanied by increase in
particle size for DXMP, ETO-P and ETO. CYT-ARA on the other hand showed
no specific trend with degree of acylation.
Compared to the empty particles, DXMP, ETO and ETO-P in the acylated
polymers were smaller in size indicating these drugs played some role in particle
formation; probably at the interface or by reacting with the polymer to form
dense and compact particles. CYT-ARA particles on the other hand were of
similar size to the empty particles. Also, ETO-P particles followed trends similar
to ETO but their sizes were smaller in all polymers compared to the ETO
particles suggesting influence of the phosphate group and water solubility on
aggregation and association of polymer molecules.
ETO and PTx when formulated using the amino acid substituted polymers
produced particles of larger size than the acylated polymers. PTx particles with
the amino acid polymers were around 240 nm in size and were the largest
compared to the all other drug polymer combinations. Thus particle size depends
upon the nature of arrangement of the polymer molecules and it is influenced by
the nature of interactions between the drug and the polymer. In this study, the
decrease of the mean particle size of copolymers might be attributed to polymer
drug interactions that may reduce the crystallinity of the polymer and modify the
solubility of the polymer in acetone. This might make the acetone droplets break
up into finer nanodroplets before the polymer precipitation.
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More hydrophobic drugs with most hydrophobic polymers have produced
particles of the smallest size thus indicating that the presence of drug and its
interaction with the polymer molecules is important in determining the
arrangement and packing efficiency of polymers to produce either dense or
loosely packed particles. More bulky drugs like ETO and PTx formed particles
of the largest size with amino acid substituted polymers. This could be explained
on basis of bulkiness and density of polymer molecules along with drugs
associated with it.
8.2.2. Drug loading
Poly (glycerol adipate) is a water insoluble polyester. The presence of
hydrophilic groups confers some hydrophilic characteristics to the backbone. The
addition of acyl groups led to an increase in polymer hydrophobicity by
decreasing the number of free OH groups on the backbone. On substituting the
pendant hydroxyl groups of the backbone with hydrophobic acyl groups (C8) in
varying proportions, marked differences were observed in the % loading of
various drugs. Amongst the acyl groups of varying chain lengths from 2 to 10,
highest drug loading was observed when the chain length of acyl group was 8
carbon atoms. Hence, all further studies were carried out with these
specifications for direct comparison with other drugs.
The 100% acylated polymer was identified as most promising drug delivery
system for DXMP with 10% drug loading and 43% drug release at the end of 15
days without any burst release, thus providing significant indication of drug
polymer interactions and its effect on drug loading and release. A consideration
of polymer drug interactions suggest that the largest amount of drug loaded per
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particle will be reached when the core-forming block is most suitably matched
with the drug to be loaded. Therefore, in order to enhance the encapsulation of
the drug, the compatibility between polymer and drug should be increased [249].
Fig. 8.2. Drug leakage during the manufacturing process. Diffusion of acetone
towards the external medium along with the drug followed by evaporation of
drug and its loss
Previous studies on poor drug incorporation have been explained only on the
basis of either hydrophilicity of polymer or water solubility of drug. DXMP,
ETO-P (both water soluble, DXMP>ETO-P) and ETO (water insoluble) showed
a similar trend despite differences in chemical structures and solubility
characteristics. They showed maximum incorporation with addition of acyl
groups. Comparing results obtained with DXMP to those of CYT-ARA and
ETO-P strengthened the hypothesis of acyl – steroid nucleus affinity. This
interaction was attributed to be the major factor responsible for maximum
incorporation of DXMP and governing its rate of release compared to CYT-ARA
1 2
3 4
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(1%) and ETO-P (1.85%) loading within the 100% acylated polymer. Only for
CYT-ARA was the best incorporation observed with the polymer backbone
while an increase in acylation decreased the amount of drug loaded in the
polymer. This has been attributed to the presence of both a sugar molecule and a
free NH2 group in its structure that could promote its interaction with the pendant
hydroxyl groups to a significant extent. Since the drug is water soluble, polymer
precipitation could also have occurred at a rate that enhanced drug loading in the
polymer.
Thus the fully functionalised polymer provided optimum hydrophilic -
hydrophobic characteristics that increased loading of DXMP and ETO compared
to the polymer backbone. Individual differences in the amount of drug loaded
within each of the acylated polymers varied depending on nature of drug and its
interaction with the polymer side groups. A significant decrease in PTx loading
with the 100% acylated polymer gave an indication of the specificity of degree of
acylation and its subsequent influence on polymer hydrophobicity. The polymer
with 40% acylation and 60% hydroxyl groups was apparently best suited to
promote drug polymer interaction. Further increase in acylation probably
decreased the affinity of the drug and failed to accommodate this extremely
hydrophobic drug within its matrix to a significant extent. However, in the case
of CYT-ARA, even a 40% acylation led to decrease in loading and for this drug
the properties of polymer in its unsubstituted form were more favourable for
better incorporation.
In order to introduce aromatic groups in the polymer, tryptophan and tyrosine
residues were substituted on the backbone. The rationale was to study the
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groups and drugs containing aromatic rings such as ETO and PTx. In addition to
water soluble drugs, versatility of the polymer to accommodate hydrophobic
drugs was also assessed. Since, some combinations contained polymers with
hydrophobic substituents along with extremely hydrophobic drugs; aggregation
of particles in absence of surfactant could be a possibility. However, all particles
were stable under the given experimental conditions.
With tryptophan substitution there was no difference in the amount of ETO and
ETO-P incorporation indicating that the phosphate group on the drug did not did
not have a significant effect on loading within this polymer. From the DSC scans
it was found that the Tg and Tm of the empty polymer increased in presence of
either drug and this increase was greater in presence of ETO (Table 7.2).
However, ETO-P incorporation was higher than ETO in the combination
polymer. Thus, although it has a similar structure as ETO, interaction with the
amino acid + acyl substituted polymer is influenced by presence of ionised
phosphate as it allows for additional interaction with the unsubstituted hydroxyl
groups on polymer.
For PTx, the degree of acylation seemed to be more important for enhanced
interaction and retention within the polymeric matrix. Also, formulation
parameters like organic/aqueous phase ratio seemed to influence PTx
incorporation more than that of ETO or ETO-P as it does not contain functional
groups that can be ionized by pH alteration or allow salt formation [250]. The
highest drug loading was achieved with the tryptophan substituted polymer
(2.1%) and organic phase/aqueous phase 1/2. Thus there is an influence of the
method of preparation and formulation parameters. A preformed matrix of drug
dissolved in polymer solution added to the aqueous phase significantly increased
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loading of water insoluble drugs using the interfacial deposition method. Drug
incorporation also depended on the affinity of the drug in the polymer and hence
the rate of precipitation of polymer and drug molecules. DXMP incorporation
was better with the IDP method than the emulsification method.
According to the previous reports by Liu et al. on the solubilization of
hydrophobic compounds in aqueous conventional surfactants and block
copolymer micellar solutions, the number of molecules solubilized is closely
correlated with molecular volume of solubilizates, and Van der Waals dispersion
forces, hydrogen bonding and dipole–dipole interactions between micellar core
and solubilizates. Calculation of the partial solubility parameters and mixing
enthalpy enables prediction of polymer–drug compatibility [251].
In a recent study by Zhang et al., drug incorporation and release of 6
hydrophobic drugs, viz. medroxyprogesterone acetate, ibuprofen, ketoprofen,
indomethacin, dexamethasone, and prednisone acetate were selected to elucidate
the effect of drug type on its encapsulation into polymeric micelles based on
amphiphilic polyphosphazenes bearing poly (N-isopropylacrylamide) and ethyl
tryptophan as side groups [167]. Both the drug loading and entrapment efficiency
for dexamethasone, medroxyprogesterone acetate and prednisone acetate was
significantly lower independent of copolymer compositions (0.2%, 0.5% and
0.51% respectively). The corresponding values, however, were higher for
ibuprofen, ketoprofen and indomethacin (3.6%, 0.9% and 7.1% respectively). In
addition, for all these drugs, the actual drug loading and entrapment efficiency
seemed to increase as the molar content of ethyl tryptophan group in the
copolymer was increased. This lower loading level of dexamethasone,
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medroxyprogesterone acetate and prednisone acetate drugs in polymeric micelles
was explained on the basis of the large molecular volume of these drugs. While
for drugs like ibuprofen, ketoprofen and indomethacin, in addition to their
relatively small molecular volume they also have carboxylic group which could
have allowed for hydrogen bonding interaction between amide groups in
PNIPAAm chains and carboxyl groups.
A similar effect of adjusting the hydrophobicity of the polymer has been reported
by Kwon et al. to enhance the encapsulation of aliphatic drugs such as
amphoterecin B [252]. Micelle-forming Poly (ethylene oxide)-b poly (L-aspartic
acid) (PEO-b-PLAA) block copolymers with stearic acid side chains on the
PLAA block were synthesised and the effect of polymer structure on micellar
properties and encapsulation of AmB was assessed. An increase in the level of
stearic acid substitution on PEO-b- poly (N-hexylstearate-L-aspartamide)
improved the encapsulation of AmB while reducing its haemolytic activity.
According to Avgoustakis et al. drug loading and encapsulation in PLGA-mPEG
nanoparticles appeared to be governed by the partition coefficient of the drug
between the organic phase and the external aqueous phase employed in
nanoparticle preparation. Relatively low loading and encapsulation values were
obtained, suggesting that the physical entrapment of drugs in PLGA-mPEG
nanoparticles could only be an option in the development of formulations of
potent drugs. Only the least water-soluble theobromine was efficiently sustained
by its entrapment in the nanoparticles, indicating that the physical entrapment of
drugs provides the means for the development of controlled-release PLGA-
mPEG nanoparticulate formulations only in the case of drugs with low aqueous
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solubility [26]. The physicochemical properties such as relative solubility of the
drug + polymer may prevent appropriate drug incorporation.
8.2.3.Drug Release
The most hydrophilic polymer backbone showed a significant burst effect and
the fastest rate of release for DXMP. However the same polymer gave a more
controlled and sustained release for CYT-ARA. Increase in acylation decreased
rate of release for DXMP while increased it for CYT-ARA and ETO-P.
However, in case of ETO-P, the release from the backbone and the acylated
polymers was incomplete. Amongst the acylated polymers and water insoluble
drugs none of the acylated polymers showed a sustained release. ETO followed a
similar profile to ETO-P. The order for rate of release was polymer backbone <
100% C8 < 40% C8 acylated polymers. For PTx, no specific trend could be
observed. Release from the 40% acylated polymer was slower than the polymer
backbone. Complete acylation showed a significant burst release.
Thus for the water soluble drugs, the acylated groups retained the steroid drugs
(DXMP) to a greater extent than drug with heterocyclic rings (ETO-P). For ETO,
both the parent compound and its water soluble counterpart showed slowest
release with the polymer backbone indicating that the acyl groups and the
phosphate groups on the drug are not predominantly involved in retaining the
drug within the polymer.
The amino acid substituted polymers especially the tryptophan substituted
polymer seemed to retain the water insoluble drugs better. The tryptophan
substituted polymer had the slowest release for ETO followed by the tyrosine
substituted polymer. For ETO-P, the combination polymer had a slower rate of
CHAPTER 8 Summary And Conclusions
220
release than either the tryptophan or tyrosine substituted polymers. Release from
the polymer backbone was slow but incomplete. ETO-P release from the amino
acid substituted polymers was faster than that of ETO. However, for both drugs it
was slower than the acylated polymer series. Thus the aromatic groups on the
polymer and the ring stacking between the drug and polymer could be
responsible for better retention of the drug within the polymer. For PTx, drug
release was slowest from the tryptophan substituted polymer and rapid from the
combined acyl-tryptophan substituted polymers compared to the 40% acylated or
the 5% tryptophan substituted polymer.
ETO and PTx incorporation and release from various polymers differed from
each other and also from water soluble drugs thus indicating a difference in the
mechanism of interaction of these drugs with the polymer molecules. ETO
incorporation was highest in the 100% acylated polymer and it decreased in
presence of aromatic rings on the polymer. Hence, an optimum level of
hydrophobicity and side group chemistry was important following which any
further modification of side chain groups was not as effective. However, release
of ETO from this polymer was faster than from the tryptophan substituted
polymer (2% loading). The particles that demonstrated controlled release for
ETO were the largest compared to its other formulations
For PTx, maximum incorporation and most controlled release was seen from the
tryptophan substituted polymer. For DXMP and PTx, particles providing the
most controlled release also had highest drug loading. Also the slowest releasing
formulations had varying sizes, 40% C8 (195.65 nm) and 5% tryptophan (240.3
nm). Hence size alone is not a primary factor influencing rate of release and is
CHAPTER 8 Summary And Conclusions
221
mainly an indication of effect of drug polymer interactions on assembly and
packing of polymer molecules into particles.
Drug release from NPs appears to be mostly influenced by the strength of
interactions between the drug and polymer which also strongly influences the
amount of drug loaded within the particles. The nature of the drug and polymer
and size of the particles are other factors that may also influence rate of drug
release. This is in contrast to various published reports where higher drug loading
and small particle size have been identified as the primary factor responsible for
the burst effect or a rapid rate of release.
Thus, it is proposed that the affinity of polymer towards the drug to be
encapsulated that actually determines drug loading efficiency and rate of release.
These are dependant upon the properties of drug and chemistry of polymer which
in turn are interrelated. Higher incorporation indicates high affinity possibly due
to factors influencing particle formation / encapsulation; however this may not
necessarily provide particles with a sustained release. Release of water soluble
drug from polymer again depends upon side group chain and its ability to retain
drug within its matrix rather than only water solubility of drug or molecular
weight and hydrophilicity of polymer alone.
A number of literature reports have attributed poor drug incorporation and fast
release of water soluble drugs using the interfacial deposition method to extreme
water solubility of the drug and its rapid release into the external aqueous phase.
Also, incorporation and release of water soluble drugs from hydrophobic
polymers has always been poor and associated with a large burst effect.
However, the % cumulative release from polymers at a fixed time point also
depends on the drug solubility in water [154]. Hydrophilic drugs with high water
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solubility may increase rate of water diffusion into matrix and accelerate bulk
erosion while highly hydrophobic drugs may inhibit water diffusion thereby
decreasing release rate and inducing surface erosion [253].
Some studies on nanoparticle formulations typically with PLGA and related
polymers have hypothesised that as polymer degradation is achieved via
hydrolysis, rate of degradation is controlled by chemistry of drug particularly
presence of OH groups or pH of water dissolved products. Rate of release of the
encapsulated agent has been correlated in some cases to the rate of degradation
of PLGA. Release of said agent occurs through both diffusion and erosion as the
polymer hydrolysis. It has also been reported that factors that may influence
formation of or retention of acidic monomers could accelerate drug release.
However, drug release rate from a degrading matrix is not necessarily correlated
to the rate of polymer degradation. Drug may diffuse or leech out of a non
degrading matrix. This is more likely to be applicable in the PGA polymer
system as TEM images of our polymer particles after drug release revealed that
most particles aggregated after the release studies, however they retained their
shape and did not show signs of degradation or disintegration (Chapter 5).
Some studies have established a correlation between nanoparticle size and its
influence on rate of drug release and drug loading to some extent. The smaller
the size of the particles more rapid the rates of drug release. On the other hand,
smaller sizes of particles have also been associated with lower drug loading and
hence rapid release of all the contents. The amounts of lidocaine released in PBS
from PLA nanoparticles in the initial phase were related to the nanosphere size
[29]. DSC and infrared studies showed that no strong chemical interaction
between drug and polymer occurred. Release kinetics of praziquantel from
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PLGA particles was governed not only by actual drug loading but also by
particle size. The higher the drug content and the smaller the particle size, the
faster the drug release [192].
In the case of nanoparticles formulated with Poly (glycerol adipate) polymers no
such direct correlation could be established. Particle size and zeta potential was
more influenced by nature of substitution on polymers and type of drug used.
Release of antiestrogen RU from various polymers (PCL, PLA, PLGA) showed
different release profiles with slowest release occurring from the most
hydrophobic polymer; PLGA. High encapsulation within all the polymers was
attributed only to properties of RU viz, poor water solubility and high
hydrophobicity [253].
Barichello et al. reported that poor interaction between drug and polymer led to
diffusion of the drug from the organic phase to the aqueous phase during
spontaneous emulsification of the polymer. However lipophilic drugs did not
suffer from leakage to the external medium and hence may be released slowly. In
our studies we have observed extremely lipophilic drugs like PTx and ETO were
released rapidly from the hydrophobic polymers. Thus, polymer/ drug
hydrophobicity alone is not a criterion for drug loading and release but strongly
suggestive that the combined chemistry of interaction between drug and polymer
is more significant.
8.2.4. Physicochemical characterisation of drug polymer interactions
Analytical techniques such as the DSC and the FTIR provided basic evidence
regarding drug polymer interactions. Drugs such as DXMP and ETO-P increased
the Tm of the 100% acylated polymer while PTx increased the Tg of the 40%
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acylated polymer thus leading to a slower rate of drug release. FTIR scans of
ETO in the tryptophan substituted and the 100% acylated polymers showed
appearance of peaks specific to the pure drug along with a marked change in the
spectra of the pure polymer thus indicating some evidence of drug polymer
interactions for the tryptophan substituted and 100% acylated polymers in the
presence of ETO. Increased Tg of the PTx loaded 40% C8 polymers indicated
polymer was in the glassy state and the antiplasticization effect was predominant
which hence showed the slowest rate of drug release.
8.3. CONCLUSIONS
A number of stable drug polymer nanoparticle formulations have been prepared
using a simple method in the absence of surfactant and were assessed for drug
loading and release.
From the various drug loading and release profiles it has been demonstrated that
contrary to the reported literature, particle size is not the primary factor
influencing drug release over the relatively small range of particle sizes seen in
this study. Particle size is influenced by the substituents on the polymer and its
interaction with the drug to form either dense or loosely packed particles.
Similarly drug polymer interactions also influence drug loading and release and
unlike commonly reported in literature hydrophilicity, molecular weight or
concentration of polymer / drug are less likely to affect these parameters in
isolation.
From our studies it has been demonstrated that particles smaller in size (DXMP
in 100% C8, ETO in 100% C8) had highest drug loading and thus presence of
more drug did not cause any expansion of the polymer matrix. Increase in
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hydrophobicity of polymers (40% C8 + 5% tryptophan) increased encapsulation
of water soluble ETO-P while it decreased the encapsulation of water insoluble
PTx. The hydrophilic polymer backbone showed highest loading for water
soluble CYT-ARA. These results suggest that there is some binding between the
drug and the polymer that depends upon the collective properties of the two and
hence it is not necessarily true that a water soluble drug will always be washed
off in the particle preparation method and be poorly incorporated.
In the same way drug release profile also varied depending upon the strength of
the interactions and ability of the polymer to retain the drug. It was found that for
hydrophobic drugs; tryptophan substituted polymers showed better retention and
slowest release (PTx in 5% tryptophan, ETO in 5% tryptophan).
The following drug polymer combinations had both, a good drug loading and a
sustained release profile and could be explored further as a promising
nanoparticle delivery system for anti cancer or anti inflammatory agents:
1. DXMP in the 100% C8 acylated polymers had the highest drug loading
(10%) and slowest drug release profile (38%w/w after 10 days).
2. ETO-P in the 40% C8 + 5% tryptophan substituted polymer with 2% w/w
loading released approximately 60% drug after 10 days.
3. PTx in the 5% tryptophan substituted polymers had a drug loading of
1.8% and released around 25% drug after 10 days.
Most conclusions drawn from the study regarding drug polymer interactions on
drug loading and release are based on circumstantial evidence. However, from
the initial DSC and IR studies certain specific drug polymer interactions have
been identified that correlate well with the results obtained for physicochemical
properties of the particles and their drug loading and release profile. A more
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detailed study involving drug chemistry, extent of loading and properties relating
to polymer chemistry is needed to determine the relationship between drug –
polymer interactions, drug incorporation and release rate.
8.4. FUTUREWORK
Having established the flexibility of the core polymer backbone to undergo
substitutions with various functional groups, a lot needs to be explored in terms
of nature and degree of substitution that could be achieved.
Modifications in terms of the monomers used in the formation of the polymer
backbone and the nature of side groups that could be attached.
The basic monomeric units could be changed to included polyhydroxyl alcoholic
groups or amino alcohol groups instead of glycerol. The successful conjugation
of tryptophan and tyrosine could be extended to various other amino acid groups
such as phenylalanine, histidine or sulphur containing cysteine. These
substituents could also be investigated along with drugs belonging to different
categories thus providing a library of polymer drug combinations that could be
assessed for their ability to form nanoparticles with good loading and release
characteristics.
The study has also helped in understanding and identifying various key factors
that primarily contribute to successful incorporation of drugs within
nanoparticles. It has also provided significant information on influence of drug
polymer interactions on drug release profiles. However this information is still in
its very basic stages. Use of in depth analytical techniques like the DSC, IR, XPS
(X-ray photoelectron spectroscopy) needs to be explored further in order to
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quantify the nature and extent of drug polymer interactions existing within
nanoparticle formulations.
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